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Pseudomonas aeruginosa is a Gram-negative, opportunistic pathogen that chronically infects 
approximately 80% of cystic fibrosis (CF) patients by early adulthood, accounting for the 
majority of morbidity and mortality in these patients. The development of chronic P. aeruginosa 
infections in the CF lung involves the formation of highly recalcitrant biofilm communities. 
Clinical observations have noted a correlation between respiratory virus infection and the 
acquisition of chronic P. aeruginosa infection by CF patients, but the mechanism underlying this 
interaction in the CF lung is not understood. In this dissertation, we hypothesized that respiratory 
viral co-infection promotes P. aeruginosa biofilm formation on airway epithelial cells (AECs).   
We demonstrate that in the presence of respiratory syncytial virus (RSV) co-infection, P. 
aeruginosa biofilm growth is significantly increased. We observed that RSV infection increased 
the release of iron-bound transferrin, suggesting that RSV infection disrupts iron homeostasis in 
the airway epithelium. Iron is an essential nutrient for P. aeruginosa biofilm growth, and both 
iron chelation and depletion of transferrin from apical secretions collected from AECs blocked 
the biofilm stimulatory effect of RSV co-infection. We also demonstrate that RSV infection 
promotes the apical release of extracellular vesicles (EVs) from AECs, which increases the 
availability of iron-loaded transferrin in the apical secretions of AECs. Interestingly, purified 
EVs stimulate P. aeruginosa biofilm growth, suggesting that host-derived EVs interact with a 
bacterium to promote chronic bacterial infections. Finally, the innate immune response to virus 
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 v 
infection, measured by type I and type III (IFN-β and -λ, respectively) interferon production, 
peaks at the same time as virus-induced biofilms growth, and treatment of AECs with either IFN 
replicates the enhanced biofilm growth observed during virus co-infection. Our data suggest a 
novel mechanism by which the host response to viral infection contributes to the development of 
chronic pulmonary P. aeruginosa infection and provide mechanistic insight into our 
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1.0  INTRODUCTION 
A fundamental requirement for the survival of all living organisms, including the 
microorganisms that constantly engage in pathogenic and symbiotic relationships with their 
hosts, is the ability to acquire nutrients from the surrounding environment. For example, 
transition metals are critical to many essential biological processes including replication, 
transcription and metabolism. As a consequence, hosts and microorganisms are both involved in 
a continuous struggle to outcompete each other for nutrients. This fosters a dynamic environment 
in which many complex interactions take place between host and microbial proteins that 
ultimately dictate whether microbes successfully colonize their hosts and in the case of 
pathogenic microorganisms, cause disease. Studies at the host-pathogen interface have identified 
many mechanisms by which the host regulates the availability of essential nutrients to limit 
microbial growth and prevent infection, a collective process termed “nutritional immunity.” One 
of the most widely studied nutrients at this interface is iron.   
Epithelial cells are present at mucosal sites throughout the body and are constantly 
exposed to both resident and infectious microorganisms, as well as other environmental factors. 
The epithelium is responsible for many cellular processes critical to tissue homeostasis and 
human health including the selective absorption of nutrients, detection of the extracellular 
environment, secretion of signaling molecules and other products that mediate cell-to-cell 
communication, and protects underlying tissues from infection by serving as the first line of 
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defense microbes encounter in the human body. Consequently, epithelial cells contribute to both 
the physical and biological barriers that are utilized to prevent colonization by pathogenic 
microorganisms and preserve human health. For example, tight junctions maintain the structural 
integrity of the epithelial layer, providing a physical barrier, that prevents dissemination of 
microorganisms into deeper tissues. In addition, epithelial cells secrete antimicrobial factors, 
such as antimicrobial peptides and secretory IgA, that create an innate biological barrier 
microorganisms must first circumvent to successfully colonize host tissues. Epithelial cells also 
play a critical role in bridging the gap between the innate and adaptive immune responses to 
invading microbes by secreting chemokines and cytokines [1-3]. In addition, the epithelium is 
involved in additional mechanisms, such as nutrient sequestration, by which hosts limit microbial 
colonization and growth. Due to these selective pressures, microorganisms have established 
countermeasures to manipulate their environments and host epithelial cells to limit host immune 
responses and colonize host tissues. Ultimately, it is these back-and-forth interactions between 
the host and microbes at mucosal surfaces that determine the fate of infections and disease 
outcomes. 
In this regard, one aspect of the Bomberger lab focuses on nutritional immunity in airway 
epithelial cells, and how these processes are altered during viral-bacterial coinfections to 
promote nutrient accessibility and infection in the respiratory tract. Compared to previously 
identified mechanisms of viral-bacterial interactions, the involvement of nutritional immunity is 
unique in several aspects that will be explained in this dissertation.  
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1.1 CYSTIC FIBROSIS PULMONARY INFECTIONS 
Cystic fibrosis (CF) is a genetic disease caused by mutations in the cystic fibrosis transmembrane 
conductance regulator (CFTR). The first description of CF was made in 1938 by Dorothy 
Andersen, who originally described mucus plugging of the pancreas and pancreatic insufficiency 
in infants who experience malnutrition and died due to pulmonary infection [4]. At the time, this 
disease was characterized by mucus plugging of the exocrine glands and patients did not survive 
past early childhood due to lung infections [4]. In the last 80 years, tremendous progress has 
been made understanding the basic biology of CF including: (i) the discovery that the sweat of 
CF patients had an abnormally high salt concentration and development of the “sweat test,” 
which led to the identification of patients with milder CF disease, (ii) identification of chloride 
transport as the basic physiological defect in CF, and (iii) the identification of the CF gene [4]. 
There have now been more than 2000 CFTR mutations identified, of which 127 mutations meet 
clinical and functional criteria for disease [5]. Deletion of phenylalanine at position 508 of CFTR 
(∆F508) is the most common mutation in CF patients. It is estimated that 70,000 individuals 
globally have some form of CF, of which 30,000 individuals are in the United States. Because 
CFTR is expressed on many cell types, including epithelial cells, CF is a multi-organ disease 
characterized by disorders of endocrine, gastrointestinal, reproductive and respiratory systems. 
However, the major determinant of mortality in CF patients is pulmonary disease. Infection with 
the Gram-negative, opportunistic Pseudomonas aeruginosa in the CF lung has been associated 
with significant morbidity and eventual loss of pulmonary function in patients [6, 7]. P. 
aeruginosa is the most common bacterial species isolated from the respiratory tract of CF 
patients, where it often establishes chronic infection and persists in the airways of patients for the 
rest of their lives [6]. The lung environment is a major factor that impacts host-pathogen 
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interactions and ultimately, a determinant of colonization of the lung by invading pathogens. 
Loss of function of CFTR is associated with changes in the lung environment, many of which 
create an environment that is favorable for P. aeruginosa colonization and chronic infection.  
1.1.1 CFTR Activity and Lung Environment  
Airway epithelial cells (AECs) are the first barrier in the respiratory tract encountered by inhaled 
pathogens and foreign particles. Besides acting as a physical barrier that prevent dissemination of 
inhaled material, ciliated cells in the airways actively contribute to removal of pathogens and 
foreign material from the lungs in a process termed mucociliary clearance [8]. This process is 
dependent upon proper airway surface liquid (ASL) hydration. The ASL consists of a periciliary 
fluid layer with an overlying mucus layer. The periciliary layer acts as a barrier between the 
mucus layer and cell surface that creates an optimal depth of ∼7 µm, which allows cilia to fully 
extend and beat in the airways [9, 10]. In the non-CF airways, apical secretion of Cl- and HCO3- 
by the CFTR anion channel promotes the movement of water into the ASL, which maintains a 
periciliary layer depth of ∼7 µm and reduces the viscosity of the mucus. This removes debris, 
including bacterial and viral pathogens, that have been trapped in the mucus from the lungs. In 
the CF lung, significantly reduced CFTR function leads to dehydration of the ASL, resulting in a 
decrease in the depth of periciliary layer and ability of cilia to beat [9]. 
In addition to its role in mucociliary transport, the composition of the ASL is very 
important innate defense mechanism of the airways. For example, antimicrobial peptides are 
produced by AECs and are important antibacterial components of the ASL [11-13]. Moreover, 
synergistic and additive killing of bacteria by antimicrobial peptides found in the ASL has been 
observed [14]. The functional activity of antimicrobial peptides is sensitive to the environment, 
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as both acidic pH and high salt concentrations decrease the antibacterial activity of antimicrobial 
peptides [14-16]. In CF, the reduction in CFTR activity has been associated with more acidic 
ASL [17-19]. In a pig model of CF, the ASL was also found to be more acidic than the ASL 
from non-CF pigs [18]. Although the concentration of antimicrobial peptides in the ASL of non-
CF and CF pigs were similar, decreased killing of Staphylococcus aureus in the presence of ASL 
from the CF pigs was observed [18]. The acidity of the ASL in CF has been associated with 
decreased HCO3- secretion due to reduced CFTR activity, and stimulation of HCO3- secretion 
alkalinized ASL collected from CF bronchial cells [17]. Interestingly, addition of HCO3- to ASL 
from CF pigs increased both the pH of the ASL but also bacterial killing in the presence of the 
ASL [18], suggesting that correcting the ASL pH defect in CF patients may be a therapeutic 
target that could increase bacterial killing in the airways of CF patients. In addition, decreased 
HCO3- secretion, lower pH and ASL dehydration have been associated with increased mucus 
viscosity in the CF lung [20-22]. MUC5AC and MUC5B, the predominant components of 
airway mucus, are abnormally compact in CF airways, which likely results from a combination 
of these changes to the ASL composition [22]. Mucus is an important part of innate immunity in 
the lung that creates a barrier between the airway surface and particulate matter, including 
infectious microorganisms. Mucociliary transport removes mucus from the airways and in the 
CF lung this process is impaired due to these mucus abnormalities, thereby creating an 
environment that is predisposed to bacterial infection. 
Iron is essential nutrient for a wide variety of cellular processes, and due to the 
requirement of iron for microbial growth, the host meticulously regulates iron so that it is 
inaccessible to pathogens. Despite this regulation, iron levels are increased in the CF lung 
compared to healthy controls (Table 1) [23-26]. Furthermore, in vitro studies have confirmed 
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that AECs with the ∆F508 CFTR mutation release greater amounts of iron than cells with 
functional CFTR [27]. Given that increased iron levels are negatively correlated with pulmonary 
function but positively correlated with bacterial burden, it has been suggested that iron may play 
an important role in facilitating P. aeruginosa infections in the CF lung [25, 28]. Taken together, 
these results suggest that defects in CFTR function are strongly associated with increased iron in 
the airways of CF patients, but it is still not understood how defects in CFTR function regulate 
iron homeostasis in the lung.  
In summary, defects in CFTR function have many consequences for innate defenses such 
as mucus clearance and iron abundance in the airways that impacts the environment in the lungs 
of CF patients. The combination of all these factors creates a setting that is conducive to bacterial 
infection in the CF airway, particularly chronic infection with P. aeruginosa, highlighting both 
the importance of all these innate defenses for normal lung function but also the broad effect that 
CFTR function has on airway physiology. However, the effect respiratory viral infection has on 
many of these components, such as iron levels, in the CF lung have not been investigated. 
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Table 1: Total Iron Concentrations in CF Airways 
Subject 
Population 







Adults 0 ng/mg protein 





Adults 0 µM 7.5 ± 2.1 µM BALF Colorimetric* [26]** 
Adults Not Assessed 
63 µM 





Adults 0 µM (0 – 13.2 µM) 
Acute: 44.4 
µM 
(17.0 – 128.7 
µM) 
Stable: 33.3 





Adults 0 µM (0 – 15.8 µM) 
Acute: 46.6 
µM 











(8.6 – 21.5 
µg/L) 
56.9 µg/L 





Pediatric Not Assessed 
32 µM 
(Range: 3.7 – 
118.5 µM) 
BALF Colorimetric* [28]**** 
*Total iron measured by colorimetric iron detection kits. Assay kits based on reaction of Fe2+ 
with chromogen to form colorimetric product. Iron is released from complexes (i.e. iron-binding 
proteins) by acidic buffer, and Fe3+ is reduced to Fe2+ by reducing agent to measure total iron in 
reaction. **Data presented as mean ± standard deviation. ***Data presented as median (range). 
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Iron concentration reported for CF patients during an acute exacerbation and clinically stable CF 
patients. ****Data presented as median (range).  
1.1.2 Chronic Infection and Biofilm Formation of Pseudomonas aeruginosa in the Cystic 
Fibrosis Airway  
Environmental isolates of P. aeruginosa are responsible for initial infections in CF patients and 
occur in infancy or early adulthood. Infections are often aggressively treated and cleared by 
antibiotics, but recurrent intermittent infections commonly follow. P. aeruginosa undergoes 
genetic adaption over time to the lung environment during waves of antibiotic treatment and the 
constant pressure imposed by the host immune system. It is hypothesized that the sinuses provide 
a protected niche that allows for the genetic adaptation of P. aeruginosa occur, and bacteria from 
the sinuses can recolonize the lungs following antibiotic eradication of P. aeruginosa in the 
airways [31]. The time over which genetic adaptations occur is variable between patients and 
bacterial isolates, but eventually clonal selection of a dominate strain occurs and establishes a 
chronic infection [7, 31].  
The development of chronic P. aeruginosa infections in the CF lung involves the 
formation of highly recalcitrant biofilm communities. Biofilms are surface-associated 
communities of bacteria, which are characterized by upregulation of antibiotic resistance genes 
and polymeric matrix production that serve to protect bacteria from the antibiotic- and host 
immune system-mediated clearance in the CF airways [32]. Biofilms in the environment perform 
a similar function whereby they protect bacterial communities from stress such as heavy metal 
intoxication and antibacterial compounds [33, 34]. Biofilm development occurs in a well-
coordinated manner in response to environmental cues, such as nutrient availability. Biofilm 
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development has been described as a temporal process involving the transition through different 
stages that begin with bacterial attachment to a surface. Attached bacteria multiply on the 
surface, form microcolonies and then ultimately mature into biofilm structures. The final step in 
biofilm development is the dispersal of bacteria from the biofilm, which can seed new sites for 
infection and colonization [32, 35, 36]. Many factors are involved in the development of P. 
aeruginosa biofilm growth, including the initiation of biofilm formation by increased production 
of the second messenger cyclic-di-GMP (c-di-GMP), QS systems, production of 
exopolysaccharides Pel and Psl, and the availability of environmental factors, such as 
extracellular DNA (eDNA) and iron [34]. Iron is required for P. aeruginosa growth and biofilm 
formation [37]. In addition, QS systems are a form of intercellular communication based on cell 
density and the accumulation of small diffusible molecules produced by neighboring bacteria in 
the environment. These systems have been shown to regulate virulence factor production, some 
of which could be important for nutrient acquisition, and are important for biofilm production in 
P. aeruginosa [38-41]. For example, a mutation in the P. aeruginosa las system (one of the QS 
systems in P. aeruginosa) formed shorter, flat biofilms compared to the biofilms formed by wild 
type bacteria, suggesting that mature biofilm formation requires intact QS systems [42]. 
Furthermore, QS regulates iron limitation-induced twitching motility. Mutations in the rhl QS 
system in P. aeruginosa increased biofilm growth in iron-limited conditions, which was linked 
with decreased twitching motility under these conditions [43]. The sputum of CF patients has 
increased abundance of P. aeruginosa QS signals, N-(3oxododecanoyl)-L-homoserine lactone 
(3OC12-HSL) and N-butyryl-L-homoserine lactone (C4-HSL), produced by the las and rhl QS 
systems, respectively [44]. This was suggestive that P. aeruginosa grows in biofilms in CF 
airways, which had been hypothesized based on the observation that P. aeruginosa was highly 
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resistant to antibiotics in the CF lung [32]. In addition, microscopic examination of the explanted 
lungs from CF patients has long demonstrated the intraluminal presence of alginate-positive P. 
aeruginosa microcolonies in the lungs of CF patients, and more recently, the use of fluorescence 
in situ hybridization peptide nucleic acid probes have also shown P. aeruginosa biofilm 
architecture in the airways of CF patients [44-46].  
The development of treatments that either inhibit biofilm growth or promote dissociation 
of the biofilms in CF airways have been of great interest because biofilms contribute to 
persistence of P. aeruginosa infections and the corresponding tissue-damaging inflammation in 
patients. In this regard, DNase treatment is known to reduce P. aeruginosa biofilm formation and 
bacterial colonization has been reduced in patient airways when treated with the therapeutic 
Pulmozyme (rhDNase I) [47, 48]. In addition, iron chelation has been shown to impair P. 
aeruginosa biofilm growth and the use of iron chelation compounds increases the efficacy of 
biofilm disruption with antibiotics [27, 49].  
1.2 RESPIRATORY VIRAL INFECTIONS IN PATIENTS WITH CYSTIC FIBROSIS 
AND OTHER CHRONIC LUNG DISEASES 
Portions of this section are adapted from the published manuscript: 
Matthew R. Hendricksa and Jennifer M. Bombergera 
Digging through the Obstruction: Insight into the Epithelial Cell Response to Respiratory 
Virus Infection in Patients with Cystic Fibrosis.  Journal of Virology, 2016. 90 (9): 4258-4261 
(Copyright  American Society for Microbiology). 
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Respiratory virus infections are common but generally self-limiting infections in healthy 
individuals. In patients with chronic lung diseases, such as CF and chronic obstructive 
pulmonary disease (COPD), respiratory viral infections are associated with acute exacerbations, 
which generally involve acute episodes of increased respiratory symptoms (i.e. cough, fever, 
increased sputum production, etc.) and decreased lung function (as measured by decline in 
FEV1), that promote disease progression [50-64]. Importantly, acute exacerbations not only 
contribute to progressive declines in lung function but also lead to decreases in quality of life for 
these patients, including psychosocial health [65-69]. This highlights the important point that 
besides the physical toll that respiratory viral infections have on patients with chronic lung 
disease, there is also a psychological burden that patients and their families must confront, some 
aspects of which are measurable and others not.  
Early clinical studies reported low detection rates of viruses in patients with chronic lung 
diseases. For example, in CF patients respiratory viral infections were associated with up to 
approximately 40 to 50% of pulmonary exacerbations [51, 52, 54, 70-72]. However, these values 
likely underestimated the true impact of respiratory viral infections on disease progression 
because they are based on insufficiently sensitive detection methods, such as cell culture and 
serology. The development of molecular diagnostics techniques by polymerase chain reaction 
(PCR) has led to (i) an increased detection rate of respiratory virus infections in patients with 
chronic lung diseases, (ii) a greater diversity of respiratory viruses identified in patients, 
including picornaviruses and human metapneumovirus [53, 55], and (iii) an increased 
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recognition that respiratory virus infections are associated with morbidity and acute 
exacerbations in these patients. The more recently reported rates of detection of respiratory viral 
infection during periods of pulmonary exacerbations in CF patients are now greater than 50% 
[53, 55-58, 61]. RNA viruses influenza A virus, human rhinovirus (hRV), and respiratory 
syncytial virus (RSV) are the most common viral infections detected in CF patients, with RSV 
promoting early respiratory tract morbidity and hRV being the most common causative viral 
agent in pulmonary exacerbation. Similarly high detection rates of respiratory virus infections 
are observed in asthma (up to 80%) and COPD (up to 60%) exacerbations as well, with influenza 
virus, hRV and RSV also being the most commonly identified viruses [62-64, 73-75]. Although 
the incidence of viral infections is not greater in patients with CF than in healthy controls, the 
severity and length of viral infections were amplified in patients with CF [55, 76]. In addition, 
respiratory viral infections in CF patients are associated with increased antibiotic use [51, 53], 
deterioration of pulmonary function [50, 51, 53, 54], and longer durations of hospitalizations [54, 
71, 77]. RSV is reported to be account for 9-58% of all reported viral infections CF patients, with 
a higher incidence in young children than adults [78]. Besides the association between 
respiratory viral infections and morbidity, clinical studies have linked respiratory viral infections 
with the development of chronic infections with the Gram-negative bacterium P. aeruginosa in 
CF patients [53, 72, 79]. The mechanisms underlying the increased severity of respiratory viral 
infections and the interactions between respiratory viruses and chronic bacterial infections in 
patients with CF and other chronic lung diseases remains poorly understood despite the fact that 
these observations have been made in the clinic for the past 30 years. Interestingly, an emerging 
body of literature is beginning to suggest that the innate immune response to respiratory viral 
infection likely plays a critical role in viral pathogenesis in chronic lung diseases. Moreover, it is 
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now appreciated in the field that the protective antiviral immune response to viral infection also 
has consequences for secondary bacterial infections by making the airway more permissive for 
bacteria, suggesting that the viral-bacterial interactions are not simply direct interactions between 
viruses and bacteria but are also facilitated by intricate relationships with host cells the airway.  
In this regard, the Bomberger laboratory focuses on understanding the relationship 
between respiratory viral infections and the development of chronic P. aeruginosa infections in 
the CF lung and how the respiratory epithelium contributes to this interaction. As will be 
described in this thesis, the mechanisms that contribute to the development of chronic bacterial 
infections in the context of respiratory viral infections provide a unique perspective on viral-
bacterial interactions in the lung, as compared with previous reports that have described synergy 
between viruses and bacteria in the respiratory tract. 
1.2.1 Respiratory Syncytial Virus (RSV) 
Respiratory syncytial virus (RSV) is an enveloped, negative-sense RNA virus that belongs to the 
Orthopneumovirus genus within the Pneumoviridae family of viruses. The single-stranded RSV 
genome has 10 genes organized as 3’-NS1-NS2-N-P-M-SH-G-F-M2-L-5’ that are transcribed 
into separate mRNA encoding single viral proteins [80]. One notable exception is the M2 
mRNA, which contains two overlapping open reading frames (ORFs) for two distinct proteins, 
M2-1 and M2-2. Translation of M2-2 is dependent upon re-initiation by ribosomes at a start 
codon that overlaps the M2-1 ORF [81, 82]. The M2-1 and M2-2 proteins are important for 
regulating RSV genome transcription and the balance between genome transcription and 
replication, respectively [83, 84]. The nucleoprotein (N), phosphoprotein (P), and RNA-
dependent RNA polymerase (L) encapsulate the RSV genome to form the ribonucleoprotein 
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(RNP) complex. In addition, the RSV genome encodes three glycoproteins that are present in the 
viral envelope: the glycoprotein (G), the fusion protein (F), and small hydrophobic protein (SH). 
The G protein is important for viral attachment to host cells, whereas the F protein is important 
for fusion of the viral envelope with host membranes for release of RSV RNP complexes into 
cells [85]. Although multiple cell surface proteins, including CX3CR1, have been shown to 
interact with the G protein, recent studies identified CX3CR1 as a cellular receptor that mediates 
RSV entry in primary, well-differentiated human bronchial epithelial cells [86, 87]. The F 
protein has also been shown to interact with host proteins such as nucleolin and TLR4, albeit 
only in immortalized cell lines, and may play some role in viral attachment [88, 89]. In addition, 
studies have shown that inhibition of clathrin- and dynamin-dependent endocytosis does not 
inhibit RSV entry into host cells and that RSV can infect cells via macropinocytosis [90]. 
Together these studies suggest that RSV potentially has overlapping mechanisms by which it can 
enter host cells. Following attachment and fusion, the RSV RNP complex is released into the 
cytoplasm, where viral genomes are transcribed and replicated. Inclusion bodies are 
hypothesized to be the location of viral transcription and replication due to the accumulation of 
RNP complex proteins and viral RNA at these sites [91-93]. Progeny virions assemble and bud 
from the surface of infected cells, and these processes are dependent upon the viral F and M 
proteins [94-96]. Budding of RSV virions from the cell surface requires intact apical recycling 
endosome sorting pathways, which involves Rab11 family interacting protein 2 (FIP2), but 
interestingly, is vacuolar protein sorting-associated protein 4 (Vps4)-independent, suggesting 
that RSV release is not dependent upon endosomal sorting complexes required for transporter 
(ESCRT) proteins [97, 98]. In addition, cholesterol rich microdomains (i.e. lipid rafts) have been 
implicated in both RSV entry and release in host cells [99, 100]. However, the exact molecular 
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details of RSV replication, assembly and budding in host cells, and particularly the host factors 
that are needed for these processes, remain to be fully elucidated.  
1.2.2 Human Rhinovirus (hRV) 
Human rhinoviruses (hRVs) are non-enveloped, positive-sense RNA viruses that belong to the 
Enterovirus genus within the Picornaviridae family of viruses. They are grouped into three 
species: hRV-A, hRV-B and hRV-C. Depending on the type, hRVs use intercellular adhesion 
molecule 1 (ICAM-1), low-density lipoprotein receptor (LDLR) family members or cadherin-
related family member 3 (CDHR3) for entry [101-103]. Upon internalization, virions undergo 
conformational changes due to cues from receptor-binding and the lower pH in endosomes and 
release viral RNA into the cytoplasm of cells [104]. The single-stranded hRV genomes are 
translated into a precursor polyprotein that is processed by viral proteases into 11 proteins, four 
of which are capsid proteins. The remaining seven nonstructural proteins mediate viral 
replication, and like with other picornaviruses, cellular membranes are remodeled to form 
replication compartments, also referred to as replication organelles, at the endoplasmic reticulum 
(ER)-Golgi interface during hRV replication [105]. The formation of replication compartments 
during picornavirus infection is dependent upon both viral and host factors [105]. It was recently 
demonstrated during hRV infection that phosphatidylinositol-4 phosphate (PI4P) and cholesterol 
are highly enriched at replication compartments [106]. There are two classes of 
phosphatidylinositol-4 kinases (PI4K) that are responsible for producing PI4P from 
phosphatidylinositol (PI), and interestingly, depending on the strain of hRV, different subsets of 
PI4Ks are important for hRV replication. For example, hRV-A1A is less sensitive to PI4K3β 
inhibition but is more sensitive to PI4K2α inhibition than hRV14, hRV16 and hRV37 [106]. 
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Similarly, multiple mechanisms are utilized by diverse strains of hRVs to promote cholesterol 
accumulation in replication compartments [106]. Of particular note, oxysterol-binding protein 
(OSBP)-like proteins are intracellular proteins important for cholesterol transport and are 
involved in hRV replication. For example, inhibition of OSBP-1, which drives PI4P-cholesterol 
exchange between the ER and Golgi, broadly suppresses replication of many hRV strains, 
demonstrating lipid flow in replication compartments is required for efficient hRV replication 
[106]. Newly, synthesized hRV RNA is encapsidated by capsid proteins to form new virions, 
which according to classical dogma are released from host cells by lysis [105]. However, recent 
studies have suggested that hRV egress can occur by additional mechanisms, including non-lytic 
release of virions packaged within phosphatidylserine lipid-enriched vesicles [107]. Other 
picornaviruses, including coxsackievirus B and hepatitis A virus (HAV), can also be released in 
membrane-enclosed vesicles, suggesting this may be a release mechanism broadly utilized by 
picornaviruses and potentially other non-enveloped viruses [108, 109].  
1.2.3 Antiviral Innate Immune Response to Respiratory Virus in Airway Epithelial Cells 
The respiratory epithelium is a critical component of the innate immune system and the primary 
site of host-pathogen interactions in the lung [110]. In addition, the airway epithelium is the 
primary site of virus replication during respiratory virus infection, including RSV infections, and 
plays a critical role in viral pathogenesis [111, 112]. When microbial ligands engage various 
families of pattern recognition receptors (PRRs), distinct signaling cascades are activated within 
AECs that coordinate the host’s response to the invading microbe. In the context of respiratory 
viral infection, the most relevant PRRs are Toll-like receptors and retinoic acid-inducible gene I-
like receptors (RIG-I like), which detect double-stranded RNA (dsRNA), a by-product of virus 
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replication. Detection of dsRNA by these receptors activates signaling cascades that culminate in 
the induction of antiviral molecules called interferons (IFN). Type I and type III IFNs are the 
major IFNs produced by AECs in response to respiratory viral infection, including RSV [113-
115]. IFNs act in an autocrine and paracrine manner to induce the production of IFN-stimulated 
genes (ISGs), which establish an antiviral state within AECs.  
1.2.4 In Vitro Models of Airway Epithelial Cells from Patients with Chronic Lung Disease 
The respiratory epithelium forms a critical mucosal barrier at which the body is constantly 
exposed to the external environment. Consequently, AECs are equipped with many complex 
functions that play critical roles in surveying, responding and clearing environmental factors, 
such as infectious agents. To better mechanistically understand many of these functions, 
investigators have commonly used cell culture models of the respiratory epithelium, including 
primary human bronchial epithelial (HBE) cells cultured on porous supports at air-liquid 
interface (ALI) [9, 116, 117]. These models are beneficial to investigators in that they allow the 
specific study of epithelial function in the absence of other cell types, control of experimental 
conditions, and because primary HBE cultures are originally obtained from explanted lungs, they 
closely resemble in vivo physiology when cultured at ALI. In addition to primary HBE cells, and 
driven mostly by the intermittent availability of primary HBE cells, many immortalized cell lines 
have been developed for the study of the respiratory epithelium in chronic lung diseases, 
including CF [118]. Both primary HBE and immortalized cell lines have been critical to our 
understanding of many of the biochemical, genetic, immunological and physiological 
mechanisms that occur at the respiratory epithelium in chronic lung diseases. For example, 
investigators compared primary CF cell cultures to non-CF cells and observed airway surface 
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liquid (ASL) height was decreased in primary CF cells, resulting in reduced reduce mucus 
transport, which is now considered a hallmark of CF lung disease [9].  
1.2.5 Impaired Antiviral Immune Response Contributes to Respiratory Virus-Induced 
CF Exacerbations 
Respiratory viruses cause significant morbidity in patients with chronic lung diseases, but the 
underlying mechanism to explain this clinical observation has not yet been elucidated. Because 
viral load is greater in patients with chronic lung diseases than control patients, the majority of 
studies have focused on mechanisms that contribute to increased viral replication in the 
respiratory epithelium. Although some studies suggest that alterations in interferon (IFN) 
signaling and IFN stimulated gene (ISG) induction may play a role in increased viral replication 
in the CF lung, a clear consensus on this topic has not been reached. Studies using primary AECs 
have shown that primary CF AECs produce reduced levels of antiviral mediators downstream of 
IFN signaling, specifically, nitric oxide synthase 2 (NOS2), 2’ ,5’-oligoadenylate synthetase 1 
(OAS1), and signal transducer and activator of transcription 1 (STAT1), in response to human 
parainfluenza virus 3 (HPIV3) [119]. This results in greater release of infectious virus from CF 
AECs compared to non-CF AECs [119]. Interestingly, similar levels of other known ISGs, such 
as MxA and PKR, were produced in both CF and non-CF cells in response to HPIV3 challenge 
[119]. In addition, a recent clinical study has demonstrated that the lower airway hRV burden is 
greater in patients with CF than in healthy controls and that the greater hRV load in CF patients 
is negatively associated with type I IFN levels in BAL fluid of the patients [120]. These studies 
raise the question of whether CF AECs are inefficient at responding to virus infection and IFN 
induction, have a blunted response to IFN and cannot signal efficiently, or respond to IFN 
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stimulation but do not produce certain ISGs. Recent work has demonstrated that CF AECs 
produce levels of type I and III IFNs similar to those of non-CF AECs in response to either virus 
infection or treatment with the dsRNA analog polyinosine-polycytidylic acid [poly(I:C)] [121-
124]. Although the majority of ISGs that have been investigated thus far are similarly expressed 
in both CF and non-CF cells in response to virus infection, a few notable ISGs have been 
observed to be differentially expressed in CF versus non-CF cells, including MxA, PKR, and 
viperin [119, 121, 124, 125]. So far, these studies have only measured a select subset of ISGs and 
an extensive study comparing the full antiviral response in CF and non-CF AECs has not been 
described yet, leaving open the possibility that many more ISGs are potentially dysregulated 
between CF and non-CF AECs. Viral infections, and the PAMPs produced during viral infection, 
are not the only triggers that induce the production of IFN in AECs. Recently, it was shown that 
bacterial infections and LPS treatment also induced type I and III IFN production in AECs and 
the airways of mice [122, 126, 127]. Although the ability to produce IFNs is similar between CF 
and non-CF AECs during virus infection, induction of type I IFN was reduced in CF cell lines 
compared to non-CF cell lines either infected with P. aeruginosa or treated with LPS [122]. One 
explanation for this defect is that TLR4 surface expression is reduced in CF AECs [128]. Thus, 
defects in the IFN response to stimulus may be attributed to both impaired IFN induction and/or 
reduced expression of a subset of ISGs, but it appears that IFN induction is dependent upon the 
stimulating ligand and signaling pathway triggered in CF AECs. In the context of respiratory 
viral infection, IFN induction appears fully intact, suggesting no defect in dsRNA PRRs or the 
associated signaling pathways. 
It is important to point out that inflammatory cytokine secretion is similar in CF and non-
CF AECs during respiratory viral infection [129]. Thus, the inflammatory response induced by 
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virus infection in CF patients does not contribute to increased morbidity in these patients. 
Because of the negative correlation between virus-induced cytotoxicity and inflammatory 
cytokine production in CF AECs [129, 130], a possible explanation for the lack of an 
exaggerated inflammatory response during viral infection could be the increased virus-induced 
death of AECs in CF. Taken together, these studies suggest that reduced antiviral responses to 
respiratory viral infections result in uncontrolled viral replication and increased viral burden, but 
not exaggerated inflammation, in the CF lung. It appears that ISG induction plays a critical role 
in determining viral burden in the CF lung, which likely has implications for virally-induced 
exacerbations in CF, although a link between the two has not yet been established in vivo. 
Further research will be needed to clearly define what defects exist in antiviral signaling 
pathways in the CF airway. Whether there is an opportunity to design specific therapeutics that 
target these pathways to limit virus infections and can be used to treat virus-induced 
exacerbations in CF patients remains to be seen.  
As in CF patients, the virus loads in asthma and COPD patients are higher following 
respiratory viral infection than in healthy controls [131, 132]. Interestingly, studies with primary 
HBE cultures have demonstrated that the antiviral innate immune response to respiratory virus 
infection is impaired in these patients as well. For example, type I and III IFN induction is 
reduced in primary HBE cells from asthmatics compared to non-asthmatic cells in response to 
hRV infection, and consequently, hRV replication is increased in asthmatic cells [133, 134].  
Moreover, the levels of IFN that are measured in the airways of asthmatic patients are inversely 
correlated with viral loads and exacerbation severity [134]. In contrast, it was recently reported 
that there is no significant difference in hRV replication or type I or III IFN production between 
primary HBE cells from asthmatic patients and healthy controls [135]. One potential explanation 
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for this contradictory result is that primary HBE cells were isolated from patients with well 
controlled asthma in this study, and the authors postulated that defective IFN induction in 
response to respiratory viral infections in asthmatic patients may be a feature of more severe, less 
well controlled disease [135]. Recently, it was shown that suppressor of cytokine signaling 1 
(SOCS1), a negative regulator of the IFN response to respiratory viruses, is upregulated in 
primary HBEs from asthmatic patients, suggesting a potential mechanism for the deficient 
antiviral responses observed during respiratory viral infections in asthma patients [136]. In 
addition, the production of inflammatory mediators and increased neutrophil influx during 
respiratory viral infections in asthma and COPD patients has been reported and likely contributes 
to the pulmonary damage patients experience during viral infections [131, 132]. 
1.2.6 Bacterial Coinfection During Respiratory Viral Infections in Chronic Lung Disease 
Patients 
Beyond the morbidity linked to respiratory viral infections alone, clinical studies have linked 
respiratory viral infections with the development of chronic infections with the Gram-negative 
bacterium P. aeruginosa in CF patients. P. aeruginosa is the most common bacterial pathogen in 
patients with CF and is well known to have deleterious effects on lung function. Seasonal trends 
have been noted in which the majority of patients with CF were initially infected with P. 
aeruginosa during respiratory viral seasons [79]. In addition, up to 85% of new P. aeruginosa 
colonization in CF patients occurred within 3 weeks following a respiratory viral infection [53]. 
In children hospitalized for severe respiratory symptoms in which a respiratory virus was 
identified, 25% of patients were later infected with P. aeruginosa [71]. Overall, 35% of patients 
who were hospitalized for severe respiratory symptoms were colonized with P. aeruginosa with 
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12-60 months, and although in the majority of these patients a respiratory virus was not detected, 
this study did not rely on PCR-based detection methods and likely underestimated the burden of 
respiratory virus infection [71]. In addition, it has been observed that a rise in antipseudomonal 
antibodies is preceded by a viral infection [72]. Although many viruses have been isolated from 
CF patients, RSV has been reported to be the most common respiratory virus associated with the 
development of chronic P. aeruginosa infections in CF patients [72]. However, the mechanisms 
underlying how respiratory viruses enhance the development of chronic infections by P. 
aeruginosa in CF patients remains poorly understood.  
An association between respiratory viral infections and bacterial coinfection has also 
been observed in asthma and COPD patients. Respiratory viral infection (only hRV infections 
were included in analysis) increased the likelihood of bacterial detection, and thus, bacterial 
burden in the upper respiratory tract in children with asthma [137]. Interestingly, both the 
likelihood of bacterial coinfection and bacterial infection within one week following hRV 
infection were increased in this study [137]. In clinical studies of COPD patients, it has been 
observed that up to 60% of patients with a viral infection also have a bacterial coinfection and 
that the presence of a viral infection increases bacterial burden of bacteria already in the lower 
airway [74, 75, 138]. Moreover, in a cohort of COPD patients with hRV-positive exacerbations 
who were negative for bacteria at presentation, 73% became positive for bacteria by day 14 post-
presentation [139]. The relationship between respiratory viral infection and subsequent bacterial 
infections has been further established in studies with experimental hRV infection in patients 
with COPD. In one study, it was shown that hRV infection increased secondary bacterial 
infection in 60% of virally-infected patients whose sputum tested negative for bacterial culture at 
the beginning of the study [140]. Bacteria investigated in this study were Streptococcus 
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penumoniae, Haemophilus influenzae, Moraxella catarrhalis, S. aureus, and Haemophilus 
parainfluenzae. In further studies with this model, it has been observed that hRV infection alters 
the respiratory microbiota in patients with COPD and that these changes are evident up to 42 
days post-hRV infection [141]. This suggests that respiratory viral infection potentially not only 
alters the abundance of what are thought of as traditionally pathogenic bacteria but also the 
overall microbial composition in the airways of COPD patients. Other studies have also made 
similar observations, showing that respiratory viral infection and the resulting antiviral immune 
response can alter the microbiome of the upper respiratory tract [142]. Interestingly, observations 
in asthma, COPD, and CF patients have similarly noted that bacterial acquisition can occur 
following peaks in respiratory virus infection [71, 137, 139]. This suggests that respiratory viral 
infections not only have short-term consequences that predispose patients to secondary bacterial 
infection at the time of viral infection, but also can have long-term consequences on airway 
physiology that makes the airway more permissive for secondary bacterial pathogen after the 
virus has been cleared. Again, very little is understood about the mechanisms underlying how 
respiratory viruses alter airway physiology to promote a more permissive environment for 
secondary bacterial infection. 
1.3 VIRAL-BACTERIAL COINFECTION IN THE RESPIRATORY TRACT 
Studies of viral-bacterial interactions in the respiratory tract have revealed many mechanisms by 
which a preceding virus infection promotes secondary bacterial infection. Many studies have 
focused on the interactions between influenza virus and secondary bacterial infections caused by 
commensal organisms of the upper respiratory tract, namely S. pneumoniae and S. aureus. 
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However, as our understanding of viral-bacterial co-infections continues to grow, it is now 
recognized that respiratory viral infections are associated with severe secondary bacterial 
infections in both acute, such as bacterial pneumonias, as well as chronic, such as CF, pulmonary 
disease settings. Moreover, the field of viral-bacterial co-infections has expanded to investigate 
interactions between diverse viral and bacterial pathogens. Although many mechanisms have 
been described by which viruses predispose the airways to secondary bacterial infection, they 
can be broadly categorized as: (i) the virus augmenting bacterial adherence to the respiratory 
epithelium or (ii) dysregulation of antibacterial immune responses due to viral infection. In this 
dissertation, we focus on the interaction between RSV and P. aeruginosa. Our data provides 
evidence that respiratory viral infection dysregulates nutritional immunity in the airways to 
promote P. aeruginosa biofilm growth, which represents an emerging mechanism by which 
viruses are observed to predispose the airways to secondary bacterial infection. 
1.3.1 Viral Infection Enhances Bacterial Adherence to Airway Epithelial Cells  
Viral infections have been described to increase bacterial attachment to respiratory epithelial 
cells through many distinct mechanisms that may play a role in establishing bacterial infections. 
Moreover, increased binding of bacteria to virus-infected cells does not appear to be dependent 
on any single respiratory virus infection and multiple combinations of bacterial and viral 
pathogens have been described. Respiratory viral infections are known to target ciliated cells and 
damage the respiratory epithelium [143, 144]. This benefits bacterial attachment by (i) impairing 
mucociliary clearance, which increases airway obstruction [145], and (ii) exposing basal cells 
and basement membrane, which provide additional sites where bacteria may readily adhere [146, 
147]. Moreover, RSV infection reduces the periciliary layer depth below the optima height of 7 
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µm required for cilia to beat, which would result in impaired mucociliary transport [10]. Viral 
infection can upregulate the expression of bacterial receptors on host AECs, such as intercellular 
adhesion molecule 1 (ICAM-1), platelet activating factor receptor (PAFR), and α5 integrin [148-
150]. For example, it was shown that influenza virus infection increased TGF-β signaling, which 
was required for augmented surface expression of α5 integrin and bacterial adherence to AECs 
during viral infection, demonstrating that the immune response to respiratory viral infection may 
play a role in upregulation of bacterial receptors on host AECs and bacterial coinfection in the 
respiratory tract [150]. Bacteria can also directly bind to viruses or viral structures on virally-
infected cells, which act as coupling agents to increase bacterial interaction with the respiratory 
epithelium [151-153]. In the case of RSV, the S. pneumoniae penicillin binding protein 1a binds 
to the RSV G proteins, which leads to increased attachment of S. penumoniae to AECs and 
increased virulence in vivo [154]. The magnitude of these effects have been reported to be 
dependent upon cell type and the strain of the viral or bacterial pathogens investigated [148, 
155]. In terms of in vivo infection, the likely explanation for the decreased bacterial clearance 
observed during coinfection in the respiratory tract is due to a combination of all these effects.  
1.3.2 Immunological Alterations in Antibacterial Immunity at the Respiratory 
Epithelium during Respiratory Viral Infection  
The respiratory epithelium is the primary site of viral replication and PRR-mediated detection of 
viral infection results in the production of type I and III IFNs that mediate the antiviral immune 
response. The release of IFNs has been observed to subvert many antibacterial response in the 
airways, and although this response is crucial for viral immunity and clearance, it creates an 
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environment that is unable to control bacterial growth and is predisposed to secondary bacterial 
infection. In a mouse model of influenza infection, type I IFN signaling was shown to be 
responsible for impaired phagocytic chemoattractant production in the airways and as a result, 
decreased macrophage and neutrophil responses during secondary bacterial infection [156, 157]. 
Conversely, in other studies, influenza infection did not lead to decreased neutrophil or 
macrophage recruitment to the airways during bacterial coinfection [158, 159], suggesting that 
mechanisms besides inflammatory cell recruitment likely contribute to diminished bacterial 
clearance. Type I IFN signaling in response to influenza infection was also shown to diminish 
Th17 immunity, including IL-17 and IL-22 production in the airways, resulting in decreased 
production of antimicrobial peptides and increased susceptibility of mice to bacterial infection in 
response to influenza infection [158-160]. Impaired antimicrobial peptide production has also 
been observed in the airway of chinchillas following RSV infection [161]. Interestingly, 
respiratory viral infection increases susceptibility to both Gram-negative (i.e. Escherichia coli 
and P. aeruginosa) and Gram-positive (S. pneumoniae and S. aureus) bacterial pathogens [156, 
159].  As a proof of principle that impairment of bacterial clearance in the airways is due to an 
antiviral immune response, independent of virally-mediated tissue injury or some other alteration 
in host physiology facilitated by viral proteins, it was demonstrated that intranasal administration 
of poly(I:C) was sufficient to induce type I IFNs in the airways and impair bacterial clearance 
from the lungs of animals [162]. Type III IFN production has also been shown to contribute to 
reduced clearance of P. aeruginosa from the airways [127], although the mechanism(s) by which 
type III IFN contributes to inhibition of bacterial clearance during viral-bacterial coinfection are 
even less well understood than those discussed for type I IFNs.  
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Besides inducing the production of type I and III IFNs, the pathways activated by the 
PRRs that sense respiratory viruses also culminate in the expression of pro-inflammatory 
chemokines and cytokines [163]. For example, RSV and hRV infections increase the release of 
the pro-inflammatory cytokine IL-6 and IL-8 from AECs [164, 165]. These signaling pathways 
must be tightly regulated to minimize over-activation and immune-mediated pathology. 
Consequently, these regulatory mechanisms may delay the response to secondary infections in 
the context of coinfections when cells continuously encounter multiple pathogens. In a mouse 
model of influenza infection, it was shown that macrophage and neutrophil recruitment to the 
airways was impaired during secondary S. pneumoniae infection [166]. Interestingly, 
macrophages isolated from influenza-infected mice were hypo-responsive to bacterial ligands in 
this study, but the authors did not provide a mechanism for TLR desensitization and postulated 
that the signaling molecules downstream of TLRs were either downregulated or functionally 
augmented as a result of viral infection [166]. Defects in phagocyte recruitment and function in 
response to respiratory viral infection have also been reported to lead to decreased bacterial 
clearance during coinfection in models of RSV, hRV and other models of influenza infection 
[167-169]. In regards to neutrophils, myeloperoxidase activity was the only functional 
impairment observed in neutrophils during viral-bacterial co-infections in these studies. In 
another study of influenza-S. pneumoniae co-infection, it was observed that there was an 
increased release of the anti-inflammatory cytokine IL-10 into the airways of animals and 
neutralization of IL-10 reduced bacterial burden and lethality [170]. Because the anti-
inflammatory properties of IL-10 can influence the function of various immune cells, it was 
proposed that IL-10 augments the function of phagocytes and create an immunosuppressive state 
in the airways that is permissive to secondary bacterial infection [170]. However, macrophages 
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and neutrophil recruitment to the airways was not impaired during coinfection with influenza and 
S. aureus, and the cells isolated from mice did not demonstrate a defect in phagocytosis [160]. 
Taken together, these studies suggest that respiratory viral infection may delay or impair the 
innate immune response to bacterial infection, creating a permissive environment that can be 
colonized, but the molecular details underlying these observations are still poorly understood and 
further work will be required to understand the intricacies of these interactions that contribute to 
differences observed between studies and models. 
Bacterial infections are also capable of modulating secondary viral infection in the 
respiratory tract. The attachment of hRV is enhanced on cells pretreated with H. influenzae due 
to   increased expression of ICAM-1, the cellular receptor for hRV [171, 172]. In addition, 
preceding bacterial infections may augment the immune response to secondary viral infections. 
For example, antigen presentation is an important process that is needed for an effective adaptive 
immune response to respiratory viral infection and it has been shown that P. aeruginosa can 
disrupt antigen presentation in AECs by altering the trafficking of TAP1 and promoting TAP1 
degradation, resulting in reduced cell surface expression and antigen availability to major 
histocompatibility complex (MHC) class I at the plasma membrane [173]. In addition, AECs 
infected with P. aeruginosa and hRV were observed to have decreased production of type I and 
III IFNs compared to cells infected with hRV alone [121]. Secondary viral infection has also 
been shown to induce dispersion of bacteria from established biofilms [174, 175]. This has 
important implications for our understanding of bacterial transmission in the respiratory tract and 
how bacterial biofilms are established in vivo, but the mechanisms underlying the relationship 
between bacteria and secondary viral infections remain poorly understood and require further 
attention. It is likely that the respiratory epithelium will be critical to these interactions as well. 
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1.4 NUTRITIONAL IMMUNITY 
During the course of infection, the host-pathogen interface is a dynamic environment where the 
multiple interactions ultimately determine whether the host clears or is colonized by the invading 
microorganism. One such interaction is the competition for nutrients. Bacterial pathogens must 
have mechanisms to facilitate their acquisition of nutrients, such as iron, from the environment to 
successfully colonize a host, establish a replicative niche, and survive during the course of 
infection. Conversely, host cells strongly oppose these bacterial processes by restricting nutrient 
accessibility for many different nutrients. Over four decades ago, nutritional immunity was 
originally coined to describe the restriction of iron by the host [176, 177] . At that time, it was 
known from animal models of bacterial infection that exogenous iron supplementation increased 
bacterial growth and virulence. For example, in a mouse model of Yersinia pestis, mice treated 
with 40 µg of ferrous iron were more susceptible to infection and had decreased survival [178]. 
Similar results were subsequently found in models of Listeria monocytogenes, E. coli and P. 
aeruginosa infections [179-181]. Since then, however, extensive studies have begun to identify 
the host mechanisms for limiting iron availability as well as address how microorganisms 
circumvent these mechanisms of nutrient limitation to colonize their hosts and cause disease in a 
number of disease settings [182]. In the field of viral-bacterial co-infections, an emerging body 
of literature demonstrates that an additional mechanism by which virus predispose to secondary 
bacterial infection is by viral subversion of nutritional immunity in the respiratory tract. 
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1.4.1 Host Mechanisms for Withholding Iron 
Iron is essential for numerous physiological processes, including DNA replication, gene 
expression, and energy generation. The utility of iron in many diverse biological processes is due 
to its role as a redox catalyst, where it can cycle between ferrous (Fe2+) or ferric (Fe3+) oxidation 
states. However, the redox potential of iron also makes it conducive to catalyzing the Fenton 
reaction in the presence of reactive oxygen intermediates and generating hydroxyl radicals that 
damage cells. Thus, it is critical that the host not only regulate the quantity and location of iron to 
restrict pathogen accessibility of iron but also limit cellular damage. There are many distinct 
mechanisms by which hosts limit free iron and maintain iron homeostasis.  
Dietary iron uptake is regulated in response to infection or high total body iron levels to 
systemically lower iron levels. Dietary iron is absorbed through enterocytes in the duodenum by 
the iron importer, divalent metal ion transporter (DMT1), after Fe3+ has been converted to Fe2+ 
by ferric reductases present at the apical membrane of enterocytes [182]. DMT1 is also localized 
to the membrane of phagocytes and pumps iron out of the phagosomal compartment to restrict 
access of iron to intracellular pathogens [182]. Once in enterocytes, the iron can either enter the 
labile iron pool, where it is either stored in the iron storage protein ferritin or used for cellular 
processes, or the iron is exported from the cells as Fe2+ into plasma by the iron exporter, 
ferroportin-1 (FPN-1), localized at the basolateral membrane of enterocytes. Ferrioxidases 
convert all Fe2+ released by enterocytes to Fe3+, which is then bound by transferrin and 
transported throughout the body. Hepcidin is a peptide produced in the liver that binds FPN-1 
and promotes its degradation in the lysosome [183]. This results in a loss of basolateral FPN-1 in 
enterocytes, a decrease in overall iron flux into plasma, and a reduction in dietary iron-absorption 
[184]. Because hepcidin is expressed in response to high iron levels in the body or infection, this 
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mechanism of iron limitation results in a hypoferremic response that lowers iron levels 
throughout the host. In addition, hepcidin reduces the levels of cell surface ferroportin and 
promotes iron retention in macrophages [185]. Hepcidin is also produced by neutrophils and 
macrophages in response to infection, suggesting that hepcidin-mediated control of ferroportin 
levels on phagocytes is also regulated in the local environment of an infection [186].   
The majority of human iron is bound to hemoproteins either inside host cells or 
extracellularly. For example, most of the iron in circulation is complexed with heme and heme is 
complexed within hemoglobin inside erythrocytes. Although some pathogens have evolved 
mechanisms to lyse erythrocytes, the host proteins haptoglobin and hemopexin bind free 
hemoglobin and heme, respectively [187]. In addition to its sequestration in erythrocytes, iron is 
stored in ferritin in other cell types, such as AECs. The availability of extracellular iron is 
extremely limited by iron-binding proteins in the extracellular environment, such as members of 
the transferrin family of iron-binding proteins. Typically, transferrin iron saturation is less than 
50%, and as transferrin saturation increases, the ability of transferrin to sequester iron and inhibit 
bacterial growth decreases. Interestingly, in CF patients, transferrin iron saturation is less than 
20% in the majority of patients [23, 188], but the clinical significance of this observation is 
unknown.  
1.4.2 Transferrin 
The transferrin family of iron-binding proteins consist of serum transferrin, lactoferrin and 
ovotransferrin. Due to their ability to sequester iron at the sites of infection, transferrin family 
members have been appreciated to have antimicrobial activity for nearly 7 decades [189]. Serum 
transferrin is a serum glycoprotein that plays a central role in iron metabolism by regulating the 
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transport and delivery of iron to tissues throughout the body. Lactoferrin was originally isolated 
from human milk but has since been found in a wide-range of mucosal secretions [190]. In 
addition to its iron-binding capabilities, lactoferrin has additional antimicrobial properties that 
are derived from the cationic properties of its N-terminus. In particular, lactoferricin and 
lactoferrampin are peptide fragments released from the N-terminus of lactoferrin by proteolytic 
cleavage that exhibit broad antimicrobial activity [191, 192]. Finally, ovotransferrin is the major 
component of egg white and was the first transferrin family protein discovered in 1944 after it 
was recognized a protein component of raw egg white was capable of binding iron and inhibiting 
bacterial growth [193]. 
Transferrin is an approximately 76 kDa serum glycoprotein with a high affinity for iron 
(Kd ∼10-22 M) [194]. Each molecule of transferrin is organized into two lobes (termed C- and N-
lobes), each with an Fe3+-binding sites. Because each molecule of transferrin binds two atoms of 
Fe3+, up to four different species of transferrin may be present at any one time [195]. Transferrin 
is present in mucosal secretions and due to its high affinity for iron, transferrin is very effective 
at binding extracellular iron. This property serves many purposes in the host including: (i) 
sequestration of iron from pathogens, (ii) keeping Fe3+ in an inert redox state to limit free radical 
production, (iii) maintaining Fe3+ in a soluble form in the body (Fe3+ is normally not soluble 
under physiologic conditions), and (iv) facilitating iron transport throughout body. Iron is 
delivered to target cells through a series of steps that are initiated when iron-loaded transferrin 
binds to the transferrin receptor (TfnR) on the plasma membrane of target cells with nanomolar 
affinity (Figure 1) [196]. In polarized epithelial cells, such as AECs, this initial binding event 
takes place at the basolateral membrane. The transferrin-TfnR complex is endocytosed in 
clathrin-coated pits and the pH of the endosome decreases as the endosome matures through the 
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action of ATP-dependent H+ pumps. As the pH decreases, the affinity of transferrin for Fe3+ 
decreases and ultimately Fe3+ is released at the significantly lower pH. Through the action of 
ferric reductases (Steap proteins), Fe3+ is converted to Fe2+ and transported into the cell by 
DMT1 to be stored in ferritin or used for cellular processes. In the acidic environment of the 
endosome, iron-free transferrin (apo-transferrin) remains bound to TfR with high affinity. The 
complex is recycled back to the basolateral membrane and apo-transferrin is released back into 
the serum, likely through a combination of the low (micromolar) affinity of apo-transferrin for 
the TfnR at physiological pH and the competition from iron-loaded transferrin in the serum.  
Due to the presence of transferrin in mucosal secretions and its importance in iron 
trafficking in the host, transferrin represents a potentially significant source of iron for invading 
microorganisms. Consequently, pathogens have evolved mechanisms by which they use 
transferrin as an iron source for growth [197-200]. For the majority of pathogens, the principal 
mechanism by which they acquire iron from transferrin is via the production of siderophores, 
which will be discussed further in the next section in regards to P. aeruginosa iron acquisition. 
Additionally, some pathogens have evolved transferrin uptake systems that are based on 
receptors that directly bind transferrin, including Neisseria meningitidis [201], Recently, it was 
demonstrated that transferrin has undergone rapid evolution in the C-lobe, in sites that overlap 
with the binding site of bacterial transferrin receptors [202]. This indicates that transferrin is 
involved in the evolutionary arms race between host iron sequestration and microbial iron 
acquisition, which has implications for bacterial (and likely other pathogens) colonization, 
virulence, and competition within communities. Furthermore, it has been demonstrated that 
pathogens have the ability to alter host cell physiology, without causing cellular lysis, to increase 
transferrin abundance at the site of infection. For example, in the context of Helicobacter pylori 
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infection of gastrointestinal epithelial cells, the bacteria promoted mislocalization of transferrin 
receptor from the basolateral to apical membrane of cells [203]. As a result, H. pylori increased 
transcytosis and apical secretion of transferrin, which can be utilized by the bacterium for growth 
[199, 203]. However, it is currently unknown how virus infections, including respiratory viral 




Figure 1: Iron Trafficking in Airway Epithelial Cells 
Transferrin binds to ferric iron (Fe3+) and delivers iron to cells throughout the body, including epithelial cells. Iron-
bound transferrin (holo-transferrin) binds to transferrin receptor (TfnR) on the basolateral cell surface and is taken 
up by epithelial cells by clathrin-mediated endocytosis. The resulting acidification of the endosome facilitates 
decreased binding affinity of transferrin for Fe3+. Iron-free transferrin (apo-transferrin) remains bound to its receptor 
at this low pH. Released Fe3+ is reduced to ferrous iron (Fe2+) and transported into the cytosol by DMT1. Apo-
transferrin is recycled back to the basolateral membrane. The low binding affinity of TfnR for apo-transferrin at 
physiological pH releases apo-transferrin into the extracellular environment, where it may bind more Fe3+. Iron is 
then utilized based on the metabolic needs of the cell. Iron can enter the mitochondria where it is incorporated into 
iron-sulfur clusters for use in DNA replication, protein synthesis, redox enzymes involved in metabolism, etc. 
Excess iron not immediately required for use is stored in the intracellular iron-binding protein ferritin. Fe2+ uptake 
and release at the plasma membrane is facilitated by the iron transporters DMT1 and ferroportin, respectively.  
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1.4.3 Pseudomonas aeruginosa Iron Acquisition  
The ability to acquire iron from the environment is essential for P. aeruginosa biofilm growth. 
When P. aeruginosa is grown under iron-limited environments or iron is limited with iron-
chelation molecules, biofilm growth is significantly impaired [27, 37, 43, 204]. Although the 
host innate immune system restricts iron availability to invading microorganisms, P. aeruginosa 
can overcome host-mediated iron limitation and acquire iron, from either heme or nonheme 
sources, through several diverse mechanisms (Figure 2). These strategies can generally be 
categorized as siderophore, heme, and free Fe2+ iron acquisition systems [187]. 
In the natural environment heme is an uncommon iron source and under aerobic 
conditions, such as the airways, iron is oxidized to insoluble Fe3+. In healthy humans, Fe3+ is 
bound to host proteins and has limited bioavailability. Consequently, P. aeruginosa other 
bacteria, and fungi, produce high-affinity Fe3+ binding proteins called siderophores that facilitate 
Fe3+ acquisition and are important for colonization [205]. P. aeruginosa produces two 
siderophores, pyoverdine and pyochelin in response to low-iron. When bound to iron, 
ferripyoverdine and ferripyochelin are first imported into the periplasm of P. aeruginosa by the 
TonB-dependent receptors FpvA and FptA, respectively (Figure 2). ATP-binding cassette 
(ABC) transporters then mediate the transfer the iron across the inner membrane (Figure 2). 
Pyoverdine has an extremely high affinity for iron, higher even than host-iron binding proteins, 
such that it is capable of displacing iron from transferrin [206]. The importance of pyoverdine to 
P. aeruginosa biofilm formation has previously been established; in bacteria unable to produce 
pyoverdine, P. aeruginosa biofilm growth was significantly decreased compared to pyoverdine-
producing bacteria [204]. Pyochelin has a lower affinity for iron than both pyoverdine and 
transferrin, and its appears to be less essential for P. aeruginosa biofilm growth than pyoverdine 
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[204]. P. aeruginosa also has the ability to utilize siderophores from other bacterial species, 
known as xenosiderophores, [205]. The use of these xenosiderophore-based iron uptake 
strategies may be beneficial in the context of multispecies communities where P. aeruginosa 
could steal ferrisiderophores from other bacterial species, but may be detrimental for chelation 
therapies that are based on siderophores produced by bacteria, such as deferoxamine (DSX).  
Although siderophores are critical to iron acquisition, siderophores also play important 
roles as signaling molecules [207]. For example, binding of FpvA by ferripyoverdine 
simultaneously initiates ferripyoverdine uptake and a signaling cascade through the anti-sigma 
factor FpvR, which controls the sigma factor PvdS. Besides the requirement of PvdS for 
expression of pyoverdine biosynthesis genes, PvdS also controls the expression of two secreted 
proteases, endoprotease (PrpL) and alkaline protease (AP) [205, 207]. Both PrpL and AP have 
been shown to degrade transferrin in vitro (Figure 2) [208, 209]. Importantly, transferrin and 
lactoferrin degradation products have been detected in the sputum of CF patients infected with P. 
aeruginosa, indicating that degradation of these host iron-binding proteins may have a role in 
iron acquisition in vivo [210]. It cannot be ruled out that other secreted P. aeruginosa proteases 
or host-derived proteases contributed to the increase in transferrin and lactoferrin degradation 
products in these patients; LasB is another protease secreted by P. aeruginosa that has been 
shown to cleave transferrin in vitro (Figure 2) [211]. 
The majority of iron in the human body is bound to hemoproteins, such as hemoglobin or 
hemopexin, where the iron is incorporated into heme. Although the concentration of free heme is 
low, P. aeruginosa has the capacity to acquire heme via two systems, the Has and Phu systems 
(Figure 2) [205]. In the Has system, a secreted heme-binding protein (HasA) captures heme 
from host-hemoproteins. The heme-HasA protein complex is recognized by the TonB-dependent 
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receptor HasR and the heme is transported into the bacterial periplasm. Conversely, heme is 
directly transported into the periplasm by the TonB-dependent receptor PhuR in the Phu system. 
ABC transporters mediate the transfer of heme from the periplasm to the cytoplasm of P. 
aeruginosa. The Has and Phu systems likely play a minimal role in iron acquisition during initial 
colonization of the CF lung when lung function is still relatively high and lung damage has not 
significantly accumulated. However, later in infection when lung damage has significantly 
accumulated in CF patients, these systems could play an important role in iron acquisition, as the 
sources of iron are likely changing. In support of this hypothesis, longitudinal analyses of 
different CF P. aeruginosa clinical isolates recently demonstrated that pyoverdine production 
decreases in clinical isolates over time, and heme utilization as the sole iron source is more 
efficient by later clinical isolates compared to earlier isolates [212, 213].  
Although Fe2+ iron abundance is relatively low in aerobic environments, Fe2+ is soluble 
and more likely to be present in anaerobic conditions. Recently, it was demonstrated that Fe2+ is 
abundant in the sputum of CF patients, and negatively correlates with disease severity in patients 
[28], suggesting Fe2+ may be a relevant iron source for bacteria in the CF lung. Soluble Fe2+ is 
acquired by P. aeruginosa by the cytoplasmic membrane Fe2+ transporter FeoB (Figure 2) [205]. 
In addition, P. aeruginosa produces redox-cycling compounds called phenazines that can convert 
Fe3+ to Fe2+ (Figure 2) [205]. It has been shown that phenazines are present in CF patient 
sputum, and similarly to Fe2+ levels, are negatively correlated with lung function, suggesting the 
importance of phenazines in vivo [214]. Phenazines have been shown to promote biofilm growth 
by a siderophore-deficient (∆pvdA∆pchE) strain of P. aeruginosa in the presence of Fe3+, as well 
as in the presence of an iron-binding proteins [215]. This last observation is of particular 
relevance as it suggests that phenazines may provide one mechanism by which P. aeruginosa 
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circumvents iron chelation, which has implications for the design and use of chelation-based 




Figure 2: Iron Acquisition Systems in Pseudomonas aeruginosa 
P. aeruginosa produces two siderophores, pyoverdine and pyochelin, that bind to ferric iron (Fe3+). Ferripyoverdine 
and ferripyochelin are imported into the periplasm of the bacterium by the TonB-dependent receptors FpvA and 
FptA, respectively. Pyoverdine has a higher affinity for iron than the host-iron binding protein transferrin (Tfn), and 
thus, can directly outcompete Tfn for Fe3+. Pyochelin has a lower affinity for Fe3+ than Tfn, and does not have this 
ability. P. aeruginosa produces multiple proteases that can cleave Tfn including: AprA, Elastase, PrpL. Cleavage of 
Tfn releases free Fe3+ into the environment to be taken up by either siderophore system. Phenazines produced by P. 
aeruginosa can reduce Fe3+ to ferrous iron (Fe2+), which can be taken up by the P. aeruginosa cytoplasmic 
membrane Fe2+ transporter FeoB. P. aeruginosa can acquire heme-bound iron via two systems, the Has and Phu 
systems. The Has system produces a secreted heme-binding protein (HasA) that captures heme, and is imported into 
the periplasm by the TonB-dependent receptor HasR. The Phu system directly transports heme into the periplasm by 
the TonB-dependent receptor PhuR. ABC transporters are responsible for transporting iron from the periplasm to the 
cytoplasm of P. aeruginosa.  
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1.5 EXTRACELLULAR VESICLES IN VIRAL AND BACTERIAL INFECTIONS 
Cell-to-cell communication is a critical component of cellular physiology that regulates 
appropriate and quick responses to cellular damage and infection, among other functions. 
Extracellular vesicles (EVs) are a form of intercellular communication that have been 
increasingly studied in the context of infectious diseases. EVs are released from most cells and 
are composed of cytosolic proteins and RNA surrounded by a lipid bilayer containing 
transmembrane proteins from the cells that release them. The protective nature of the lipid 
bilayer allows the transfer of functional proteins and RNAs between cells that can change the 
physiology of recipient cells. For example, EVs have been shown to transfer ISGs between 
hepatocytes that protected recipient cells against hepatitis B virus infection [216]. In addition, 
mRNA and microRNA is packaged into EVs, and although the mRNAs can be translated into 
proteins, the majority of studies have focused on the identification of microRNAs and their 
functions in recipient cells [217-219]. Bioactive lipids are also transferred in EVs to recipient 
cells and mediate signaling that alters target cells [220]. For example, prostaglandin E2 
containing EVs were shown to promote natural killer (NK) T cell anergy [221]. Thus, EVs are 
ubiquitously produced messengers, potentially containing numerous bioactive molecules that 
may contribute to host defense or promote pathogenesis during the course of an infection. 
EVs released during an infection can either be host-derived or pathogen-derived. For 
example, Gram-negative bacteria produced outer membrane vesicles (OMVs) that impact both 
bacteria-bacteria and bacteria-host interactions [222]. Recently, Gram-positive bacteria 
membrane vesicles have also been described [223]. In addition, parasites release EVs that 
mediate parasite-parasite and parasite-host interactions [224, 225]. During viral infections, EVs 
are generated by host cells and are thought to have an important role in virus infection, but owing 
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to the biophysical similarities between viruses and EVs, the line between host-derived EV and 
virions is often blurry [217, 226]. 
EVs derived from cells during infection are divided into three categrories: exosomes, and 
microvesicles or ectosomes, and apoptotic-bodies. Originally, EVs were first described during 
studies following the trafficking of TfnR in the context of maturing reticulocytes. The 
distinguishing trait of these EVs were that they originated within endosomal compartments 
referred to as multivesicular endosomes or multivesicular bodies (MVBs) and were subsequently 
released into the extracellular environment following fusion of the MVB with the plasma 
membrane [227, 228]. Because reticulocytes lose TfnR as they mature and TfnR was present on 
these vesicles, it was believed that this was an alternative mechanism by which cells could 
downregulate receptors and dispose of components no longer needed. The term exosome was 
coined a few years following this observation to refer to this population of EVs, which generally 
have a size that is equivalent to that of the vesicles that accumulate in MVBs (less than 150 nm) 
[229]. In the mid-1990’s, however, it was found that these vesicles might have functions 
important for intercellular communication. In one study, it was demonstrated that exosomes 
isolated from B-cells contained major histocompatibility complex (MHC) class II molecules and 
were able to induce T cell proliferation and IL-2 secretion from hybridomas [230]. Additionally, 
it was demonstrated that exosomes isolated from DCs pulsed with tumor peptide could be added 
to mice and reduce the growth of established tumors in vivo [231]. Membrane-derived vesicles 
were also described and suggested to also have a function in intercellular communication around 
the same time [232-235]. Microvesicles or ectosomes are vesicles that bud off the plasma 
membrane with sizes that range from 100 nM to 1 µM [236, 237]. Both microvesices and 
exosomes have similar buoyant density and contain cytoplasmic and membrane-bound molecules 
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(i.e. proteins and RNAs), but there are generally additional protein markers associated with 
exosomes [238, 239].  Apoptotic bodies are larger vesicles up to 4 µM in size, and unlike other 
extracellular vesicles, they contain nuclear fractions (i.e. DNA) and are annexin V-positive [238, 
239]. Because of the overlapping sizes and biophysical characteristics, EVs are defined by their 
cellular origin. Since traditional EV purification methods co-isolate different subtypes of EVs, 
the general term EVs should be used when the intracellular origin of the vesicles has not been 
determined, and functional activity should be attributed to the general vesicle population and not 
to a single subtype of vesicle. 
1.5.1 EV Biogenesis 
Multiple mechanisms have been proposed as essential for EV biogenesis and release. Although 
both exosomes and plasma membrane-derived EVs have been described for approximately the 
same amount of time in the literature, much more is known about the formation of exosomes and 
the topic has been extensively reviewed recently [240, 241]. In all cases, it’s likely that a number 
of key events must take place for EV formation to occur. Notably, mechanisms that regulate lipid 
curvature are essential for budding and release of EVs from membranes. In addition, the proteins 
and other cellular components that are loaded into EVs appear to be regulated, at least at a 
certain level. In the case of an infection, signals that regulate EV formation, either by increasing 
or reducing EV biogenesis and release, are also important to consider. In the case of exosomes, 
many of these pathways have been described, while release of membrane-derived EVs is less 
well understood. 
Endocytic compartments are highly dynamic and regulate the internalization and 
subsequent degradation and/or recycling of transmembrane proteins, such as receptor-ligand 
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complexes, within cells. As endosomes mature to late endosomes, they accumulate intraluminal 
vesicles (ILVs) that are formed as a result of the inward budding of the endosome membrane and 
form MVBs [242]. Fusion of the MVB with the plasma membrane releases these ILVs as 
exosomes. Alternatively, MVBs may fuse with the lysosome, leading to the degradation of the 
ILVs and their components. Both endosomal sorting complex required for transport (ESCRT)-
dependent and ESCRT-independent mechanisms of ILV formation and thus, exosome biogenesis 
have been described [243-245]. ESCRT proteins also play an important role in plasma 
membrane-derived EV release [236], and ESCRT-independent pathways are also beginning to be 
described for membrane-derived EV release [240, 241]. In addition, Rab proteins are regulators 
of vesicular transport between endocytic compartments and the plasma membrane within cells. 
Thus, Rab proteins play an essential role in the decision in whether MVBs are directed to the 
plasma membrane or lysosome, and thus, exosome release. Rab proteins implicated in 
controlling exosome release include Rab11a, Rab27a, Rab27b and Rab35 [246-248]. 
Although many mechanisms have been implicated in EV biogenesis and release, a 
complete understanding of EV formation still has been elusive and it appears that the 
mechanisms thus far described for EV biogenesis may be cell type specific. For example, 
exosome release was reduced from MCF7 breast cancer cells following ALIX (an ESCRT-
associated protein) depletion but not in HeLa cells [243, 249]. Moreover, knockdown of some 
ESCRT components but not others decreases exosome release from cells [243]. The same 
observation has been made when Rab proteins have been examined in EV biogenesis [247]. 
Another paradox of the field is that complete inhibition of EV release from cells is never 
observed in studies when only single (ESCRT -dependent or -independent) pathways are 
inhibited [216, 250]. This suggests that the mechanisms of EV formation are not independent and 
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there is likely overlap in the previously described mechanisms of EV release, and that 
compensatory mechanisms likely exist. Because cellular physiology is altered during the course 
of infections, generally as a result of the pathogen actively manipulating host processes, further 
studies are needed to examine EVs are formed before we can fully understand the importance of 
EVs in the context of an infection and whether EVs are more beneficial to the host or the 
pathogen. 
1.5.2 The Role of EVs in Virus Infections 
EVs share many functional and structural features with viruses that make them extremely 
difficult to separate from viruses, including: (i) the size of the majority of EVs is about the size 
of many RNA viruses (<300 nm), (ii) EVs have a similar buoyant density to some RNA viruses, 
(iii) at least in the case of enveloped viruses, both EVs and viruses contain protein and RNA 
enclosed by a lipid bilayer, (iv) EVs and viruses form at the plasma membrane or at endocytic 
compartments, (v) EVs can bind to receptors on recipient cells and enter via endocytosis, (vi) 
EVs can also fuse with recipient cells, and (vii) EVs can deliver genetic material and other 
functional molecules that can change the physiology of recipient cells [217, 226]. It is likely that 
a population of diverse vesicles are released by cells during a virus infection, and that in the 
absence of techniques that sufficiently separate these vesicles, phenotypes assigned to EVs 
should be attributed to the overall population and not a specific subset of vesicles [226]. Because 
of the similarities outlined above, current techniques make it difficult to separate EVs consisting 
entirely of host cell components, on one extreme, from EVs that carry viral proteins or genomic 
elements but do not consist of all the virus-specific molecules required for infectivity on the 
other extreme [226]. This is different for nonenveloped viruses because they can be separated 
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from EV-enclosed virions and EVs with neutralizing antibodies, but it is likely that a 
heterogeneous population of EVs is still released by cells infected with noneveloped viruses. The 
release of EVs by virus-infected cells has been reported to play various roles in the pathogenesis 
of viral infections that can be categorized as either pro- or antiviral. It is currently unknown if the 
functions described for EVs produced during virus infection can be attributed to any single 
subpopulation of EV within the total EV population. Rather, it is likely that the functional 
characteristics reported thus far in the literature are the net effects of the total EV population.   
1.5.2.1   EV Facilitation of Viral Infection 
Numerous mechanisms have been described whereby EVs contribute to viral infection, but the 
potential pro-viral effects of EVs can be broadly broken into two categories: (i) host evasion or 
(ii) expansion of viral tropism.  
EVs isolated from cells infected with hepatitis C virus (HCV) replicons that do not 
produce structural viral proteins have been shown to contain HCV RNA [251]. In these studies, 
it was demonstrated that HCV RNA is transferred in EVs to naïve cells, where a new infection 
was induced [251, 252]. Because HCV RNA was spread to uninfected cells in these studies and 
was partially resistant to neutralizing antibodies [251-254], it strongly suggests that HCV spread 
in EVs is an immune evasion strategy utilized by the virus that promotes viral spread. This is 
likely a common mechanism by which viruses evade immune recognition and antibody 
neutralization, as others have found that hepatitis A virus (HAV), coxsackievirus B, poliovirus, 
and enterovirus 71 (EV71) are also released in EVs [107-109, 250]. Notably, it has been found 
that enteroviruses are released in phosphatidylserine (PS)-positive EVs originating from the 
autophagosome [107]. PS lipids are well known to be anti-inflammatory and inhibit the 
production of pro-inflammatory cytokine production in macrophages [255, 256]. As a 
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consequence, it has been proposed that PS-positive vesicles containing virus may actively 
attenuate the immune response in macrophages [257]. In addition, viral proteins can be packaged 
into EVs and transferred to uninfected immune cells, where the proteins can modulate the host 
immune responses to virus [217]. 
Besides promoting the spread of virus by protecting viral genomes from immune 
recognition during transmission from an infected cell to an uninfected cell, the packaging of viral 
RNA into EVs may have other biological implications. For example, the packaging of viral RNA 
into EVs may help expand viral tropism and induce viral infection in tissues that would 
otherwise not normally be infected by free virus particles. This was recently demonstrated with 
EV71. Mice were injected with either free-EV71 virions or EVs containing EV71 RNA (EV-
EV71) [250]. The mice that were injected with free EV71 had increased accumulation of viral 
RNA in the brain and intestines, whereas EV71 RNA was significantly more enriched in the liver 
and spleen of animals injected with EV-EV71 [250]. Moreover, EV-EV71 promoted the 
infection in a receptor-independent manner, since EV-EV71 could induce a productive infection 
in a non-permissive cell line that lacked the EV71 receptor [250]. Taken together, these 
observations demonstrate that the accumulation of viral RNA in tissues, and hence overall viral 
tropism, may be expanded when viral RNA is packaged in EVs. While this might suggest that 
viral association with EVs reduces the necessity of viral receptors on host cells for infection, this 
may not always be true and instead may be specific for the subpopulation of EV that is hijacked. 
For example, PS-positive EVs containing poliovirus were highly infective when added to naïve 
cells [107]. However, infection could be inhibited by either addition of a CD155 (poliovirus 
receptor) neutralizing antibody or by masking the PS lipids with Annexin V prior to infection 
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[107]. In the case of EV71, the authors’ data suggested that exosomes and not PS-positive EVs 
were the hijacked vesicle subpopulation [250].  
Despite extensive studies on the role of EVs during viral infections, very little is known 
about the composition and function of EVs to respiratory viral infections. Recently, rhinovirus 
infection was shown to alter the microRNA profile of EVs isolated from the nasal secretions of 
patients [258]. Analysis of the RSV secretome revealed that approximately one third of the total 
proteins secreted from AECs during RSV infection were secreted on EVs [259]. The functional 
consequences of respiratory viral infection on EVs released from AECs is still poorly defined. 
However, it is likely that many of the pro- and antiviral functions previously described for EVs 
will be broadly applicable to EV biology during respiratory viral infection.  
1.5.2.2   Suppression of Viral Infection by EVs 
As previously discussed, studies have shown that HCV RNA can be transferred from infected to 
uninfected cells via EVs [251]. However, the presence of viral genomes in EVs likely represents 
a double-edged sword that, while beneficial to the virus and viral spread, also has been shown to 
prime the immune system to viral infection. For example, it has been shown that EVs can shuttle 
HCV RNA between neighboring cells that triggers IFN-α production in neighboring dendritic 
cells (DCs) [260]. Importantly, the authors observed similar results using subgenomic replicon 
cells that replicate HCV RNA but do not produce infectious virus particles [260]. The presence 
of viral RNAs in EVs has also been reported to stimulate the innate immune response in 
uninfected cells for infections with other viruses, including Epstein-Barr virus (EBV), human 
immunodeficiency virus (HIV), and hepatitis B virus (HBV) [261-263]. For example, EVs 
released by HBV-infected hepatocytes induced NKG2D ligand expression in macrophages [263]. 
NKG2D is an immunoreceptor found on NK cells, and ligation of the receptor by NKG2D 
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ligands, including those expressed on macrophages, are known to activate NK cells and induce 
NK cell-mediated IFN-γ production, which mediates antiviral immunity [264, 265]. Studies also 
suggest that EVs prime the innate immune response to viral infection by other mechanisms that 
do not require transferring viral RNA between cells. Virus-resistant cells have been shown to 
produce EVs containing host miRNA. Delivery of the vesicle-associated miRNAs conferred viral 
resistance to recipient cells, making them resistant to a number of viral infections [266]. In 
addition, it was demonstrated that EVs produced by macrophages treated with type I IFN 
contained antiviral molecules that were transferred to hepatocytes and restricted subsequent 
HBV infection in these cells [216]. These studies imply that antiviral immunity can be 
transferred between cells by two distinct mechanisms: (i) soluble proteins (i.e. IFNs) that rely on 
receptor-mediated signaling to establish an antiviral state within cells, and (ii) the intercellular 
transfer of antiviral molecules to recipient cells via EVs.   
1.5.3 The Role of EVs in Bacterial Infections 
The role of host-derived EVs in bacterial infections is less well understood than with other 
infections. Still, it is now beginning to be appreciated that bacterial infection influences the 
content and function of EVs produced by the host. Although the majority of these studies have 
specifically focused on how mycobacterial infection alters the physiology of EVs produced by 
infected cells, new studies have shown that many similar concepts likely apply to the role of EVs 
in other bacterial infections.  
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1.5.3.1 Compositional and Functional Differences of EVs Isolated during Mycobacterial 
Infections 
Host-derived EVs have the potential to transfer bacterial proteins between mammalian cells, 
much like EVs-derived from virally infected cells. For example, during Mycobacterium 
tuberculosis infection, mycobacterial lipids and proteins are released from the phagosome and 
traffic to late endosomes in macrophages, where they can be loaded on EVs and released into the 
extracellular environment [267, 268]. In addition, EVs isolated from the serum of tuberculosis 
patients were shown to contain mycobacterial proteins, and thus, likely play some role in the 
pathogenesis of M. tuberculosis [269]. In some cases, the transfer of bacterial components leads 
to the stimulation of certain immune responses. For example, EVs isolated from macrophages 
infected with Mycobacterium bovis contain the mycobacterial components lipoarabinomannan 
(LAM) and 19-kDa lipoprotein [270]. Moreover, EVs isolated from the bronchoalveolar lavage 
fluid (BALF) of mice infected with M. bovis also contained LAM and 19-kDa lipoprotein [270]. 
LAM and 19-kDa lipoprotein are components of the mycobacterial cell wall that are well known 
mycobacterial PAMPs, and consequently, have immunomodulatory functions [271-276]. For 
example, it has also been shown that uninfected macrophages secrete pro-inflammatory 
cytokines and chemokines in response to EVs isolated from M. tuberculosis-infected 
macrophages [277]. In addition, uninfected macrophages treated with EVs isolated from M-
tuberculosis-infected macrophages in vitro or from BALF of infected mice induced a pro-
inflammatory response in uninfected macrophages, measured by TNF-α production [270]. This 
response is primarily driven by the presence of 19-kDa lipoprotein, as extracellular vesicles 
isolated from macrophages infected with a knockout strain of M. tuberculosis that lacks 19-kDa 
lipoprotein fails to induce such responses [278].  
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Proteomic analysis has also identified many other mycobacterial proteins on EVs isolated 
from monocytes infected with M. tuberculosis, as well as changes in the composition of host 
proteins on EVs isolated from these infected monocytes [279, 280]. These changes may also play 
roles in the immune responses generated by EVs isolated from monocytes, but this has not yet 
been investigated. It is important to note that many of the EV purification methods will isolate 
both host-derived, as well as bacterial-derived membrane vesicles during bacterial infection. 
Hence, many of the observations that report changes in EV composition or function during 
bacterial infection could be the net result of a mixed population of host- and bacterial-derived 
EVs. In support of this hypothesis, it was recently shown that M. tuberculosis-infected 
macrophages release two distinct EV populations; one population contains host proteins 
classically used to identify EVs, while the other population contains M. tuberculosis molecules 
[281]. It was the vesicle population that contains molecules from the bacteria that elicit an 
immune response in uninfected macrophages [281], suggesting that bacterial-derived and not 
host-derived EVs transport mycobacterial proteins between cells to drive immune response in 
uninfected cells. However, it has been observed that EVs isolated from macrophages treated with 
M. tuberculosis culture filtrate proteins (CFP) contained mycobacterial proteins, namely 19-kDa 
lipoprotein, and induced a more predominate Th1 response in mice treated with the EVs 
compared to BCG treated mice, as measured by flow cytometry  [282]. This provided evidence 
that mycobacterial proteins can be loaded onto host-derived EVs, even in the absence of bacterial 
infection in the EV-producing cell, and that host-derived EVs can stimulate immune responses. 
Conversely, EVs isolated from M. tuberculosis-infected macrophages did not activate Th1 CD4+ 
T cells in vitro [283]. Because both host-derived and bacterial-derived EVs are released from M. 
tuberculosis-infected macrophages, these observations suggest that the bacterial-derived vesicles 
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contain molecules that that inhibit T cell responses. Taken together, these studies suggest that at 
least two distinct subpopulations of EVs are produced during M. tuberculosis infection, which 
promote disparate immune responses.  
As has previously been described here, Rab27a may play an important role in EV 
biogenesis. Recently, it has been demonstrated that EVs isolated by M. tuberculosis-infected 
Rab27a-deficient macrophages produced less vesicles than wild type macrophages [284]. EVs 
isolated from Rab27a-deficient macrophages infected with M. tuberculosis induced a decreased 
pro-inflammatory response in uninfected cells compared to the response induced by EVs from 
wild type macrophages [284]. Ag85A has previously been identified on EVs produced by 
macrophages infected with M. tuberculosis [279]. Both Rab27a-deficient and wild type mice 
were infected with M. bovis expressing a DsRed-Ag85A conjugate and the number of DsRed-
specific T cells were measured. Interestingly, T cells from Rab27a-deficient animals produced 
less INF-γ in response to ex vivo stimulation with DsRed compared to T cells from WT animals 
[284]. One interpretation of this result is that host-derived EVs are important for inducing a pro-
inflammatory response and activating T cells during M. tuberculosis infection and that depletion 
of EVs impairs one mechanism by which antigens are presented to the immune system. 
However, in light of the other studies presented here, another possible interpretation of this 
observation is that the balance between pro-inflammatory host-derived EVs and immune-
dampening bacterial vesicles has been skewed, and bacterial-derived EVs have a greater 
influence on the immune system than host-derived EVs. Whether this is the case is unknown, but 
further highlights a challenge of the field moving forward will be to discriminate between host- 
and bacterial-derived EVs. In the case of M. tuberculosis infection this could have important 
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implications, namely do variations in EV production and EV-mediated antigen presentation 
predict disease outcome (i.e. latent versus active disease).  
1.5.3.2 The Role of EVs in Other Bacterial Infections  
Host-derived EVs have been shown to also be secreted from cells during the course of infection 
by a number of other bacterial pathogens besides mycobacteria. For example, Neisseria 
gonorrhoeae increases the secretion of cIAP2 on EVs derived from endocervical epithelial cells 
[285]. cIAP2 is an inhibitor of apoptosis protein (IAP) with E3 ubiquitin ligase function that 
regulates apoptosis, necroptosis, and RIPK1 signaling [286, 287], and the importance of cIAP2 
secretion on EVs has not been established. It is known that deletion of cIAP2 results in increased 
cell death in the context of both bacterial and viral infections [288, 289]. Because cIAP2 release 
on EVs corresponded to depletion of intracellular cIAp2 and cell death during N. gonorrhoeae 
infection, it has been speculated this is a host defense mechanism by which cells promote cell 
death during bacterial infection. However, this may also be a process co-opted by N. 
gonorrhoeae to transfer cIAP2 between cells to prevent highly inflammatory cell death during 
bacterial infection. Additionally, EVs isolated from Legionella pneumophila-infected 
macrophages stimulate a robust pro-inflammatory response in uninfected macrophages [290]. 
Interestingly, when host-derived EVs were depleted, either by blocking their release with neutral 
sphingomyelinase (SMase) inhibitor GW4869 or by depletion using CD63 immunoprecipitation, 
uninfected macrophages still responded to EVs [290]. Taken together, these results also suggest 
that host-derived and bacterial-derived EVs may contribute to the host response to bacterial 
infection, as was discussed during mycobacterial infection.  
In the case of some bacterial infections, EVs released by host cells during the course of 
infection have not been shown to interact with the immune system, but have other roles that 
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contribute to bacterial pathogenesis. One example is the ability of EVs to transfer bacterial toxins 
between host cells. Anthrax lethal toxin is an A-B toxin and a virulence factor produced by 
Bacillus anthracis, composed of three protein subunits know as protective antigen (PA), lethal 
factor 9LF) and edema factor (EF). The PA subunit is involved in cell binding, while the other 
two protein subunits contain enzymatic activity of the toxin. LF is a protease that targets MAPK 
kinases [291]. It has been shown that PA is found on ILVs and interestingly, disruption of ILV 
formation via ALIX knockdown by RNA interference (RNAi) resulted in increased association 
of LF with endosomes and delayed cleavage of MAPK kinases in cells treated with PA and LF 
[292]. Because MAPK kinase cleavage is also dependent upon transport of LF to late 
endosomes, it was hypothesized that LF could be loaded into ILVs. This hypothesis was recently 
confirmed and extended to show that EVs released from host cells deliver LF into naïve cells 
[293]. In addition, it has been shown that EVs released from cells treated with Clostridium 
perfringens enterotoxin (CPE) or S. aureus α-toxin contain these toxins, but it was not observed 
that the toxins were transferred to mammalian cells [294, 295]. Importantly, all these studies 
were performed with purified toxin, in the absence of live bacteria, suggesting that the EVs being 
studied were purely host-derived. This excluded the possibility that toxin-loaded bacterial EVs 
“contaminated” the EV populations being investigated and therefore, did not contribute to the 
observations. Overall, the loading of bacterial toxins onto host-derived EVs could be a common 
phenomenon during bacterial infections, but further investigation will be required to understand 
the significance of this observation and whether this is beneficial to the bacterial infection or 
host.  
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1.5.4 Bacterial-Derived Outer Membrane Vesicles 
Both Gram-negative and Gram-positive bacteria have been described to release vesicles into the 
extracellular environment [222, 223]. As discussed above, these bacterial-derived vesicles are 
potentially co-purified with host-derived EVs. Thus, further studies will be essential to determine 
the relative contribution of host EVs and bacterial EVs to many of the functions described above. 
Because these vesicles contain bioactive proteins, many of which are virulence factors, they have 
many functions that are critical to bacteria-bacteria and bacteria-host interactions. For example, 
OMVs produced by P. aeruginosa have been shown to contain many bacterial toxins, including 
CFTR inhibitory factor (Cif) [296]. Studies have shown that OMVs fuse with host cells, 
delivering Cif to the cytoplasm of host cells and induces the degradation of CFTR as well as 
TAP1 [173, 296, 297]. TAP1 plays a key role in antigen presentation, and therefore, degradation 
of TAP1 has important implications for adaptive immunity. It has been proposed that OMVs are 
a source of iron that can be utilized by bacteria for growth [298, 299], although it is unknown if 
OMVs produced by one bacterial species can be utilized by a second bacterial species. 
Additionally, data suggest that OMVs also contribute to bacterial defense by acting as decoys for 
antimicrobial peptides and bacteriophages, thereby promoting bacterial survival in the presence 
of potential antibacterial factors that target the outer membrane of Gram-negative bacteria [300]. 
Thus, OMVs and other bacterial-derived vesicles have many functions that affect host 
physiology and promote bacterial survival. Whether these vesicles will be useful for vaccines or 
other therapeutics because of the many potential antigens and PAMPs associated with them is an 
area that will require future investigation.    
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1.6 SUMMARY 
Although our fundamental understanding of viral-bacterial interactions in the airways is rapidly 
increasing, there is still very little understood about the underlying mechanisms for the clinical 
observation that respiratory viral infections are associated with P. aeruginosa colonization in the 
CF lung. In this dissertation, I report that RSV infection stimulates P. aeruginosa biofilm growth 
through the release of iron and the host-iron binding protein transferrin. Iron levels are increased 
in the CF airway, and this is the first study to directly demonstrate that respiratory viral infection 
is one mechanism by which iron levels are increased in the CF lung. In addition, I extend these 
studies to show that EVs released by AECs during RSV infection promote P. aeruginosa biofilm 
formation, and that iron-loaded transferrin is bound to the outside of EVs were it may be utilized 
by P. aeruginosa as an iron source. Taken together, the findings in this dissertation have greatly 
improved our understanding of viral-bacterial co-infections in the respiratory tract, providing 
evidence that nutritional immunity is at the interface of viral-bacterial interactions in the airways, 
as well as increasing our understanding for how the host contributes to chronic bacterial 
infections in the lung. 
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2.0  MATERIALS AND METHODS 
2.1 MATERIALS 
2.1.1 Cell Culture and Reagents 
The immortalized human CF bronchial epithelial cell line CFBE41o- (herein referred to as 
“CFBEs”), derived from a ∆F508 homozygous CF patient, were generously provided by Dr. J.P. 
Clancy (University of Cincinnati). CFBE cells were cultured in MEM (Thermo Fisher, Catalog 
number: 11095098) supplemented with 10% fetal bovine serum (FBS; Gemini Bio-Products, 
Catalog number: 100-106), 2 mM L-glutamine (Fisher Scientific, Catalog number: MT2500Cl) 
and 5 U/mL penicillin-5 µg/mL streptomycin (Sigma Aldrich, Catalog number: P0781) and 0.5 
µg/mL Plasmocin prophylactic (InvivoGen, Catalog number: ant-mpp). Cells were seeded as 
monolayers onto transwell inserts with 0.4 µM pore size (Corning Life Sciences), coated with 
collagen and fibronectin, at the densities listed in Table 2 and grown at air-liquid interface (ALI) 
at 37°C and 5% CO2 for 7-10 days to allow cell polarization before assays were performed. In all 
experiments where apical secretions (referred to as conditioned media) were collected, MEM 
was added to the apical compartment of CFBE41o- cells at the volumes indicated in Table 2.  
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Growth Area (cm2) 




6.5 0.33 7.5 x 104 0.1 
12 1.12 2.5 x 105 0.5 
24 4.67 1 x 106 1 
75 44 4 x 106 5 
 
In biotic biofilm imaging experiments, CFBEs were seeded onto 40 mm glass coverslips 
(Bioptechs) at a density of 3 x 106 cell per coverslip and cultured for 7-10 days prior to use. 
Primary CF and non-CF human bronchial epithelial cells (HBEs) were obtained from the 
explanted lungs of CF and non-CF patients in accordance with protocols approved by the 
Institutional Review Board (IRB) of the University of Pittsburgh. Primary HBE cells were 
seeded on 6.5 mm transwell inserts with 0.4 µM pore size (Corning Life Sciences) at 2.5 x 105 
cells per filter and cultured for 4-6 weeks at air-liquid interface at 37°C and 5% CO2, prior to use 
to allow for differentiation.  
2.1.2 Bacterial and Viral Strains 
Pseudomonas aeruginosa strain PAO1 carrying the pSMC21 plasmid that constitutively 
expresses green fluorescent protein (GFP; kind gift from Dr. George O’Toole, Geisel School of 
Medicine at Dartmouth) was used for these studies.   
The following viruses were studied: respiratory syncytial virus (RSV) line A2, human 
rhinovirus serotype 14 (hRV14), human adenovirus serotype 5 (Ad5) and human 
metapneumovirus subgroup A2 (hMPV). hRV14 and Ad5 were kind gifts from Dr. Carolyn 
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Coyne (University of Pittsburgh) and hMPV was generously provided by Dr. John Williams 
(University of Pittsburgh School of Medicine).  
2.1.3 Quantitative Reverse Transcriptase PCR Primers 
Primers used in qPCR assays were purchased from Sigma Aldrich and are listed in Table 3.   
 
Table 3: qPCR Primers 
Gene Primer Sequence (5’-3’) 
Adv5 Forward Reverse 
CAG CGT AGC CCC GAT GTA A 
TTT TTG AGC AGC ACC TTG CA 
G3PDH Forward Reverse 
CGA CCA CTT TGT CAA GCT CA 
AGG GGA GAT TCA GTG TGG TG 
hRV14 Forward Reverse 
GGC GCC ATA TCC AAT GGT GT 
TCC ACC TGA TCG AAC GTC CA 
IFN-β Forward Reverse 
GAG CTA CAA CTT GCT TGG ATT CC 
CAA GCC TCC CAT TCA ATT GC 
IFN-λ1 Forward Reverse 
CGC CTT GGA AGA GTC ACT CA 
GAA GCC TCA GGT CCC AAT TC 
ISG56 Forward Reverse 
TTC GGA GAA AGG CAT TAG A 
TCC AGG GCT TCA TTC ATA T 
RSV Forward Reverse 
GCT CTT AGC AAA GTC AAG TTG AAT GA 
TGC TCC GTT GGA TGG TGT ATT 
 
2.1.4 Antibodies 
The primary antibodies used for western blot analysis are listed in Table 4. Secondary antibodies 
used included goat anti-mouse HRP conjugate (Bio-Rad, Catalog number: 172-1011), goat anti-




Table 4: Primary Antibodies 
Protein of Interest Company Catalog Number Dilution 
Actin BD Biosciences 612656 1:500 
Albumin (Mouse) GeneTex GTX77024 1:1000 
ALIX EMD Millipore ABC40 1:500 
Calnexin Santa Cruz Biotechnology sc-70481 1:100 
CD81 Thermo Fisher PA5-13582 1:250 
DMT1 EMD Millipore ABS983 1:500 
Ezrin BD Biosciences 610603 1:100 
Ferritin Abcam ab75972 1:500 
Ferroportin-1 EMD Millipore ABS1021 1:500 
Flotillin-1 BD Bioscience 610820 1:500 
GM130 BD Biosciences 610822 1:100 
Hsp90 Enzo Life Sciences ADI-SPA-830 1:500 
IL-28Rα GeneTex GTX46261 1:500 
Lactoferrin Santa Cruz Biotechnology sc-25622 1:500 
MHC Class I LifeSpan Biosciences LS-C107394 1:1000 
RSV Meridian Life Science, Inc. B65840G 1:1000 
Transferrin (Human) Santa Cruz Biotechnology sc-52256 1:250 
Transferrin (Mouse) GeneTex GTX77131 1:500 
Transferrin Receptor BD Biosciences 612125 1:500 
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Tsg101 GeneTex GTX70255 1:500 
 
The antibodies used for immunoprecipitation experiments were: rabbit anti-transferrin 
(Abcam, Catalog number: ab1223) and rabbit anti-GFP (Santa Cruz Biotechnology, Catalog 
number: sc-8334).  
2.1.5 Cytokines 
Human IFN-β was acquired from PBL Assay Science (Catalog number: 11415-1). Human IFN-
λ1 (IL-29) was purchased from R&D Systems (Catalog number: 1598-IL-25) and reconstituted 
in PBS containing carrier protein (0.1% BSA).  
2.1.6 Small Interfering RNA (siRNA) 
FlexiTube siRNA targeting IL-28Rα was acquired from Qiagen and MISSION siRNA universal 
negative control (negative control) was acquired from Sigma Aldrich. The siRNAs were used at 
a final concentration of 15 nM following dilution in HiPerfect transfection reagent (Qiagen, 
Catalog number: 301705) and 1x OptiMEM Reduced Serum Media + GlutaMAX supplement 





Table 5: Commercial siRNAs 
Gene Symbol Organism Catalog Number 
IL-28Rα Human SI03076521 
Universal Negative Control Human, Mouse, Rat SIC001 
 
2.2 METHODS 
2.2.1 Virus Infections 
For all virus infections, the apical and basolateral compartments of CFBE cells or primary CF 
and non-CF HBEs were washed in MEM supplemented with 2 mM L-glutamine two times. The 
media in the basolateral chamber of the transwell was replaced with MEM supplemented with 
10% FBS and 2 mM L-glutamine (antibiotic-free growth media). 
Stocks of RSV were prepared from and virus titers were determined by plaque assay on 
NY3.2 cells, an immortalized murine fibroblast cell line from STAT1-/- mice [301, 302]. For 
virus infection, CFBE or primary CF and non-CF HBE cells were inoculated with RSV 
[multiplicity of infection (MOI) of seeded cells = 1, unless otherwise noted] diluted in MEM, no 
phenol red (Thermo Fisher, Catalog number: 51200038), supplemented with 2 mM L-glutamine. 
Cells were placed at 37°C, 5% CO2 for 2 hours before the apical media was removed and cells 
were maintained at ALI. Infections were allowed to proceed for 72 hours. After 72 hours 
monolayer integrity was compromised. 
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Stocks of Ad5 and hRV14 were obtained from Dr. Carolyn Coyne, where viruses where 
expanded and tittered in HeLa cells. For virus infections, CFBE cells were washed and 
inoculated with Ad5 (MOI=1) or hRV (MOI=1, unless otherwise noted) diluted in MEM 
supplemented with 2 mM L-glutamine. Virus was prebound to cells for 2 hours at 4°C and any 
unattached virus was washed away. Infections were allowed to proceed for 24 hours before 
cellular monolayers were disrupted.  
Stocks of hMPV was acquired from Dr. John Williams, where stocks were prepared and 
tittered in LLC-MK2 cells [303]. For virus infections, CFBE cells were inoculated with hMPV 
(MOI=1) diluted in MEM supplemented with 2 mM L-glutamine. As with RSV, cells were 
placed at 37°C, 5% CO2 for 2 hours before the apical media was removed and cells were cultured 
for 72 hours. 
2.2.2 Pseudomonas aeruginosa Culture 
For all bacterial infections, overnight cultures of P. aeruginosa were grown at 37°C in Lysogeny 
Broth (LB) with continuous agitation. 
2.2.3 Biotic Biofilm Imaging 
Live cell imaging was used as previously described to image bacterial biofilm growth on 
epithelial cells in the presence or absence of virus infection (Figure 3) [27, 304, 305].  Briefly, 
CFBE cells were seeded onto 40 mm glass coverslips (Bioptechs) as described in Section 2.1.1 
and infected with RSV for 24 hours before epithelial cell nuclei were stained with Hoechst 
33342 (Thermo Fisher, Catalog number: H3570). Immediately after Hoechst staining, cells were 
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transferred into a FCS2 closed system, live-cell micro-observation chamber (Bioptechs), 
assembled according to the manufacturer’s instructions, and mounted on the stage of a Nikon Ti-
inverted microscope (Figure 2.1). In this system, MEM (no phenol red) supplemented with 2 
mM L-glutamine maintained at 37°C, 5% CO2 is continuously perfused at a flow rate of 50 
mL/hour across cells using a peristaltic pump, to simulate mucociliary movement in the airways. 
For bacterial infections, cells were infected with GFP expressing PAO1 (MOI=25, PAO1-GFP) 
via injection of PAO1-GFP into the chamber through a two-way valve. Bacteria were allowed to 
attach for 2 hours in the absence of media perfusion. Biofilms were then grown for 4 hours in the 
presence of perfusion. After a total of 6 hour PAO1-GFP infections, z-stack images of 6-10 
random fields from each flow chamber were acquired and bacterial biofilm biomass was 
quantified using COMSTAT image analysis software, as described previously [305].  
For attachment assays, P. aeruginosa attachment on CFBE cells was imaged after 1 hour 
of bacterial infection with PAO1-GFP in the absence of perfusion. Bacterial counts were 






Figure 3: The setup for live-cell biotic biofilm imaging.  
A FCS2 closed system, live-cell micro-observation chamber is placed on the stage of a Nikon Ti-inverted 
microscope. Enlargement: Cross-sectional view of the micro-observation chamber indicating the location of airway 
epithelial cells (AECs) in relation to PAO1-GFP biofilm growth and media perfusion within chamber.  
 
2.2.4 Static Co-culture Biotic Biofilm Assay 
For static co-culture biotic biofilm infection experiments, CFBE or primary CF and non-CF cells 
were infected with viruses as described in Section 2.2.1. Overnight cultures of P. aeruginosa 
were washed twice in MEM supplemented with 2 mM L-glutamine and the optical density at 600 
nm (OD600) was measured using a SpectraMax M2 Microplate Reader (Molecular Devices) and 
normalized to OD600 = 0.5 in MEM supplemented with 2 mM L-glutamine. For bacterial 
infections, cells were inoculated with OD600 normalized P. aeruginosa diluted in MEM 
supplemented with 2 mM L-glutamine. The total volume of media added to the apical 
compartment of cells is listed in Table 2 and the volume of OD600 normalized P. aeruginosa is 
listed in Table 6 for different transwell insert sizes used. These inoculation volumes correspond 
to a MOI of 25 on the respective transwell insert sizes. Bacteria were allowed to attach for 1 
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hour, after which unattached bacteria were removed and the apical media was replaced with 
MEM supplemented with 2 mM L-glutamine and 0.4% L-arginine. Biofilms were then grown for 
an additional 5 hours. After a total of 6 hour P. aeruginosa infections, apical media was 
discarded and cells were washed twice with MEM supplemented with 2 mM L-glutamine to 
remove unattached bacteria. Biofilms were disrupted and collected in MEM supplemented with 2 
mM L-glutamine and 0.1% Trition X-100 (Bio-Rad, Catalog number: 1610407). Colony-forming 
units (CFU) were determined by plating serial dilutions of bacteria on LB agar plates. The 
plating was carried out by plating 10 µL aliquots of these dilutions using the track-dilution 
method [306, 307]. These plates were incubated overnight at 37°C and then counted. CFU counts 
were divided by insert membrane growth area listed in Table 2 to normalize bacterial counts 
between transwell insert.  
 
Table 6: Properties of Transwell Inserts for Static Co-culture Biotic Biofilm Assays 
Insert Diameter (mm) Density of CFBE41o- Seeded (cells/insert) 
Volume of OD600 
Normalized (OD600 = 0.5) 
P. aeruginosa Used (µL) 
6.5 7.5 x 104 2 
12 2.5 x 105 7 
24 1 x 106 28 
 
2.2.5 Conditioned Media Collection 
CFBE or primary CF and non-CF cells were infected with RSV as described in Section 2.2.1. At 
48 hours post-infection (hpi), MEM (no phenol red) supplemented with 2 mM L-gluatamine 
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were added to the apical compartment for the final 24 hours of virus infection to collect apical 
secretions from cells. The volume of MEM added to the apical compartment is listed in Table 2. 
At the end of 72 hour virus infection, apical airway surface liquid [herein referred to as 
“condition media” (CM)] was collected and centrifuged at 1,400 x g for 3 minutes to remove cell 
debris.  
2.2.6 Extracellular Vesicle Isolation 
For experiments with extracellular vesicles, CFBE cells were seeded onto 75 mm transwell 
inserts at a density of 4 x 106 cells/insert and infected with viruses as described in Section 2.2.1 
and cultured in MEM supplemented with 10% exosome-depleted FBS (Systems Biosciences, 
Catalog number: EXO-FBS-250A-1) and 2 mM L-glutamine added to the basolateral 
compartment of the transwell insert. Extracellular vesicles were isolated from conditioned media 
of CFBE cells using differential ultracentrifugation, as described previously (Figure 4) [308-
311]. Briefly, CM collected from CFBE cells was centrifuged at 1,400 x g for 3 minutes to pellet 
cells. Supernatants were centrifuged at 10,000 x g for 30 minutes, transferred to new tubes and 
filtered through syringe filter unit, 0.22 µm pore size (Millipore, Catalog number: SLGV033RS). 
The filtrate was centrifuged for 90 minutes at 100,000 x g in a Optima L-90k Ultracentrifuge 
with a SW-60Ti rotor (Beckman Coulter). All pellets were resuspended in 1 mL MEM, no 
phenol red, supplemented with 2 mM L-glutamine.  
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Figure 4: Flow chart for extracellular vesicle isolation from CFBE cells. 
The length and speed of each centrifuge spin are indicated. Pellets from the first spins are discarded and the 
supernatants are kept for the next step. In the last spin, supernatants are discarded and pellets are kept.  
 
2.2.7 Static Abiotic Biofilm Assay 
For static abiotic biofilm assays, CM or extracellular vesicles were isolated as described in the 
sections 2.2.4 and 2.2.5. Overnight cultures of P. aeruginosa expressing GFP (PAO1-GFP) were 
washed twice in MEM supplemented with 2 mM L-glutamine and the optical density at 600 nm 
(OD600) was measured using a SpectraMax M2 Microplate Reader (Molecular Devices). Cultures 
were normalized to OD600 = 0.5 and added to CM or extracellular vesicles supplemented with 
 69 
0.4% L-arginine in a volume of 7 µL. Biofilms were grown for 6 hours on 35 mm uncoated 
glass-bottom dishes (MatTek Corporation, Catalog number: P35G-1.0-14-C) at 37°C, 5% CO2. 
After 6 h hours, biofilms were fixed in 2.5% glutaraldehyde overnight at 4°C and washed one 
time in phosphate buffered saline (PBS) the next morning. Z-stacks images of at least 10 random 
images were taken for each dish using a Nikon Ti-inverted microscope. Nikon Elements Imaging 
Software version 4.11 was used to measure biofilm volume and substratum area. Biofilm 
biomass was calculated as the biofilm volume divided by substratum area.   
For attachment assays in static conditions, P. aeruginosa attachment on glass was imaged 
1 hour following the addition of OD600 normalized PAO1-GFP to extracellular vesicles in glass-
bottom dishes. Bacterial counts were measured using Nikon Elements Imaging Software version 
4.11.  
2.2.8 96-Well Microtiter Biofilm Assay 
Biofilm growth on plastic microtiter dishes was performed as previously described [312, 313], 
with minor modifications. Briefly, biofilms were grown in 96-well round bottom plates 
(Corning, Catalog number: 2797) after the addition of approximately 108 CFU P. aeruginosa 
into the indicated growth conditions for 24 hours at 37°C, 5% CO2. Biofilm growth was 
quantified by crystal violet staining as measured by absorbance at 550 nm. Absorbance readings 
were measured by a SpectraMax M2 Microplate Reader (Molecular Devices).  
 70 
2.2.9 IFN Treatment 
Cells were washed twice with MEM supplemented with 2 mM L-glutamine. IFN-β or IFN-λ 
were diluted in MEM supplemented with 2 mM L-glutamine to a final concentration of 1000 
U/mL or 100 ng/mL, respectively. Unless otherwise specified, IFN-β was added to the 
basolateral compartment of cells for 18 hours and IFN-λ was added to the apical compartment of 
cells for 12 hours.  
2.2.10 mRNA Extraction and qPCR 
Total RNA from cells was extracted using the RNeasy Mini Kit (Qiagen), according to the 
manufacturer’s instructions. RNA concentration was measured using a nanodrop. 
Complementary DNA (cDNA) synthesis was performed with iScript cDNA Synthesis Kit (Bio-
Rad). Gene expression was evaluated using quantitative real-time PCR (qPCR) with iQ SYBR 
Green Supermix (Bio-Rad). PCR reactions were performed on a StepOne Real-Time PCR 
System (ThermoFisher). The abundance of mRNAs of interest (Primers listed in Table 3) were 
normalized to GAPDH.  
2.2.11 ELISA 
To measure apical secretion of IFN-β and IFN-λ, CM was collected from CFBE cells infected 
with RSV as outlined in Section 2.2.5 and frozen at -80°C until analyzed. IFN-β and IFN-λ (IL-
29/IL-28B) concentrations were measured using the Human IFN-β ELISA Kit (R&D Systems, 
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Catalog number: 41410-1) and Human IL-29/IL-28B DuoSet ELISA Kit (R&D Systems, 
Catalog number: DY1598B), according to the manufacturer’s instructions. 
2.2.12 Western Blot Analysis (Immunoblot) 
Total protein concentration of all samples was determined using the Pierce 660 nm Protein Assay 
Kit (Thermo Fisher, Catalog number: 22662). Equal amounts of protein were loaded for analysis 
on Mini-PROTEAN TGX Precast Gels (Bio-Rad). Protein was transferred onto PVDF 
membranes using a Trans-Blot Turbo Transfer System (Bio-Rad, Catalog number: 1704150) and 
Trans-Blot Turbo PVDF Transfer Packs (Bio-Rad, Catalog number: 1704157). Antibodies used 
are listed in Table 3. Antibodies were diluted in PBS supplemented with 0.1% bovine serum 
albumin Fraction V (ThermoFisher, Catalog number: 15260037) at the concentration indicated in 
Table 3. Western Lightning ECL Pro (PerkinElmer, Catalog number: NEL122001EA) was used 
to develop blots. ImageJ software was used for densitometry on scanned blots. 
2.2.13 siRNA Transfection 
FlexiTube siRNA targeting IL-28Rα was used to selectively reduce protein expression of IL-
28Rα, by methods described previously [297]. Briefly, MISSION siRNA universal negative 
control served as negative control for siRNA experiments. For siRNA transfection, CFBE cells 
were seeded on 24 mm transwell inserts at a density of 1 x 105 cells/insert. On day 3, post-
seeding, cells were transfected with 15 nM siRNAs using HiPerfect transfection reagent 
(Qiagen), according to the manufacturer’s protocol. 1x OptiMEM Reduced Serum Media + 
GlutaMAX supplement was used as culture media during transfections. After 24 hours, apical 
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and basolateral media were removed and cells were cultured at ALI at 37°C and 5% CO2 in 
MEM supplemented with 10% FBS, 2 mM L-glutamine, 5 U/mL penicillin-5 µg/mL 
streptomycin and 0.5 µg/mL Plasmocin prophylactic. Cells were treated with IFN-λ for biofilm 
assays 4 days after transfection. The efficiency of IL-28Rα knockdown was assessed by western 
blot analysis.  
2.2.14 Divalent Metal Analysis 
To measure release of divalent metals in CM during 72 hour RSV infection of CFBE or primary 
CF and non-CF cells, MEM (no phenol red) supplemented with 2 mM L-gluatamine was added 
to the apical compartment at the beginning of virus infection and removed 72 hpi. Extracellular 
vesicles were isolated as outlined in section 2.2.5. Total amounts of copper, iron and zinc were 
measured using the QuantiChrom Copper Assay Kit (BioAssay Systems, Catalog number: 
DICU-250), QuantiChrom Iron Assay Kit (BioAssay Systems, Catalog number: DIFE-250) and 
QuantiChrom Zinc Assay Kit (BioAssay Systems, Catalog number: DIZN-250), respectively. 
2.2.15 Immunoprecipitation 
For transferrin depletion experiments, transferrin was immunoprecipitated from CM or 
extracellular vesicles. 5 µg Rabbit anti-human transferrin or rabbit anti-GFP was bound directly 
to 50 µL Protein G Agarose Beads (Thermo Fisher, Catalog number: 20398) overnight at 4°C. 
CM or extracellular vesicles was incubated with antibody-Protein G complexes for 2 hours at 
4°C with continuous rotation. Supernatants were collected and used directly in static abiotic 
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biofilm assays. Transferrin abundance bound to antibody-Protein G complexes and in 
supernatants was analyzed by western blot analysis.    
2.2.16 Plaque Assays 
Viral titers were determined by plaque assay on NY3.2 cells, as described previously [301, 302], 
with minor modifications. Briefly, NY3.2 cells were seeded in 24-well polystyrene tissue culture 
plates (Fisher Scientific, Catalog number: 08-772-1) at a density of 4 x 105 cells per well. To 
measure release of infectious viral particles from CFBE cells, CM or extracellular vesicles were 
collected as described in Section 2.2.5 and Section 2.2.6, respectively, and serially diluted in 
DMEM + GlutaMAX (Thermo Fisher, Catalog number: 10567-014) supplemented with 1% FBS 
and 25 mM HEPES acid. Serial dilutions were added to plated NY3.2 cells and incubated for 2 
hours at 37°C, 5% CO2, after which cells were overlaid with Methyl Cellulose-Polyethylene 
Glycol solution for 48 hours. Goat anti-RSV antibody (Meridian Life Science, Catalog number: 
B6580G), donkey anti-goat alkaline phosphatase conjugated antibody (Santa Cruz 
Biotechnology, Catalong number: 2355) and SigmaFast BCIP/NBT tablets (Sigma Aldrich, 
Catalog number: B5655) were used to detect plaque forming units (PFU). 
2.2.17 Bacterial Growth Curves 
Extracellular vesicles were isolated from CFBE cells as outline in Section 2.2.6. Overnight 
cultures of P. aeruginosa were washed twice in MEM supplemented with 2 mM L-glutamine 
and the optical density at 600 nm (OD600) was measured using a SpectraMax M2 Microplate 
Reader (Molecular Devices). Washed bacteria were added to extracellular vesicles to a final 
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concentration of OD600 = 0.05 and added to 96-well polystyrene tissue culture plates (Fisher 
Scientific, Catalog number: 08-772-1), covered with breathable optically clear seal (Sigma 
Aldrich, Catalog number: Z380059). Plates were placed in SpectraMax M2 Microplate Reader, 
prewarmed to 37°C, and OD600 was measured every 20 minutes.  
2.2.18 Transferrin Transcytosis 
Transferrin transcytosis was assessed as described previously with minor modifications [203, 
314]. Briefly, CFBE were infected with RSV for 48 hours as described in Section 2.2.1. After 
this time, the media in the transwell basolateral chamber was replaced with antibiotic-free 
growth media supplemented with 25 µg/mL transferrin biotin-XX-conjugate (Thermo Fisher, 
Catalog number: T23363). MEM (no phenol red) supplemented with 2 mM L-gluatamine was 
added to the apical compartment to collect apical secretions from cells. After 24 hour incubation 
at 37°C, 5% CO2, the media from the apical compartment was collected and centrifuged at 1,400 
x g for 3 minutes. Supernatants were added to Streptavidin Agarose Resin (Thermo Fisher, 
Catalog number: 20349) and incubated overnight at 4°C with continuous rotation. Resin was 
washed twice in MEM supplemented with 2 mM L-glutamine, once in high salt solution (200 
mM NaCl, 400 mM NaOAc, pH 7.4) and once more in MEM supplemented with 2 mM L-
glutamine. Affinity-purified proteins were eluted by incubation at 95°C for 5 minutes in 2X 
Laemmli Sample Buffer supplemented with 0.1 M Dithiothreitol (DTT) and analyzed by western 
blot analysis for transferrin. 
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2.2.19 Extracellular Vesicle Association with P. aeruginosa Plate Reader Assay 
AECs were infected with RSV as outlined in section 2.2.1. AECs were stained with CellTracker 
Deep Red (Thermo Fisher, Catalog number: C34565) 48 hpi, and extracellular vesicles were 
isolated from CFBE cells as outline in Section 2.2.6 24 hours later. Overnight cultures of P. 
aeruginosa were washed twice in MEM supplemented with 2 mM L-glutamine. The optical 
density at 600 nm (OD600) was measured using a SpectraMax M2 Microplate Reader (Molecular 
Devices). Washed bacteria were added to extracellular vesicles to a final concentration of OD600 
= 0.15 and grown at 37°C. At the indicated times, bacteria were washed twice in MEM 
supplemented with 2 mM L-glutamine. After final wash, bacteria were resuspended in 200 µL 
and CellTracker Deep Red fluorescence was measured using a SpectraMax M2 Microplate 
Reader [Molecular Devices); excitation: 630 nm, emission: 650 nm].  
2.2.20 In vivo RSV Infection Model 
For in vivo RSV infection studies, pathogen-free breeder BALB/cJ mice were purchased from 
The Jackson Laboratory at 6-7 weeks of age. For the duration of breeding and pregnancy, mice 
were maintained in pathogen-free facilities at the University of Pittsburgh Division of Laboratory 
Animal Resources as described previously [315]. Animal protocols were carried out in 
accordance with the guidelines in the NIH Guide for the Care and Use of Laboratory Animals 
and approved by the University of Pittsburgh Institutional Animal Care and Use Committee 
(IACUC, Protocol number: 14023340).  
The neonatal mice (pups) from the resulting pregnancies were intranasally inoculated 
with 5 x 105 PFU/gram of body weight with RSV line 19 (kindly provided by Dr. Martin Moore, 
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Emory University, Atlanta, GA) or PBS for negative controls. Stocks of RSV line 19 were 
propagated in HEp-2 cells and titred in HEp-2 cells, as described previously [315-317]. At the 
indicated time points, bronchoalveolar lavage fluid (BALF) was harvested for analysis by iron 
assay and western blot analysis for albumin and transferrin abundance or used in static abiotic 
biofilm assays. HBSS containing 3 mM EDTA was used to obtain BALF. Viral titers at the 
indicated time points were previously assessed by plaque assay [315]. 
For histological analysis, mice were infected with RSV line 19 and lungs were harvested 
7 days post-infection, fixed in 4% paraformaldehyde and embedded in paraffin blocks. Tissues 
sections were stained with H&E, as described previously [315].  
2.2.21 Statistics 
GraphPad Prism Software version 6.0 was used for all statistical analysis. Means were compared 
using Student’s t test, or for multiple comparisons, one-way analysis of variance (ANOVA) with 
Tukey’s post hoc test to evaluate statistical significance. All data are shown as mean ± SD of 
biological replicates within individual experiments. Ρ < 0.05 was considered statistically 
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Unless otherwise specified, all data presented in this chapter is published in the Proceedings of 
the National Academy of Sciences of the United States of America. Specific author contributions 
are listed in the figure legend. Figure 19B and C was not published in this article. Data for figure 
19B and C was provided by Dr. Jeffrey A. Melvin, a post-doc in the Bomberger Lab, and is 
indicated in the figure legend. 
3.1  INTRODUCTION 
Viral-bacterial interactions impact the development and evolution of chronic infections at many 
mucosal surfaces, including in the airways [318-320]. In cystic fibrosis (CF) lung disease, viral 
infections are linked to pulmonary function decline, increased antibiotic use, prolonged 
hospitalizations and increased respiratory symptoms [78]. Respiratory syncytial virus (RSV) is 
one of the most common viral pathogens identified in CF patients and leads to disease 
progression, promoting early respiratory tract morbidity and reductions in lung function [54, 56, 
71]. Beyond the morbidity associated with virus infection alone, RSV is one of the most 
common viral pathogens identified in cases of coinfection in CF. In clinical studies, RSV, and 
other respiratory viruses, have been linked to the development of Pseudomonas aeruginosa 
coinfections and to the conversion to chronic P. aeruginosa colonization in CF patients [51, 53, 
71, 72, 321]. Although clinical associations between viral infection and the acquisition of P. 
aeruginosa is clear, the basic biology underlying this interaction is not well understood.  
The transition of acute bacterial infections to chronic infections often involves the 
development of bacterial aggregates, or biofilms. The combination of an up-regulation of 
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antibiotic resistance genes and the production of a polymeric matrix surrounding the biofilm 
serves to protect bacteria from the hostile environment in the host [322]. The development of 
biofilm in human disease has been studied intensely for its involvement in disease progression in 
CF. Biofilm development at a mucosal surface requires initial attachment of bacteria to a surface, 
followed by the formation and growth of microcolonies, resulting in the development of bacterial 
biofilms, which can undergo regulated dispersal and ultimately seed new surfaces [32, 36]. Our 
present understanding of bacterial biofilm development is largely limited to single-organism 
infections. Although we have long known of polymicrobial communities colonizing human 
tissues, there is a surprising gap in our understanding of how these communities develop, how 
they impact human disease and hot how defense mechanisms influence the relationship between 
microorganisms in polymicrobial infections. Because our current antimicrobial approaches have 
limited success for chronic infections, elucidating the mechanism by which biofilms develop 
during polymicrobial infections may identify new therapeutic targets to combat biofilm 
persistence.  
Many environmental cues have been described as contributing to the conversion of P. 
aeruginosa to biofilm mode of growth. For example, iron is known to be one such cue, as the 
lack of iron in the environment prevents the formation of P. aeruginosa biofilms [27, 37]. 
Nutrient iron is tightly regulated in the host through complex interactions among uptake, storage 
and use in host cells. Nutritional immunity postulates that, because iron is required for microbial 
growth, respiration and metabolism, the host employs many regulatory pathways to sequester 
iron [182, 187]. In CF, elevated levels of iron in the airways of infections patients are correlated 
with frequency of exacerbation and have been proposed to play a role in airway colonization [24, 
323]. In addition, the sputum of CF patients contains elevated levels of ferrous iron, and these 
 80 
levels correlate with disease severity [28]. Although increased iron in sputum is associated with 
CF lung disease severity, it is still unknown how iron homeostasis is altered in CF and how this 
alteration relates to airway infection (bacterial, fungal or viral).  
Using CF lung disease as a model to understand viral-bacterial interactions at a mucosal 
surface, we use a co-culture system for bacterial biofilm development in association with the 
airway epithelium. In this study, we use RSV to demonstrate that virus coinfection dramatically 
enhanced P. aeruginosa biofilm growth in association with airway epithelial cells. In addition, 
we show that virus infection impairs nutritional immunity, allowing the apical release of 
transferrin and thus, increasing bioavailability of iron to promote the growth of P. aeruginosa 
biofilms. These findings offer new insight into the complex interaction among two pathogens 
and the host during polymicrobial infections, and suggest a mechanism by which nutritional 
immunity plays a critical role in regulating bacterial persistence in the airways.  
3.2 RESULTS 
3.2.1 Respiratory virus infections promote P. aeruginosa biofilm growth on airway 
epithelial cells 
To determine if respiratory virus infections promote P. aeruginosa biofilm growth on airway 
epithelial cells (AECs), human ∆F508/∆F508 cystic fibrosis bronchial epithelial cells 
(CFBE41o-, hereafter referred to as “AECs”) were grown as polarized monolayers and infected 
with RSV followed by infection with GFP-tagged P. aeruginosa (strain PAO1) in a flow 
chamber (Figure 3). Biofilm growth was then analyzed by live-cell microscopy, as described 
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previously [27, 305]. We observed that RSV coinfection significantly enhanced P. aeruginosa 
biofilm growth on the surface of AECs (Figure 5A). Surprisingly, RSV coinfection increased P. 
aeruginosa biofilm growth in a time-dependent manner, with maximal biofilm growth peaking at 
72 hours post-RSV infection (Figure 5B), as measured in a static co-culture biofilm model 
[305]. We also found that RSV infection induced biofilm growth on primary CF bronchial 
epithelial (HBE) cells (Figure 5C) and increased biofilm growth of three CF clinical isolate 




Figure 5: Respiratory viral infection promotes the growth of P. aeruginosa biofilm on AECs. 
(A, Left) P. aeruginosa (GFP) biofilms imaged by live-cell microscopy after 6 hr of growth. AEC cell nuclei are 
shown with Hoechst (blue) staining. (Right) Biofilm biomass was quantified using COMSTAT (black bars, left y 
axis). RSV RNA was measured by quantitative RT-PCR (qRT-PCR) to assess RSV infection (red bar, right y axis). 
(B) RSV-enhanced biofilm growth is time dependent. In a static coculture biofilm assay, AECs were infected with 
RSV (striped bar) or were mock infected [Eagle’s minimal essential media (MEM) control; black bars] for the 
indicated times followed by P. aeruginosa infection. P. aeruginosa biofilm was assessed by colony-forming units 
(CFU) enumeration (left y axis). RSV RNA was measured by qRT-PCR to assess RSV infection (red bars, right y 
axis). (C) RSV stimulates the growth of P. aeruginosa biofilm on well-differentiated CF HBEs. P. aeruginosa 
biofilms were grown on primary CF HBEs using the static coculture biofilm assay and were quantified by CFU 
enumeration. RSV, RSV-infected AECs. For all experiments n ≥ 3. Data are presented as mean ± SD; *P < 0.05 




Figure 6: RSV-enhanced growth of P. aeruginosa biofilms with CF clinical isolates. 
RSV infection promotes biofilm formation by CF P. aeruginosa clinical isolates in a static coculture biofilm assay. 
In a static coculture biofilm assay, AECs were infected with RSV (striped bars) or were mock-infected (MEM 
control; black bars) for 72 hr and then were infected with the indicated clinical isolates of P. aeruginosa. Biofilms 
were quantified by CFU enumeration. Data provided by L.P.L., D.K.F., and J.M.B. 
 
Patients with other chronic lung diseases, such as chronic obstructive pulmonary disease 
(COPD), are also susceptible to both acute and persistent infections by P. aeruginosa [324]. This 
suggests that P. aeruginosa can form biofilms on AECs independent of the mutations in the 
cystic fibrosis transmembrane conductance regulator (CFTR) ion channel, which are the 
underlying cause of CF and CF lung disease [325]. In agreement with this hypothesis, we found 
that RSV infection increased P. aeruginosa biofilm growth on primary non-CF HBE cells in a 




Figure 7: RSV enhances P. aeruginosa biofilm on well-differentiated non-CF HBEs. 
(A) P. aeruginosa biofilms were grown on non-CF HBEs in a static coculture biofilm assay following 72 hr RSV 
infection and were quantified by CFU enumeration. (B) RSV RNA was measured by qRT-PCR to assess RSV 
infection, which is equivalent in CF and non-CF HBE cells. RSV, RSV-infected AECs. For all experiments n ≥ 3. 
Data are presented as mean ± SD; *P < 0.05 versus control. Data provided by L.P.L., D.K.F., and J.M.B. 
 
3.2.2 Stimulation of bacterial biofilm formation is induced by infection of AECs by 
disparate viruses 
To examine whether virus-enhanced P. aeruginosa biofilm formation was specific for RSV 
coinfection, we infected AECs with human rhinovirus-14 (hRV14) or adenovirus-5 (Ad5), two 
additional respiratory viral pathogens commonly found in CF patients [78], before bacterial 
infection. Coinfection with hRV14 or Ad5 also increased the growth of P. aeruginosa biofilms 
on AECs in static co-culture biofilm assays (Figure 8). Taken together, these results indicate that 
several respiratory viruses relevant to CF lung disease can stimulate the growth of P. aeruginosa 




Figure 8: Other respiratory viruses enhance the growth of P. aeruginosa biofilm on AECs. 
P. aeruginosa biofilms were grown in a static coculture biofilm assay on AECs infected with hRV or AdV or were 
mock-infected (MEM control). Biofilms were quantified by CFU enumeration (black bars, left y axis). Viral RNA 
was measured by qRT-PCR to assess virus infection (red bars, right y axis). hRV14, hRV14-infected AECs. Ad5, 
Ad5-infected AECs. For all experiments n ≥ 3. Data are presented as mean ± SD; *P < 0.05 versus control. Data 
provided by L.P.L., D.K.F., and J.M.B. 
 
3.2.3 Viral-stimulated bacterial biofilm formation is not caused by direct virus-P. 
aeruginosa interaction  
Using an abiotic biofilm growth assay in a 96-well microtiter dish [312], we found no difference 
in biofilm formation in P. aeruginosa biofilms grown in the presence or absence of RSV (Figure 
9A). In addition, although bacterial attachment was increased when cells were infected 
simultaneously with RSV and P. aeruginosa (Figure 9B), as has been shown previously reported 
[152], P. aeruginosa attachment was not increased on cells infected with RSV (for 72 hours) 
prior to bacterial infection (Figure 9B). Although we observed increased attachment of P. 
aeruginosa to AECs that were simultaneously infected with P. aeruginosa and RSV, biofilm 
growth was only moderately increased compared to P. aeruginosa biofilm formation on cells not 
infected with RSV (Figure 9C). Whereas, on cells infected with RSV prior to bacterial infection, 
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biofilm formation was greatly and much more robustly increased (Figure 9C). Moreover, 
biofilm growth on the apical surface of AECs infected with RFP-tagged RSV (RSV-RGP) 
showed a random distribution (Figure 9D, Person correlation coefficient of 0.072 +/- 0.021), 




Figure 9: RSV-stimulated biofilm growth is not caused by direct viral-P. aeruginosa interaction. 
(A) P. aeruginosa biofilms were grown in MEM ± RSV for 24 hr in the 96-well microtiter biofilm assay. Biofilms 
were quantified by crystal violet staining and were measured as absorbance at 550 nm. Biofilms growth is presented 
as the percentage of growth in MEM alone. (B) P. aeruginosa attachment is reduced on AECs with preceding RSV 
infection. AECs were infected with P. aeruginosa (PA), simultaneously with RSV and P. aeruginosa (RSV + PA), 
or with RSV before infection with P. aeruginosa (RSV pretreat + PA). P. aeruginosa (GFP) adherence on AECs 
was imaged by live-cell microscopy after 1 hr of bacterial infection. Bacterial counts were normalized to the number 
of epithelial cells per field by counting nuclei (10 fields were counted per treatment, repeated three times). (C) The 
growth of P. aeruginosa biofilm is enhanced only on AECs with preceding RSV infection. P. aeruginosa biofilms 
were imaged by live-cell microscopy after 6 hr of growth on AECs, and biofilm biomass was quantified by 
COMSTAT. AECs were infected and are labeled along the x axis as in B. (D) P. aeruginosa biofilms are randomly 
distributed on AECs infected with RSV. Cells were infected with RSV-RFP for 24 hr followed by PAO1-GFP 
infection, and biofilm growth (green) was imaged after 5 hr by live-cell microscopy. Hoechst (blue) staining shows 
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epithelial cell nuclei. For all experiments n ≥ 3. Data are presented as mean ± SD; *P < 0.05 versus control. Data 
provided by L.P.L., D.K.F., and J.M.B. 
 
Previous studies have shown that viral infection can increase bacterial attachment by 
inducing damage to the respiratory epithelium, which increases bacterial access to basal cells and 
basement membrane [146, 147]. Although we did not observe increased adherence of bacteria to 
AECs infected with RSV for 72 hours prior to bacterial infection, this does raise an interesting 
point about whether viral infection increases cellular cytotoxicity. Previously, it has been 
described that RSV infection increases damage to bronchial epithelial cell cultures by increasing 
cell death and loss of cilia [112]. However, in our study, cytotoxicity was not detected during 
RSV infection, as measured by lactate dehydrogenase release (Figure 10A) and transepithelial 
electrical resistance, a measure of epithelial barrier integrity (Figure 10B). Together, these 
results suggest that RSV infection promotes the formation of P. aeruginosa biofilm growth on 
AECs via a mechanism independent of increased adherence of bacteria to cells. 
 
 
Figure 10: The AEC monolayer is intact during RSV infection. 
(A) Epithelial integrity was assessed by the lactate dehydrogenase release assay at 72 hpi for various doses of RSV 
[Multiplicity of infection (MOI) = 0.001-5] Means are not significantly different from the uninfected control. (B) 
Transepithelial electrical resistance measurements were used to assess epithelial integrity over the course of 72-hr 
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RSV infection. AECs were infected with RSV (red triangles) or were mock-infected (MEM control, black circles) 
for the indicated times. Data provided by L.P.L. and J.M.B. 
 
3.2.4 Antiviral IFN signaling increases the growth of P. aeruginosa biofilms on AECs 
Host cells, including AECs, commonly respond to viral infections and establish an innate 
immune response against the virus through the inductions of antiviral IFNs. Because we 
observed enhanced biofilm growth by diverse respiratory viruses (Figure 8), we wanted to 
determine if the innate antiviral immune response to respiratory viral infection had a role in 
increased P. aeruginosa biofilm growth during respiratory virus infections. To do so, we first 
measured type I (IFN-β) and type III IFN (IFN-λ) production following RSV infection. We 
observed that IFN-β and IFN-λ levels in the apical airway surface liquid increased during the 
course of RSV infection, peaking at 72 hours post-RSV infection (Figure 11). Although both 
IFN-β and IFN-λ were produced by AECs in response to RSV infection, IFN-β was produced to 
a lesser extent than IFN-λ. This suggests a poor type I IFN response to RSV infection by AECs 
in our model, which is consistent with previous reports showing low type I IFN responses in 
other in vitro models of RSV infection, such as primary pediatric bronchial epithelium cell 
cultures and nasal epithelial cells [112, 113, 115]. Additionally, this reflects the low type I IFN 
levels measured in infants following RSV infection [114, 115, 326, 327].  Interestingly, P. 
aeruginosa biofilm growth also peaked at 72 hours post-respiratory viral infection (Figure 5), 
suggesting that a temporal association between IFN-β and IFN-λ production and increased P. 




Figure 11: IFN-β and IFN-λ secretion from AECs during RSV infection. 
Cells were infected with RSV for the indicated number of hours (hpi), and (A) IFN-β and (B) IFN-λ1/3 (IL-29/IL-
28B) release was measured by ELISA. For all experiments n ≥ 3. Data are presented as mean ± SD; *P < 0.05 
versus control. ELISA measurements performed by B.A.F.  
 
We next sought to determine if IFN signaling was sufficient to enhance P. aeruginosa 
biofilm growth in the absence of respiratory viral infection due to the temporal association 
between peak IFN production and P. aeruginosa biofilm formation during RSV infection. Due to 
the relatively robust IFN-λ response (compared to IFN-β) to RSV infection we and others have 
observed in AECs [112, 113, 115], we first focused on the role IFN-λ signaling may play in P. 
aeruginosa biofilm growth. Treatment of AECs with purified IFN-λ1 (IL-29, 100 ng/mL) 
increased the growth of P. aeruginosa biofilm on the surface of AECs in both our biotic biofilm 
imaging and static co-culture biotic biofilm assays (Figure 12A-B). We measured ISG56 
expression to confirm that IFN-λ treatment led to increased ISG expression in AECs (Figure 
12B). The IFN-λ receptor is a heterodimer composed of IL-28Rα and IL-10Rβ. To confirm that 
signaling through IFN-λ receptor was required for IFN-λ-stimulated P. aeruginosa biofilm 
growth, we used RNA interference (RNAi) to selectively knockdown IL-28Rα in AECs and 
therefore, disrupt IFN-λ receptor signaling.  In cells treated with siIL-28Rα, IFN-λ-stimulated 
biofilm formation was reduced (Figure 12C). This suggests that IFN-λ must signal through the 
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IFN-λ receptor to enhance P. aeruginosa biofilm growth. Knockdown of IL-28Rα was 
confirmed by western blot of whole cell lysate samples (Figure 12D). Together these results 
suggest that IFN-λ signaling is sufficient to stimulate P. aeruginosa biofilm growth in the 
absence of respiratory viral infection.  
 
 
Figure 12: Type III IFN (IFN-λ) signaling stimulates the growth of P. aeruginosa biofilm. 
(A and B) IFN-λ treatment stimulates the growth of P. aeruginosa biofilm on AECs. P. aeruginosa biofilm growth 
increased on AECs treated for 12 hr with IFN-λ1 (100 ng/mL, as assessed by live-cell microscopy (A) or in static 
coculture biofilm assay (B). (A) Epithelial cell nuclei are shown with Hoechst (blue) staining. The P. aeruginosa 
biofilm (GFP, green) biomass was calculated for each condition using COMSTAT. (B) P. aeruginosa biofilm was 
assessed by CFU enumeration (black bars, left y axis). IFN-λ1 signaling was confirmed with ISG56 induction by 
qRT-PCR (green bars, right y axis). (C) Signaling via IL-28Rα is required for biofilm growth during IFNλ 
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treatment. AECs were transfected with scrambled siRNA (siNeg) or siRNA targeting IL-28Rα (siIL28Rα) and were 
treated with IFN-λ1 (100 ng/mL) for 12 hr, and P. aeruginosa biofilms were grown in a static coculture biofilm 
assay. P. aeruginosa biofilm growth was quantified by CFU enumeration and displayed as fold change compared 
with siNeg-transfected cells. (D) siRNA-mediated knockdown of IL-28Rα was assessed by measuring protein 
abundance for each condition by Western blot and is displayed as the percent of IL-28Rα in cells transfected with 
siNeg (control). For all experiments n ≥ 3. Data are presented as mean ± SD; *P < 0.05 versus control. Data 
provided by L.P.L. and J.M.B. 
 
In addition to antiviral defense, the IFN response to respiratory viral infection has been 
shown to be necessary for the increase in bacterial growth in the lungs of animals during 
respiratory viral co-infection [156-158]. In these studies, targeted deletion of IFN receptors 
decreased bacterial burdens in animals co-infected with a respiratory virus to levels observed in 
PBS control animals that did not have a viral infection [157, 158]. To test whether IFN-λ 
signaling was necessary for the increase in P. aeruginosa biofilm growth observed during RSV 
co-infection, we treated cells with a neutralizing antibody against IL-10Rβ during RSV infection 
to inhibit IFN-λ signaling. This antibody has previously been shown to inhibit IL-10Rβ signaling 
in relation to IFN-λ treatment [328, 329]. In the presence of the IL-10Rβ neutralizing antibody, 
we observed reduced P. aeruginosa biofilm growth during RSV infection (Figure 13). It is 
worth noting that the decrease in P. aeruginosa biofilm growth we observed was not a complete 
reduction to biofilm formation measured on control cells. This result suggests that IFN-λ 




Figure 13: IFN-λ signaling is required for the growth of virus-stimulated P. aeruginosa biofilm. 
Cells were infected with RSV or were mock-infected (MEM control) for 72 hr and were treated with IL-10Rβ-
neutralizing antibody (IL-10Rβ antibody; 10 µg/mL) (gray bars) or were left untreated (black bars). P. aeruginosa 
biofilms were grown in static coculture biofilm assays. The growth of P. aeruginosa biofilms was quantified by 
CFU enumeration. RSV, RSV-infected AECs.  For all experiments n ≥ 3. Data are presented as mean ± SD; *P < 
0.05 versus control. Data provided by L.P.L. and J.M.B. 
 
We also investigated the role IFN-β may play in P. aeruginosa biofilm induction during 
respiratory viral infection. Similar to INF-λ treatment, we observed that IFN-β treatment 
increased P. aeruginosa biofilm growth on AECs in our biotic biofilm imaging and static co-
culture biotic biofilm assays (Figure 14A-B). We observed a reduction in IFN-β-mediated P. 
aeruginosa biofilm formation on AECs that were treated a neutralizing antibody targeting 
IFNAR (to inhibit IFN-β-mediated signaling in cells treated with IFN-β) (Figure 14C). Finally, 
we also observed a decrease in P. aeruginosa biofilm growth on AECs during RSV co-infection 
in the presence of IFNAR neutralizing antibody (Figure 14D). The decrease in P. aeruginosa 
biofilm growth was not a complete abrogation of biofilm formation in response to respiratory 
viral infection. This is similar to what we observed in experiments using a IL-10Rβ neutralizing 
antibody to block IFN-λ signaling during RSV co-infection. Taken together, these data support 
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the conclusion that IFN signaling in response to respiratory viral infection and necessary and 
sufficient to enhance the growth of P. aeruginosa biofilms. Additionally, these data suggest that 
a common target(s) of both IFN-β and IFN-λ signaling are responsible for increased P. 




Figure 14: IFN-β treatment enhances the growth of P. aeruginosa biofilm. 
(A-B) The growth of P. aeruginosa biofilm increased on AECs treated with IFN-β (1000 U/mL) for 18 hr, as 
measured by live-cell microscopy (A) or in static coculture biofilm assays (B). (A) Epithelial cell nuclei are shown 
with Hoechst (blue) staining and P. aeruginosa biofilm (GFP, green) biomass was calculated using COMSTAT. (B) 
P. aeruginosa biofilm was assessed by CFU enumeration. (C) Signaling through IFNAR is required for biofilm 
growth induced by IFN-β treatment. AECs were treated with IFNAR-neutralizing antibody (5 µg/mL) during 18-hr 
treatment with IFN-β (1000 U/mL), and P. aeruginosa biofilms were grown in a static coculture biofilm assay. 
Control corresponds to mock IFN-β treatment in the absence of IFNAR-neutralizing antibody. The growth of P. 
aeruginosa biofilm was quantified by CFU enumeration. (D) Neutralizing IFNAR prevents the RSV-stimulated 
growth of P. aeruginosa biofilm. AECs were infected with RSV (“RSV infected”) and were treated with 
neutralizing IFNAR-antibody (5 µg/mL). P. aeruginosa biofilms were grown in a static coculture biofilm assay. The 
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growth of P. aeruginosa biofilm was quantified by CFU enumeration. Uninfected, mock infection (MEM control). 
For all experiments n ≥ 3. Data are presented as mean ± SD; *P < 0.05 versus control. Data provided by L.P.L., 
D.K.F, and J.M.B. 
 
Furthermore, these results imply that IFN-β and IFN-λ proteins do not interact directly 
with P. aeruginosa to stimulate biofilm formation and P. aeruginosa cannot utilize IFNs as a 
nutrient source to support biofilm growth. In support of this conclusion, when either IFN-β and 
IFN-λ was added directly to P. aeruginosa in a 96-well microtiter biofilm assay (in the absence 
of AECs), no biofilm growth was observed (Figure 15). 
 
 
Figure 15: IFN-λ and IFN-β do not interact directly with P. aeruginosa and stimulate biofilm growth. 
P. aeruginosa was grown in the presence or absence of (A) IFN-λ (200 ng/mL) or (B) IFN-β (1000 U/mL) diluted in 
MEM for 24 hr in the 96-well microtiter biofilm assay. Biofilm growth was measured as absorbance at 550 nm 
following crystal violet staining and is presented as OD550. n = 3; data are presented as mean ± SD. 
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3.2.5 Iron released from RSV-infected AECs stimulates P. aeruginosa biofilm growth 
Because we did not observe that RSV infection enhanced P. aeruginosa adherence to AECs, we 
next determined whether the apical airway surface liquid [hereafter termed “conditioned 
medium” (CM)] from RSV-infected cells was capable of enhancing biofilm growth in the 
absence of AECs. We found that CM from RSV-infected cells increased biofilm growth on 
abiotic surfaces, as assessed by static abiotic biofilm assay (Figure 16A) and a 96-well 
microtiter biofilm assay (Figure 16B). Because we observed that CM from RSV-infected cells 
stimulated biofilm growth, we hypothesized that RSV infection and induced the release of 
biofilm stimulatory factor(s). Iron is an essential nutrient for many bacteria and is required for 
the formation of P. aeruginosa biofilm on both abiotic and biotic surfaces [27, 37, 204]. To 
determine if iron homeostasis is altered during RSV infection, we measured total iron levels in 
CM from mock- or RSV-infected cells. RSV infection resulted in a time-dependent (Figure 
17A) and dose-dependent (Figure 17B) increase in extracellular iron in the CM collected from 
AECs. In addition, RSV infection resulted in an increased in extracellular iron in CM collected 
from primary CF HBEs (Figure 17C) and primary non-CF HBEs (Figure 17D). Importantly, the 
presence of iron in CM was required for the enhancement of biofilm growth in response to RSV 
infection because an iron-chelating agent (Chelex-100) dramatically decreased CM-induced 
biofilm growth (Figure 18). When exogenous iron (FeCl3) was added to CM from RSV-infected 
cells after treatment with Chelex-100, biofilm growth was restored (Figure 18). Collectively, 
these results indicate that RSV infection enhances iron release by AECs, thus increasing iron 




Figure 16: Apical secretions from RSV-infected AECs stimulate P. aeruginosa biofilm formation. 
RSV infection stimulates the release of a biofilm-stimulatory factor that promotes P. aeruginosa formation. AECs 
were infected with RSV or were mock-infected (MEM control) for 72 hr, and the apical CM was collected. (A) P. 
aeruginosa (GFP) was grown in the presence of CM in static abiotic biofilm assays. Fluorescent microscopy was 
used to measure the growth of P. aeruginosa (GFP, green), and biomass was quantified using Nikon Elements (grid 
unit = 9 µm). (B) P. aeruginosa biofilms were grown in CM for 24 hr in 96-well microtiter biofilm assays. Biomass 
was quantified by crystal violet staining and absorbance was measured at 550 nm. For all experiments n ≥ 3. Data 




Figure 17: RSV infection enhances iron release from AECs. 
(A) Total iron was increased in apical CM collected from AECs infected with RSV or mock-infected (MEM control) 
for the indicated number of hours post infection (hpi). (B) Total iron in the apical CM collected from AECs infected 
with RSV at the indicated MOI or mock-infected (MEM control) for 72 hours. (C and D) Total iron in the apical 
CM collected from primary CF (C) and non-CF (D) HBEs infected with RSV or mock-infected (MEM control).  




Figure 18: Iron in RSV CM is required for the growth of P. aeruginosa biofilm growth. 
96-well microtiter biofilm assays were performed to measure the growth of P. aeruginosa in CM. Divalent metal 
cations were chelated with Chelex-100 (labeled “Chelex” in the figure), and iron was added back with FeCl3 (8 µM) 
after Chelex-100 treatment. RSV, RSV-infected AECs. RSV, RSV-infected AECs. For all experiments n ≥ 3. Data 
are presented as mean ± SD; *P < 0.05 versus control. 
 
3.2.6 Transferrin is apically released by AECs in response to RSV infection 
Nutritional immunity is a process by which host cells restrict access to free iron and other trace 
metals by sequestering them inside cells, across anatomical barriers and bound to molecules that 
have a high affinity for metals ions. Because increased iron abundance in CM contradicts these 
principles, we sought to identify the mechanism by which RSV infection increases luminal iron 
release. To begin to examine the mechanism by which RSV infection promotes apical iron 
release, we investigated whether the abundance of iron transporters and iron-binding proteins in 
AECs was altered by virus infection. We did not observe a significant difference in the 
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abundance of the iron exporter, ferroportin, or the iron importer, divalent metal-ion transporter 1 
(DMT1), during RSV infection (Figure 19A).  Similarly, the abundance of iron-biding proteins, 
including transferrin, ferritin and lactoferrin, was not changed by RSV infection (Figure 19A). 
Although this suggests AECs are not actively changing free iron transport during RSV infection 
by changing proteins levels of iron transporters, it does not exclude the possibility of either the 
membrane abundance or the activity of these transporters being altered by RSV infection. To 
address both of possibilities and test whether free iron was being released by AECs during RSV 
infection, we measured iron concentrations of CM filtered through 3 kDa filters, which would 
retain protein bound iron. We found that when CM was filtered through 3 kDa filters, all of the 
iron was retained by the filter in the concentrate (Figure 19B), implying that iron present in CM 
is protein-bound. Because we observed that iron was required for P. aeruginosa biofilm 
formation in CM from RSV-infected cells (Figure 18), we also probed whether CM filtered 
through 3 kDa filters was capable of stimulating biofilms. Using a 96-well microtiter biofilm 
assay, we found that P. aeruginosa biofilm growth was not increased in the presence of CM from 
RSV-infected cells that had been filtered through 3 kDa filters and the biofilm stimulatory 
activity was retained in the concentrate from these filtrations (Figure 19C). Taken together, 
these results support the conclusion that P. aeruginosa is utilizing protein-bound iron, and not 




Figure 19: RSV infection does not increase free-iron release from AECs. 
(A) RSV infection does not affect the abundance of iron transporter proteins in AECs infected with RSV or mock-
infected (MEM control) for 72 hr, as measured by Western blot analysis. (B-C) Apical CM was collected from 
AECs infected with RSV or mock-infected (MEM control) for 72 hr and subjected to 3 kDa filtration. Cond. Media, 
CM not filtered; 3 kDa Filtrate, flow-through from 3 kDa filtration; 3 kDa Concentrate, media that did not flow 
through 3 kDa filter. (B) Total iron levels in apical CM following 3 kDa filtration. (C) P. aeruginosa biofilms were 
grown in apical CM following 3 kDa filtration for 24 hr in 96-well microtiter biofilm assay. Biofilm growth was 
measured as absorbance at 550 nm following crystal violet staining. For all experiments n ≥ 3. Data are presented as 
mean ± SD; *P < 0.05 versus control. J.A.M. provided data for panels C and D.   
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Since we observed increased iron levels in CM from RSV-infected cells (Figure 17), 
with no corresponding changes in the expression of iron transporters or free iron in CM, we next 
examined whether RSV infection alters the release of iron-binding proteins into CM. Indeed, we 
found increased abundance of transferrin in the CM from RSV-infected AECs (Figure 20A). 
Transferrin is a host iron-binding protein that can be used as a source of iron and can support the 
growth of multiple bacterial species, including P aeruginosa [197-199, 211]. Notably, transferrin 
promotes biofilm growth by P. aeruginosa in a dose-dependent manner [27]. To determine 
whether transferrin is necessary for the stimulation of biofilm growth by CM from RSV-infected 
cells, we grew P. aeruginosa in transferrin-depleted CM and found that a significant reduction in 
biofilm growth when CM from RSV-infected cells was depleted of transferrin (Figure 20B). We 
confirmed that our immunoprecipitation reactions completely removed transferrin from CM by 
western blot analysis (Figure 20C). Collectively, these data suggest that RSV infection 





Figure 20: Transferrin release increases in response to virus infection in vitro. 
AECs were infected with RSV or were mock-infected (MEM control) for 72 hr and then apical CM was collected. 
(A) RSV infection increases transferrin abundance in apical CM, as measured by Western blot analysis. (B) 
Transferrin depletion reduces the growth of P. aeruginosa biofilm in RSV CM. Apical CM was collected from 
RSV-infected AECs depleted of transferrin by immunoprecipitation (RSV-Tfn IP). P. aeruginosa (GFP) biofilms 
were grown in transferrin-replete and –depleted RSV CM in static abiotic biofilm assays. Biofilm biomass was 
quantified using Nikon Elements (grid unit = 8.5 µm). (C) Transferrin depletion was achieved by 
immunoprecipitation of transferrin from CM using an anti-transferrin polyclonal antibody. Western blot analysis 
was used to verify transferrin depletion from CM. For all experiments n ≥ 3. Data are presented as mean ± SD; *P < 
0.05 versus control. 
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3.2.7 RSV infection increases the availability of airway iron in vivo 
To extend our in vitro findings to what might occur in vivo, we used a neonatal mouse model of 
RSV infection [315] and measured iron levels in the bronchoalveolar lavage fluid (BALF) up to 
1 week post infection. RSV infection increase iron concentrations in the airways significantly, 
compared with mock-infected controls (Figure 21A). In agreement with the increased abundance 
of iron, BALF from RSV-infected mice was able to support in vitro P. aeruginosa biofilm 
growth (Figure 21C). Although RSV infection resulted in increased inflammation, there was no 
evidence of server bronchiolar epithelial damage or of sloughing or rupture of the epithelial 
barrier, which could account for the increase of iron in the airways (Figure 21D-E). In addition, 
consistent with our finding in polarized human AECs, transferrin abundance was increased in the 
BALF of RSV-infected mice (Figure 21B), further supporting a role for iron release as a key 




Figure 21: Transferrin release increases in response to RSV infection in vivo.  
(A and B) Total iron (A) and transferrin abundance (B) were increased in BALF recovered from neonatal mice 
infected with RSV or mock-infected (PBS control) for the indicated number of days post infection (dpi), as 
measured by iron assay or Western blot analysis, respectively. (C) BALF recovered from neonatal mice infected 
with RSV stimulates the growth of P. aeruginosa biofilm growth in vitro. P. aeruginosa (GFP) biofilms grown in 
BALF recovered from neonatal mice infected with RSV 5 dpi in static abiotic biofilm assays. Biofilm biomass was 
quantified using Nikon Elements (grid unit = 7.5 µm). (D) Lung pathology in mice following infection. Mice were 
infected with RSV for 7 days; then lungs were harvested, sliced, and stained with H&E. Each panel represents an 
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individual mouse from the indicated group. (Scale bar, 25 µm). (D) At 2 and 7 dpi, BALF was collected and assayed 
for protein content by Bradford assay. N=4 or 5 mice per treatment group. Means are not significantly different from 
PBS controls. Horizontal lines indicate mean values. Alb, albumin; RSV, RSV infection; Tfn, transferrin. All 
experiments were repeated, with at least four mice per group. * P < 0.05. Katherine Eichinger and Kerry Empey 
performed mouse infections, H&E staining, and collected BALF. All assays with BALF performed in Bomberger 
Lab by myself. 
 
3.3 DISCUSSION 
Respiratory viral infections trigger exacerbations in chronic lung disease such as CF and 
predispose patients to bacterial colonization, but identifying the molecular mechanism(s) 
underlying viral-bacterial interactions has been elusive [53, 54, 56, 71, 72, 79]. Because of the 
paucity of animal models to study the development of chronic bacterial infections, we used a 
unique coculture model in which the early stages of P. aeruginosa biofilm development in 
association with polarized human AECs can be observed by high-resolution, live-cell imaging. 
We demonstrate that respiratory virus infection of CF and non-CF AECs results in the increased 
formation of bacterial biofilm. Moreover, in this study we show that biofilm growth is increased 
through a dysregulation of host nutritional immunity mechanisms, resulting in the increased 
release of iron-bound transferrin during virus infection, which originates in at the basolateral 
membrane of AECs and is transcytosed to the apical compartment of cells. This release of iron-
bound transferrin promotes the transition of P. aeruginosa to a biofilm mode of growth. 
Importantly, our findings propose a molecular mechanism underlying the common clinical 
observation that respiratory virus infection in patients with chronic lung disease promotes 
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chronic bacterial colonization and disease progression [51, 53, 56, 71, 72, 79, 330]. Our study 
has important implications, beyond CF pathogenesis, for understanding how complex microbial 
communities interact during disease in the lung.  
Few studies have investigated the interaction between viruses and P. aeruginosa in the 
airways. It has been shown that P. aeruginosa may modulate the antiviral response, although the 
consequences of these interactions on the progression of P. aeruginosa infection and virus 
infection remain unclear [121, 173]. Previous studies have shown that RSV coinfection promotes 
bacterial adherence to nonpolarized and ciliated AECs [152, 154, 331]. In our model using well-
differentiated AECs, we show that preceding RSV infection decreased P. aeruginosa adherence 
to AECs while greatly enhancing the development of bacterial biofilm. We interpret these 
results, coupled with abiotic biofilm assays that are not altered with virus exposure, as indicating 
that a direct interaction between virus and bacteria is not responsible for enhancement of P. 
aeruginosa biofilm growth during respiratory viral infection. Instead, using a coculture model of 
biofilm development in association with the respiratory epithelium, our data suggest a 
mechanism by which the host innate immune response to the viral pathogen creates a local 
environment at the mucosal surface that promotes chronic bacterial infection. The molecular 
details of this mechanism are explored further in this dissertation. 
Although the antiviral effects of IFNs are well recognized [332], studies now suggest that 
an appropriate antiviral IFN response to respiratory viral infection has unfavorable effects on 
secondary bacterial infections. For example, in acute models of influenza-bacterial coinfections, 
the increased bacterial load in the airways of mice after influenza challenge has been attributed 
to the antiviral IFN response to the virus [156-158]. Little is known about how IFN induction or 
signaling pathways influence chronic bacterial infection. In acute models of P. aeruginosa 
 109 
infection, the ability to clear P. aeruginosa infection is improved significantly in mice lacking 
IL-28Rα, indicating that IFN-λ signaling may contribute adversely to pulmonary P. aeruginosa 
infection in vivo [127]. Our data extend previous findings to suggest that IFN signaling also 
promotes the growth of P. aeruginosa biofilms.   
Our study suggests the dysregulation of nutritional immunity, specifically iron 
homeostasis, as a primary mechanism by which RSV promotes the transition of P. aeruginosa to 
a biofilm mode of growth. Iron plays an essential role in the development of biofilms on abiotic 
surfaces and in association with AECs for P. aeruginosa and other bacterial species [27, 37, 43, 
204]. A strong positive correlation has been reported among increased iron levels, P. aeruginosa 
burden and disease severity in the CF lung, but the effect of respiratory viral infection on iron 
levels has not been investigated [24, 25, 28]. In our studies we found that, during the corse of 
infection, RSV increased apical iron release from the airway epithelium and that iron chelation 
dramatically reduced biofilm growth, implying that iron chelation is effective in counteracting 
virus-mediated iron release and biofilm growth. Although P. aeruginosa biofilms grown on 
AECs display significantly high antibiotic resistance than biofilms formed on abiotic surfaces, 
the use of iron chelation compounds significantly increases antibiotic-mediated disruption of 
biofilms on cells [49]. Moreover, it has been demonstrated recently that P. aeruginosa dispersed 
from biofilms by chemical induction is highly sensitive to iron stress [333]. This high sensitivity 
to iron limitation suggests that iron chelation compounds may play a role in preventing the 
spread of bacteria to new infection sites. A novel approach to inhibiting P. aeruginosa growth 
and biofilm formation uses the transition metal gallium (Ga3+) to disrupt P. aeruginosa iron 
metabolism [334, 335]. Therefore, the co-administration of iron chelators that can prevent 
bacterial iron acquisition and compounds that disrupt bacterial iron metabolism may be an 
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important therapeutic strategy during respiratory virus seasons to prevent the development and 
spread of chronic bacterial infections in CF patients.  
Iron is a critical nutrient for many cellular processes in humans, but the quantity and 
location of iron must be regulated tightly to prevent infection [182]. Even in the absence of 
infection, extracellular iron is bound to high-affinity iron-binding proteins, such as transferrin, to 
maintain extremely low levels of free iron. We found that RSV infection promoted the apical 
release of transferrin from AECs and that transferrin contributed significantly to the formation of 
P. aeruginosa biofilms. Moreover, our data suggest that RSV infection does not promote the 
release of free iron and therefore, that the iron released during viral infection is protein-bound. 
Our data suggest that the iron is bound to transferrin. The mechanism(s) by which P. aeruginosa 
responds to the environmental conditions imposed by RSV infection, including the presence of 
transferrin, are important to consider. One mechanism by which P. aeruginosa overcomes iron 
sequestration is through the siderophore pyoverdine, which facilitates iron acquisition from 
transferrin and is important for bacterial growth and biofilm formation [204, 206]. The presence 
of pyoverdine in CF sputum suggests the importance of pyoverdine-mediated iron uptake by P. 
aeruginosa in the CF lung [336]. Taken together, these studies suggest that pyoverdine-mediates 
acquisition of iron from transferrin may be an important mechanism by which chronic P. 
aeruginosa infections initially develop in the CF lung and that respiratory viral infection may 
instigate such a microenvironment. In support of this hypothesis, longitudinal analyses of CF 
clinical isolates suggest that P. aeruginosa pyoverdine production is high early in infection and 
then production decreases as chronic infections continue to progress over the life time of patients 
[212, 213]. 
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In summary, many clinical studies in patients with chronic lung disease report viral-
bacterial interactions that result in poor bacterial clearance and disease progression. In the 
current study, we demonstrate that respiratory viral infections dysregulate host iron homeostasis 
mechanisms, promoting harmful secondary bacterial infections. By improving our mechanistic 
understanding of viral-bacterial coinfections, these studies aid in the development of new 
treatments to target complex infectious diseases. Moreover, because mounting clinical evidence 
suggest that many infectious diseases are polymicrobial in nature, our studies likely have 
implications for studying complex microbial communities during other disease processes.  
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4.0  EXTRACELLULAR VESICLES RELEASED BY AIRWAY EPITHELIAL 
CELLS DURING RESPIRATORY VIRUS INFECTION PROMOTE PSEUDOMONAS 
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4.1 INTRODUCTION 
Extracellular communication is a critical component of many host processes. Extracellular 
vesicles (EVs) are small membrane-enclosed vesicles that are produced by most cell types, and 
secreted into the extracellular environment. Biologically active proteins, RNAs and lipids can be 
packaged into EVs and delivered to target cells, where they impact many biological processes 
[216, 218, 221, 337]. EVs have been isolated from lung epithelial cells, as well as from the 
bronchoalveolar lavage fluid (BALF) and sputum collected from patients with chronic lung 
diseases, such as asthma and cystic fibrosis (CF) [338-342]. Although EVs seem to play roles in 
both normal tissue homeostasis and in the progression of inflammation in the airways, little is 
known about what function EVs have in the airways during an infection [343].  
During viral infection, EVs mediate intercellular communication that is beneficial to the 
viral life cycle by delivering viral particles and genetic elements between neighboring cells that 
help establish productive infections [217]. For example, EVs released from hepatitis C virus 
(HCV) infected cells contained replication competent viral RNA that successfully establish 
infection in naïve cells [251, 252]. In addition, EVs transport molecules that promote viral 
replication by suppressing host immune responses, such as the antiviral interferon (IFN) 
response, as has been demonstrated during enterovirus 71 (EV71) infection [250]. However, 
viral infections do not often occur in isolation and there is an increasing appreciation for the 
prevalence and severity of polymicrobial infections involving viruses. Viral-bacterial interactions 
in the respiratory tract have received notable attention due to the severity of secondary bacterial 
infection following viral infection in both acute infections, such as pneumonias, and chronic 
diseases, such as CF lung disease. Although synergistic virulence is commonly observed in these 
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infections, it remains poorly understood how EVs impact viral-bacterial polymicrobial infections 
in the airways.  
CF is a genetic disease caused by mutations within the cystic fibrosis transmembrane 
conductance regulator (CFTR) ion channel. Reduced CFTR function in the airways results in 
thick mucus secretions that are difficult to clear due to decreased innate defenses, such as 
mucociliary clearance [325, 344]. This creates a favorable environment for microbial 
colonization and persistence. Pseudomonas aeruginosa is a commonly isolated bacterial 
pathogen in the CF lung that forms chronic infections in the airways of most adult CF patients, 
and causes much of morbidity and mortality in patients. The development of chronic P. 
aeruginosa infections in the CF lung often involves the transition to a biofilm-associated 
lifestyle, which can protect the bacteria from the host immune response and antibiotics [44, 46]. 
P. aeruginosa is rarely the only microbe that is present in the CF lung [6]. Extensive amount of 
research has focused on bacterial communities and bacterial-bacterial interactions in the CF lung. 
However, much less is known about the mechanisms underlying viral-bacterial interactions in 
the CF lung, despite clinical studies strongly linking respiratory viral infection with P. 
aeruginosa coinfection and the development of chronic P. aeruginosa infection in patients [53, 
55, 71, 72, 79, 330].  Because antimicrobials are ineffective at treating chronic infections in the 
CF lung, a better understanding of the factors that drive biofilm development in the airways may 
help identify alternative therapeutic strategies to either prevent chronic bacterial infections or 
treat already established biofilms. 
Many environmental factors contribute to P. aeruginosa biofilm growth, including the 
nutrient iron. Although iron is essential for microbial growth and the host tightly regulates iron 
accessibility to prevent infection, iron levels in the CF lung are significantly increased compared 
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to non-CF airways [23, 24, 26, 29]. Increased iron levels are correlated with increased bacterial 
burden and decreased pulmonary function in the CF lung, but the mechanisms that contribute to 
increased iron levels in the CF airways are unknown [25, 28]. We have shown the respiratory 
viral infection produces an environment that promotes P. aeruginosa biofilm growth through the 
increased release of iron into the airways (Chapter 3), suggesting virus infection alters iron 
homeostasis in the lung. Many proteins involved in metal homeostasis have been identified on 
EVs [345], but it is not known what function EVs have in metal homeostasis, and which metal 
and metal-binding proteins are loaded onto EVs in the lung and how airway infection alters 
metal abundance in EV populations in the airways.   
To gain a better understanding of how EVs impact viral-bacterial interactions at a 
mucosal surface, we determined whether EVs isolated from AECs influence P. aeruginosa 
biofilm development during respiratory viral coinfection in a model of CF lung disease. In this 
study, we show that EVs isolated from AECs during respiratory viral infections enhance P. 
aeruginosa biofilm growth. In addition, we show that virus infection increases iron accessibility 
to promote P. aeruginosa biofilm growth. Our results demonstrate that the release of EVs in the 
respiratory tract is an important factor in the interactions that occur during polymicrobial 
infections. Additionally, our study offers new insight into our understanding of nutritional 
immunity in the lung and how the host contributes to the development of bacterial biofilm-
associated infections during respiratory viral infection. 
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4.2 RESULTS 
4.2.1 Extracellular vesicles isolated from AECs stimulate P. aeruginosa biofilm growth 
during respiratory viral infection 
Previously, we have observed that in the apical secretions collected from RSV-infected AECs 
[termed “conditioned media” (CM)], was capable of enhancing P. aeruginosa biofilm growth 
(Figure 22A). To determine if EVs were required for CM-mediated bacterial biofilm formation, 
we depleted apical secretions from RSV-infected cells of EVs and measured biofilm formation in 
the presence of vesicle-depleted CM. We found that CM from RSV-infected cells that had been 
depleted of EVs by ultracentrifugation was unable to stimulate P. aeruginosa biofilm growth 
(Figure 22A), implying that EVs are required for virally-induced P. aeruginosa growth in CM. 
In addition, we filtered CM through 100 kDa filters, which would trap any large protein 
complexes or vesicles but allow smaller, soluble proteins to flow-through. Filtrate from RSV-
infected AECs was unable to stimulate P. aeruginosa biofilm formation compared to CM 
(Figure 22B). However, we observed that concentrate from RSV-infected cells maintained the 
ability to greatly increase biofilm growth, similar to CM that had not been filtered (Figure 22B). 
Taken together, these results suggest that respiratory viral infection increases EV release from 




Figure 22: EVs are required for P. aeruginosa biofilm growth in apical secretions from RSV-infected AECs. 
AECs were infected with RSV or mock-infected (MEM control) for 72 hr and the apical CM was collected. CM was 
depleted of EVs by (A) ultracentrifugation or (B) 100 kDa filtration. (A) P. aeruginosa (GFP) biofilms were grown 
in the presence of CM in static abiotic biofilm assays. Fluorescent microscopy was used to measure biofilm growth. 
Biomass was quantified using Nikon Elements (unit grid = 7.5 µm). (B) P. aeruginosa were grown in CM for 24 hr 
in a 96-well microtiter biofilm assay following 100 kDa filtration. Biofilm growth was measured as absorbance at 
550 nm following crystal violet staining. Cond. Media, CM not filtered; 100 kDa Filtrate, flow-through from 100 
kDa filtration; 100 kDa Concentrate, media that did not flow through 100 kDa filter. For all experiments n ≥ 3. Data 
are presented as mean ± SD; *P < 0.05 versus control. 
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To determine if EVs released from airway epithelial cells, ∆F508/∆F508 cystic fibrosis 
bronchial epithelial cells (CFBE41o-, referred to as “AECs” hereafter), during respiratory viral 
infection were capable of enhancing P. aeruginosa biofilm growth, we isolated EVs from AECs 
infected with RSV using ultracentrifugation. We measured biofilm growth in the presence of 
EVs but in the absence of AECs, as described previously [346]. Interestingly, we found that EVs 
from RSV-infected cells significantly increases biofilm growth in the absence of AECs on 
abiotic surfaces, as measured by fluorescent microscopy and 96-well microtiter biofilm assays 
(Figure 23A-B). Further experiments are planned to determine whether EVs isolated from RSV-
infected, non-CF AECs also stimulate P. aeruginosa biofilm growth. Based on our observations 
that RSV co-infection increases biotic biofilm growth of P. aeruginosa on non-CF HBEs 
(Figure 7A), we hypothesize that EVs isolated from non-CF cells infected with RSV will also 
stimulate P. aeruginosa biofilm growth. We observed that many of the proteins commonly used 
as protein markers for EVs were also present in the EVs we isolated from AECs, while the 
absence of GM130 (a Golgi marker) and calnexin (an endoplasmic reticulum marker) confirmed 
no cell debris in our EV preparations (Figure 24A). Furthermore, the size and morphology of the 
isolates EVs were confirmed by electron microscopy and Nanoparticle Tracking Analysis (NTA) 
(Figure 24B-C). RSV infection increased the release of EVs from AECs, as assessed by both 
western blot and NTA. We observed that although EVs contained RSV proteins and RNA 
(Figure 24D-E), the EVs population we isolated did not contain infectious viral particles, as 
measured by plaque assay (Figure 24F). These data suggest that infectious RSV particles are not 
responsible for the biofilm stimulatory activity of EVs isolated from RSV-infected AECs. These 
results are consistent with previous observations that purified RSV does not stimulate P. 
aeruginosa biofilm formation (Figure 9A), further suggesting that infectious RSV particles are 
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not responsible for virus-mediated biofilm growth. To examine whether EV-mediated P. 
aeruginosa biofilm growth was specific to RSV infection, we isolated EVs from AECs infected 
with another respiratory virus commonly found in CF patients, human rhinovirus (hRV). 
Interestingly, we observed that EVs from hRV-infected cells also increased P. aeruginosa 
biofilm growth in the absence of AECs, as measured by fluorescent microscopy (Figure 23C).  
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Figure 23: Respiratory viral-infected AECs release EVs that stimulate P. aeruginosa biofilm growth. 
(A and B) AECs were infected with RSV or mock infected (MEM control) for 72 hr and then EVs were isolated 
from apical CM. (A) P. aeruginosa (GFP) was grown in the presence of isolated EVs in static abiotic biofilm assays. 
Fluorescent microscopy was used to measure the growth of P. aeruginosa, and biomass was quantified by Nikon 
Elements (grid unit = 8 µm) (B) P. aeruginosa biofilms were grown for 24 hr in 96-well microtiter biofilm assay. 
Biomass was quantified by crystal violet staining and absorbance was measured at 550 nm. (C) AECs were infected 
with hRV (MOI = 0.1) or mock infected (MEM control) for 72 hr and then EVs were isolated from apical CM. P. 
aeruginosa (GFP) biofilms were grown in the presence of EVs in static abiotic biofilm assays. Biofilm biomass was 
quantified using Nikon Elements (grid unit = 10 µm). Control, EVs from mock-infected AECs; RSV, EVs from 
RSV-infected AECs. For all experiments n ≥ 3. Data are presented as mean ± SD; *P < 0.05 versus control. 
 121 
 
Figure 24: Characterization of EVs released by AECs. 
EVs were prepared from AECs following 72 hr infection with RSV or mock infected (MEM control). (A) Western 
blot analysis of EV and non-EV marker proteins in whole cell lysates (WCL) and EVs. n=3. (B) Nanoparticle 
Tracking Analysis (NTA) of EVs released by AECs. n=2. (C) Electron microscopy of EVs prepared from mock-
infected AECs was performed to verify the size and morphology of AEC-released vesicles. (D) Western blot 
analysis of RSV proteins in WCL and EV preparations. IB = immunoblot. n=3. (E-F) EVs were prepared from 
AECs following 72 hr RSV infection. qRT-PCR analysis was performed for the RSV N and L genes in cells and in 
EVs prepared from those cells. n=2. (F) Plaque assay of conditioned media (Cond. Media) and EVs collected from 
AECs infected with RSV for 72 hr. n= 3. Data are presented as mean ± SD; *P < 0.05 versus control. 
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To further examine the mechanism by RSV EVs stimulate P. aeruginosa biofilm growth, 
we next investigated whether EVs from RSV-infected AECs increase bacterial attachment to an 
abiotic surface. We found that there was no difference in the number of bacteria that attached in 
the presence of EVs from uninfected and RSV-infected cells (Figure 25A). Moreover, there was 
no difference in P. aeruginosa attachment between EVs or in minimal media (MEM) (Figure 
25A). Because EVs from RSV-infected cells stimulated biofilm growth but did not increase 
bacterial attachment, we hypothesized that EVs from RSV-infected AECs increase bacterial 
growth. To test this hypothesis, we compared the growth of P. aeruginosa in EVs isolated from 
uninfected and RSV-infected AECs, and we found that RSV EVs significantly enhanced P. 
aeruginosa growth compared to EVs from uninfected cells (Figure 25B). Taken together, these 
results indicate that EVs isolated from RSV-infected cells contain biofilm stimulatory molecules, 
which are either absent or present in significantly reduced levels on EVs from uninfected AECs, 




Figure 25: RSV EVs increase P. aeruginosa growth but not adherence to abiotic surfaces. 
(A) P. aeruginosa (GFP) was grown in the presence of EVs isolated from AECs in static abiotic biofilm assays. 
After 1 hr, any unattached bacteria were washed away and attached bacteria were measured using fluorescent 
microscopy. Nikon Elements was used to count bacteria. (B) Growth kinetics in EVs isolated from AECs infected 
with RSV or mock-infected (MEM control) for 72 hr. For all experiments n ≥ 3. Data are presented as mean ± SD; 
*P < 0.05 versus control. 
 
4.2.2 RSV infection increases iron bioavailability on extracellular vesicles to promote 
biofilm growth  
Iron is required for many biological processes, including P. aeruginosa biofilm growth on both 
abiotic and biotic surfaces [27, 37, 43, 204]. We have previously observed that RSV infection 
increases extracellular iron in CM collected from AECs (Figure 17). However, it is not known if 
iron and other metals are loaded into EVs released by the respiratory epithelium. To examine if 
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EV contain iron and RSV infection altered iron abundance in EVs, we measured total iron in 
EVs collected from uninfected and RSV-infected AECs and observed that RSV infection 
increased total iron in EVs isolated from AECs (Figure 26A). Although iron is necessary for P. 
aeruginosa biofilm formation, other transition metals are abundant in biological systems and are 
involved in important physiological processes. For example, zinc supplementation has recently 
been shown to increase P. aeruginosa biofilm growth [347]. In addition, copper is a redox-active 
metal that participates in many redox reactions in bacteria and has been shown to be increased in 
the sputum of CF patients, along with zinc and iron [30, 348]. Therefore, we also measured the 
abundance of other transition metals in extracellular vesicles to determine if virus infection was 
increasing the abundance of other metals in EVs. We found that virus infection caused a slight 
increase in zinc concentrations in EVs, but that copper concentrations were unchanged by RSV 
infection (Figure 26B-C).  
 
 
Figure 26: RSV infection increases iron release on EVs. 
AECs were infected with RSV or mock-infected (MEM control) for 72 hr and EVs were isolated from apical CM. 
(A) Total iron, (B) zinc, and (C) copper in the EVs from AECs. RSV, RSV-infected AECs. For all experiments n ≥ 
3. Data are presented as mean ± SD; *P < 0.05 versus control. 
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Importantly, the presence of iron was necessary for P. aeruginosa biofilm growth in the 
presence of EVs isolated from RSV-infected cells because chelation of iron, using the iron-
chelating agent Chelex-100, significantly decreased biofilm formation in the presence of EVs 
(Figure 27A). NTA was performed after Chelex-100 treatment to verify that EV abundance or 
morphology was not changed by iron chelation (Figure 27B). Future experiments will test the 
hypothesis that adding back exogenous iron sources to chelated EVs will restore biofilm growth. 
Taken together, these results suggest that P. aeruginosa utilizes iron localized on EVs to form 
biofilms during RSV coinfection. Moreover, RSV infection increases total iron abundance in 




Figure 27: Iron is required for P. aeruginosa biofilm growth. 
EVs were isolated from AECs infected with RSV or mock-infected (MEM control) for 72 hr. Divalent metal cations 
were chelated with Chelex-100 (labeled “+ Chelex”). (A) P. aeruginosa (GFP) was grown in the presence of EVs in 
static abiotic biofilm assays and fluorescent microscopy was used to measure biofilm growth. Nikon Elements was 
used to quantify biofilm growth (grid unit = 8.0 µm). RSV, RSV-infected AECs. For all experiments n ≥ 3. Data are 




4.2.3 RSV infection increases transferrin abundance on extracellular vesicles  
Nutritional immunity postulates that the host restrict the availability of nutrients from bacteria 
and other pathogenic microorganisms. In regard to metal restriction, one the strategies utilized by 
the host is the chelation of metals with high-affinity proteins that sequester metals from 
pathogens, such as lactoferrin and transferrin. In response to iron limitation P. aeruginosa 
increases the production of the siderophores pyochelin and pyoverdine [205]. Thus, we measured 
pyoverdine production during P. aeruginosa biofilm growth in the presence of EVs to determine 
whether EVs provide an iron-restricted or iron-replete environment for biofilm formation. We 
observed that pyoverdine production in the presence of EVs is not changed by RSV infection 
(Figure 28A). Moreover, the levels of pyoverdine produced by P. aeruginosa grown in the 
presence of EVs mirrored pyoverdine production in iron-restricted environments (i.e. MEM or 
iron-bound transferrin) (Figure 28A). Conversely, pyoverdine production was significantly 
higher when P. aeruginosa biofilms were grown in the presence of EVs compared to an iron-
replete environment (i.e. FeCl3) (Figure 28A). In these experiments, we grew P. aeruginosa in 
the same levels of iron as measured in our EV preparations (i.e. 10 µM FeCl3 and 5 µM holo-
transferrin). Taken together, these data suggest that iron associated with EVs is sequestered from 




Figure 28: RSV infection increases transferrin abundance in EVs. 
EVs were isolated from AECs infected with RSV or mock-infected (MEM control). (A) P. aeruginosa was grown in 
the presence of EVs, FeCl3 (10 µM) or holo-transferrin (5 µM) in static abiotic biofilm assays. At the end of assays, 
supernatants were removed and analyzed for pyoverdine (excitation: 400 nm, emission: 447 nm) and normalized to 
the density of bacteria (OD600). (B) RSV infection increases transferrin abundance in EVs, as measured by Western 
blot analysis. RSV, RSV-infected AECs. For all experiments n ≥ 3. Data are presented as mean ± SD; *P < 0.05 
versus control. 
 
Because RSV infection increases iron abundance in our EV preparations and P. 
aeruginosa responds to EVs with increased pyoverdine production, we next examined whether 
RSV infection alters the release of iron-binding proteins on EVs that may sequester iron. 
Interestingly, we found that RSV infection increased the abundance of only transferrin within our 
preparations of EVs (Figure 28B). Transferrin supports the growth of many bacterial species, 
including P. aeruginosa, and is a component of airway secretions that can promote P. 
aeruginosa biofilm growth [27]. Importantly, we have previously shown RSV infection increases 
the apical release of transferrin, and that biofilm growth in the presence of RSV coinfection 
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requires transferrin secretion from AECs (Figure 20B). Collectively, these results demonstrate 
that RSV infection of AECs increases apical transferrin release on EVs.  
4.2.4 RSV infection increases transcytosed transferrin release on EVs in the apical 
compartment 
Because transferrin is primarily a serum glycoprotein that is taken up and recycled at the 
basolateral membrane of cells, we next determined whether transferrin in the basolateral 
compartment of cells is transcytosed and released apically on EVs. We have previously 
determined that RSV infection promotes the transcytosis of transferrin from the basolateral to 
apical compartment of cells (Appendix A), but it is unknown if the transcytosed transferrin is 
released on EVs. We determined whether transferrin is transcytosed apically and loaded on EVs 
during RSV infection by adding biotinylated transferrin to the basolateral media and then 
assayed for biotinylated transferrin on EVs 24 hours later (Figure 29A). We found that 
biotinylated transferrin was associated with EVs released apically by AECs, and that 
significantly more biotinylated transferrin was released in association with EVs during RSV 
infection (Figure 29B). Interestingly, we observed that all the transferrin that was associated 
with apically released EVs was affinity purified due to the absence of transferrin in the 
supernatant we collected from the streptavidin resin (Figure 29B), indicating that the transferrin 
loaded onto EVs originated in the basolateral compartment. Additionally, we conclude that the 
transcytosed transferrin was localized to the outside of EVs because streptavidin resin would not 
have been able to access proteins on the inside of vesicles. This suggests that we would have 
affinity purified EVs loaded with transferrin in our experiments. To test this hypothesis, probed 
for marker proteins of EVs and found that ALIX, Tsg101, Hsp90, and MHC-I were affinity 
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purified with biotinylated transferrin (Figure 29B). Interestingly, we observed that CD81 and 
Flotillin-1, as well as small amounts of ALIX, Tsg101, Hsp90 and MHC-I, were present in the 
supernatant we collected from the streptavidin resin (Figure 29B), indicating these proteins were 
not affinity purified with biotinylated transferrin. Thus, our data suggest at least two EV 
populations exist, one of which is transferrin-positive. In addition, we observed that RSV 
proteins were present in the EV population that was affinity purified with biotinylated 
transferrin, as well as the vesicle population that was negative for biotinylated transferrin 
(Figure 29C), indicating RSV proteins are present in two EV populations we purified. To 
determine whether transferrin-positive EVs were necessary for biofilm growth in the presence of 
EVs from RSV-infected AECs, we grew P. aeruginosa in EVs that had been depleted of 
transferrin-positive vesicles. We found a significant decrease in P. aeruginosa biofilm growth in 
the presence of EVs when transferrin-positive vesicles were removed from our EV preparations 
(Figure 29D). Taken together, these data support that conclusion that at least two EV 
populations are released by AECs. One of these vesicles populations contains transcytosed 
transferrin loaded on the outside of vesicles, and are necessary for P. aeruginosa biofilm growth 
in the presence of EVs isolated from RSV-infected AECs.   
P. aeruginosa utilizes two siderophores, pyochelin and pyoverdine, to acquire iron. 
Pyoverdine has a higher affinity for iron and is capable of acquiring iron directly from transferrin 
[206]. Because we have previously observed that P. aeruginosa produces pyoverdine in the 
presence of EVs and that transferrin is on the outside of EVs, we hypothesized that P. 
aeruginosa acquires iron from EVs using its siderophores during biofilm growth. Our lab has 
previously demonstrated that a P. aeruginosa mutant (∆pvdA∆pchE) unable to produce either of 
its siderophores (pyoverdine or pyochelin) has a decreased ability to form biofilms during RSV 
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co-infection where iron-loaded transferrin abundance is increased. We found that P. aeruginosa 
biofilm growth in the presence of EVs from RSV-infected cells was reduced with a ∆pvdA∆pchE 
mutant compared to wild type P. aeruginosa (Figure 30). Collectively, these results suggest that 
P. aeruginosa siderophores are required for the full biofilm induction observed in the presence of 
EVs isolated from RSV-infected AECs. EVs are a likely source of multiple nutrients besides 
iron-loaded transferrin, and our data indicate that the nutrient-rich environment potentially 





Figure 29: Transferrin released on EVs in the apical compartment of AECs is transcytosed. 
(A) AECs were infected with RSV or mock-infected (MEM control) for 48 hr. Biotin-transferrin was added to the 
basal chamber of RSV or mock-infected AECs at a final concentration of 25 µg/mL. EVs were collected from the 
apical CM of AECs 24 hours later and biotinylated-transferrin was affinity-purified from EV preparations with 
streptavidin-coated beads. Bead-bound proteins, which are positive for biotin, were eluted from the resin with 
Laemmli Sample Buffer supplemented with dithiothreitol (DTT) (Tfn IP) and separated by SDS-PAGE. Supernatant 
from the streptavidin resin (IP Sup), which are negative for biotin, was also separated by SDS-PAGE. (B) 
Transcytosed transferrin and protein markers of EVs proteins were measured by Western blot analysis in Tfn IP 
(biotin-positive) and IP Sup (biotin-negative) fractions. (C) Tfn IP (biotin-positive) and IP Sup (biotin-negative) 
fractions were analyzed by western blot analysis for RSV proteins. IB = immunoblot. (D) P. aeruginosa (GFP) was 
grown in the presence of EVs in static abiotic biofilm assays following biotin affinity purification to remove 
transferrin-positive vesicles. Biofilm growth was measured by fluorescent microscopy, and biomass quantified by 





Figure 30: Biofilm formation of P. aeruginosa ∆pvdA∆pchE mutant in presence of EVs. 
(A and B) AECs were infected with RSV or mock infected (MEM control) for 72 hr and then EVs were isolated 
from apical CM. (A) P. aeruginosa WT or ∆pvdA∆pchE mutant (GFP) was grown in the presence of isolated EVs in 
static abiotic biofilm assays. Fluorescent microscopy was used to measure the growth of P. aeruginosa, and biomass 
was quantified by Nikon Elements (grid unit = 9 µm). For all experiments n ≥ 3. Data are presented as mean ± SD; 
*P < 0.05 versus control. 
4.2.5 Extracellular vesicles interact with P. aeruginosa  
EVs commonly deliver biologically molecules (i.e. proteins, RNAs and/or lipids) to modify the 
function of recipient cells. Because we observed that EVs isolated from RSV-infected AECs 
stimulated P. aeruginosa biofilm growth, we focused on determining whether EVs deliver 
biofilm stimulatory molecules to bacteria during RSV infection. To begin testing this hypothesis, 
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we first examined whether P. aeruginosa can interact with fluorescently labeled EVs from 
uninfected and RSV-infected AECs. We used the CellTracker Deep Red, a fluorescent dye that 
labels the cytoplasm of cells, and thus, the inside of EVs released by AECs (Figure 31A). We 
then isolated EVs from uninfected and RSV-infected cells and measured the ability of P. 
aeruginosa to bind fluorescently labeled EVs when grown in the presence of these vesicles. We 
observed that EV association with P. aeruginosa increases over time, and interestingly, that P. 
aeruginosa associated with a greater amount of EVs isolated from RSV-infected than uninfected 
cells (Figure 31B). This is likely a consequence of RSV infection promoting increased EV 
release from AECs (Figure 23). However, these experiments were carried out over short 
intervals with planktonic bacteria and did not examine whether EVs associated with P. 
aeruginosa during biofilm development. Therefore, to further test whether EVs associate with P. 
aeruginosa, we performed static abiotic biofilm assays with EVs and measured EV association 
with P. aeruginosa biofilms by Western blot analysis. We observed the presence of host EV 
marker proteins (MHC-I and TfnR) in bacterial biofilms (Figure 31C), confirming an increased 
association of EVs from RSV-infected cells with P. aeruginosa biofilms. Further experiments 
will need to be performed to validate the interaction of EVs with P. aeruginosa, and we have 
plans to perform flow cytometry and fluorescent microscopy to confirm the interaction between 
P. aeruginosa and fluorescent EVs. Collectively, these results demonstrate that AEC-derived 




Figure 31: EVs associate with P. aeruginosa. 
AECs were infected with RSV or mock-infected (MEM control). 48 hpi AECs were stained with CellTracker Deep 
Red and EVs were isolated from cells 24 hours later. (A) Fluorescence of EV preparations was measured with 
fluorescent plate reader (excitation: 630 nm, emission: 660 nm). (B) P. aeruginosa was grown in the presence of 
fluorescent EVs for the indicated number of hours and then washed with MEM two times. P. aeruginosa 
fluorescence was measured with plate reader (excitation: 630 nm, emission: 650 nm). (C) P aeruginosa biofilms 
were grown in the presence of EVs in static abiotic biofilm assays, and Western blot analysis of P. aeruginosa 
biofilm whole cell lysate (WCL) was used to measure the association of EVs with P. aeruginosa biofilms. RSV, 
RSV-infected AECs. n=2. Data are presented as mean ± SD.  
 
To validate the importance of transferrin loading onto EVs for P. aeruginosa biofilm 
induction by EVs isolated from RSV-infected AECs, we grew P. aeruginosa in the presence of 
either free iron or free iron-bound transferrin (Figure 32) we observed that biofilm formation 
was significantly less than in the presence of EVs from RSV-infected cells. Because the iron 
amounts we used were equivalent to what was measured on EVs isolated from RSV-infected 
cells, these data imply that the delivery of iron on EVs is important for promoting P. aeruginosa 
biofilm growth during RSV coinfection. Taken together, these results are consistent with the 
conclusion that RSV infection increases transcytosed transferrin on EVs, thereby providing an 
accessible iron source for P. aeruginosa during biofilm growth. Additionally, these results 
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suggest that EVs released by AECs during RSV infection interact with P. aeruginosa and this 
may be a mechanism by which nutrient-rich microenvironments are created near the bacteria to 
promote biofilm growth.   
 
 
Figure 32: Free iron sources do not stimulate P. aeruginosa biofilm growth. 
P. aeruginosa was grown in the presence of FeCl3 or holo-transferrin in static abiotic biofilm assays. Biofilm growth 
was measured by fluorescent microscopy and Nikon Elements was used to quantify biomass (grid unit = 7.5 µm). 
Representative static abiotic biofilm assay in the presence of EVs isolated from AECs infected with RSV (72 hr 
infection) is shown for comparison. Biomass of P. aeruginosa biofilm growth in the presence of EVs isolated from 
RSV-infected cells is shown with hatched bar (data obtained from Figure 23A for comparison). No significant 
difference in P. aeruginosa biofilm growth was observed between different iron sources and MEM. RSV, RSV-
infected AECs. EVs, Extracellular Vesicles. For all experiments n = 3. Data are presented as mean ± SD.  
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4.3 DISCUSSION 
EVs are membrane-encapsulated vesicles released by most cell types, including in the airways, 
into the extracellular environment that facilitate physiological changes in neighboring cells. 
Although EVs have been studied in the context of viral pathogenesis to modify the local 
environment to the benefit of the host or the virus [217], very little is understood about the role 
of EVs in polymicrobial infections in the respiratory tract. Here, we demonstrated that EVs 
released from the respiratory epithelium during RSV infection stimulates P. aeruginosa biofilm 
growth through a mechanism dependent upon increased iron-loaded transferrin release on EVs. 
The transferrin is oriented on the outside of vesicles, which makes it an accessible iron source for 
P. aeruginosa biofilm formation. Moreover, we show the EVs associate with P. aeruginosa and 
that EVs loaded with iron-bound transferrin are much more efficient at stimulating P. aeruginosa 
biofilm growth than free iron or iron-bound transferrin of equal concentrations. Importantly, our 
findings propose a novel role for EVs during viral-bacterial co-infections as a virally-induced 
nutrient source for bacteria. Our studies provide further understanding for the clinical 
observation that respiratory viral infection promotes chronic bacterial infections in patients with 
chronic lung disease [53, 71, 72, 79]. Importantly, the findings presented here further 
demonstrate that respiratory viral infection alters the lung environment to make it more 
susceptible to secondary bacterial infection, and increases our understanding how viruses and 
bacteria interact in the lung.  
Although EVs are known to be secreted into the airways [338, 343], very little is known 
about the biological function of EVs during respiratory infections. During virus infection in other 
organs, EVs are known to facilitate viral spread by protecting the genomes from antibody-
mediated neutralization or transferring pro-viral molecules between cells [250-252]. 
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Alternatively, it is also known that EVs can transfer antiviral molecules between cells that inhibit 
virus infection [216, 266], or may contain molecules with neutralizing activity against viruses, as 
has been shown with respiratory epithelial-derived EVs that contain sialic acid [339]. How EVs 
impact the outcome of viral-bacterial infections or how host-derived EVs influence bacterial 
behavior in the airways remain unanswered questions. In our study, RSV infection increases the 
apical release of EVs from AECs to promote P. aeruginosa growth and biofilm development. 
We interpret these findings to suggest that during respiratory viral infection the airway 
epithelium releases EVs that interact with bacterial pathogens to create a local nutrient-rich 
environment at the mucosal surface that promotes bacterial biofilm growth, which are associated 
with chronic infections. The increased release of EVs from the respiratory epithelium is 
consistent with other studies that have observed epithelial cells increase EV release in response 
to stress (i.e. infection.) [250, 349-351]. Interestingly, our study demonstrates that increased EV 
release in response to one infection promotes a secondary infection.  
Previous studies of viral-bacterial interactions in the respiratory tract have mainly 
identified two mechanisms by which virus infection promotes secondary bacterial infections and 
decreases bacterial clearance: (i) increased bacterial adherence to virally infected cells, and (ii) 
alterations in the antibacterial immune response induced by viral infection [352]. Recently, 
studies have begun investigating how the nutritional environment in the airways is altered by 
respiratory viral infections to the benefit of bacteria. For example, it has been shown that 
influenza A infection increases the abundance of sialylated mucins in the airways, which is used 
as a nutrient source that promotes S. pneumoniae growth [353]. In the work presented in this 
dissertation, we have shown the RSV infection increases iron levels in the airway surface liquid 
to promote P. aeruginosa biofilm growth (Chapter 3). Here, we have extended these studies to 
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show that the release of iron on EVs released by AECs is one mechanism by which RSV 
infection promotes P. aeruginosa biofilm growth. EVs contain biologically active proteins, lipids 
and RNAs, and our study demonstrates that iron, and potentially other nutrients, are also present 
on host-derived EVs and contribute to host-pathogen interactions in the airways. 
Iron is required for many biological processes in humans, but it is tightly regulated to 
limit the levels of accessible iron during an infection and to prevent iron intoxication by a 
process that is termed nutritional immunity [182, 187]. Previous studies have demonstrated the 
requirement of iron for P. aeruginosa biofilm formation [27, 37, 43, 204]. Moreover, bacterial 
burden and decreased pulmonary function are correlated with increased iron levels in the CF 
lung [25, 28], but the impact of respiratory viral infections on the nutritional environment in the 
airways is not well understood. We have previously shown that RSV infection dysregulates this 
process to promote the apical release of iron-loaded transferrin to stimulate P. aeruginosa 
biofilm growth (Chapter 3), but the mechanism by which iron-loaded transferrin was released 
by AECs was unidentified. Our current study suggests that one mechanism by which RSV 
infection increases the release of iron-loaded transferrin is on EVs from the respiratory 
epithelium. Importantly, the transferrin is localized on the outside of EVs, making it accessible to 
bacterial pathogens, and iron chelation significantly reduced biofilm growth in the presence of 
EVs released by RSV infected cells, suggesting that iron chelation is a potential therapeutic 
strategy to disrupt EV-mediated biofilm growth during virus infection. Previous results have 
demonstrated that iron chelation inhibits P. aeruginosa biofilm growth on AECs and that iron 
chelators augment antibiotic-mediated disruption of biofilms on cells [27, 49, 354]. Due to our 
incomplete knowledge on the biological importance of EVs to airway physiology, iron chelators 
may be an important and most effective therapeutic strategy that effectively counteracts EV-
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mediated bacterial infections in the airways of CF patients during respiratory viral seasons. 
Furthermore, it will be imperative in future studies to determine if other nutrients besides iron are 
loaded onto EVs and can be utilized as a nutrient source by P. aeruginosa. 
Our study demonstrates that iron-loaded transferrin is localized to the outside of EVs, 
thereby making the iron accessible to bacterial pathogens that are able to circumvent transferrin-
mediated iron sequestration. P. aeruginosa is particularly proficient at acquiring iron from the 
environment, and has been shown to overcome transferrin-mediated iron sequestration through 
the production of siderophores [206]. Our data demonstrate that a ∆pvdA∆pchE mutant unable to 
produce siderophores has a reduced ability to form biofilms in the presence of EVs from RSV-
infected cells. Whether P. aeruginosa uses other mechanisms to overcome transferrin-mediated 
iron sequestration and acquire iron from EVs is an area of future investigation. Previously, we 
have demonstrated P. aeruginosa produces proteases capable of degrading transferrin 
(Appendix A), but determining whether transferrin and other surface proteins loaded onto EVs 
are degraded by P. aeruginosa is unknown but could help define the interaction that exists 
between P. aeruginosa and EVs. Moreover, longitudinal analysis of P. aeruginosa clinical 
isolates from CF patients suggest that pyoverdine production is higher in early isolates and that 
later isolates have increased expression of other iron-acquisition systems (i.e. heme-acquisition 
systems) [212, 213]. It will be of interest to see if EVs from RSV-infected cells stimulate P. 
aeruginosa biofilm growth with early and late clinical isolates, or if the interaction between EVs 
and P. aeruginosa changes over time. 
EVs commonly exert their biological effects on the local environment by delivering 
biologically molecules (i.e. proteins, RNAs and/or lipids) to recipient cells. Although the 
interaction between host-derived EVs and bacteria has not been investigated before, our data 
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suggest that EVs derived from the airway epithelium associate with P. aeruginosa, regardless of 
RSV infection. We interpret these results, coupled with increased iron-bound transferrin bound 
to EVs-derived from RSV infected cells, to indicate that EV association with P. aeruginosa 
during RSV coinfection creates a microenvironment that is rich in nutrients and promotes 
bacterial biofilm formation. Previous reports have demonstrated that host-derived EVs bind to 
the surface of parasites, which either protects parasites from immune-mediated lysis or promotes 
parasite killing depending upon the type of infection and cell type that produces the EVs [351, 
355]. It is not clear what mechanism is responsible for EV association with P. aeruginosa, but 
interesting areas of future investigation will be aimed at understanding if the association of EVs 
with bacteria is specific to P. aeruginosa, how EVs associate with bacteria, and what bacterial 
and host factors are required for the interaction between P. aeruginosa and EVs. Moreover, it 
will be interesting to see if host molecules are delivered directly into the periplasm of P. 
aeruginosa and thereby, bypassing its outer membrane.  Also, it is not known if EVs derived 
from other cell types also interact with bacteria. Although these questions were beyond the scope 
of this study, they are interesting areas of future investigation that could potentially have 
implications for drug delivery. 
Due to the structural similarity between RNA virus particles and EVs, which may contain 
viral components, it is extremely difficult to specifically separate virions and EVs, and it has 
been suggested that during virus infection a diverse population of vesicles are released from cells 
[217, 226]. We observed that at least two distinct subpopulations of EVs were released from 
AECs during RSV infection, one of which were transferrin-positive EVs. Because depletion of 
transferrin-positive EVs significantly reduced P. aeruginosa biofilm growth in the presence of 
EVs from RSV-infected cells, we conclude that this subpopulation of EVs was responsible for 
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the biofilm stimulatory effect of EVs released during RSV infection. Thus, we interpret our 
findings to suggest that during RSV infection a diverse population of EVs are released by AECs, 
and that it is specifically the increase in the subpopulation of transferrin-positive EVs that is 
responsible for increased P. aeruginosa biofilm growth.  
Clinical studies strongly correlate respiratory viral infection with the acquisition of 
chronic P. aeruginosa infection in CF patients, as well as poor bacterial clearance in other lung 
diseases as a result of viral-bacterial coinfections, but the mechanisms underlying these 
interactions remain poorly understood. In this report, we demonstrate that respiratory viral 
infection increases the release of EVs from epithelial cells in the airways and are utilized as a 
nutrient source for secondary bacterial infection. Our data suggest a novel nutrient acquisition 
pathway for bacteria and provide mechanistic insight into nutritional immunity in the lung. 
Because it is appreciated that many infectious diseases are polymicrobial and EVs are released 
by most cell types throughout the body, our studies likely have implications for host-pathogen 
and pathogen-pathogen interactions in other diseases.  
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5.0  IMPLICATIONS OF DISSERTATION: CONCLUSIONS AND FUTURES 
DIRECTIONS 
In this dissertation, we have provided mechanistic understanding for the clinical observation that 
respiratory viral infection is well correlated with P. aeruginosa colonization and infection in CF 
patients by coupling biochemical, cell biological and novel live-cell imaging approaches. 
Whereas the majority of studies on viral-bacterial interactions in the respiratory tract have 
focused on alterations in bacterial attachment or host immunity, our studies provide evidence that 
respiratory viral infections also alter nutrient levels in the airways. Complex and incompletely 
understood interactions between the host, virus and bacteria determine disease outcomes in these 
infections. In this body of work, we have specifically addressed questions involving P. 
aeruginosa biofilm growth during viral-bacterial coinfections in the lung, and outlined one 
mechanism by which respiratory viruses interact with P. aeruginosa to promote biofilm 
formation. Because synergy is often reported between viral and bacterial pathogens and there is a 
growing appreciation for the prevalence of polymicrobial infections, identifying functional 
relationships between viruses and bacteria likely has implications for other disease settings 
besides the CF lung and will provide new insight into important biology at mucosal surfaces. 
Our studies demonstrate that respiratory viral infection stimulates the formation of P. 
aeruginosa biofilms on the airway epithelium. We further showed that RSV infection increases 
the apical release of iron and the host-iron binding protein transferrin from AECs, which were 
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required for the P. aeruginosa biofilm growth during RSV coinfection. We extended these 
studies to a mouse model of RSV infection and showed that the virus infection increased both 
iron and transferrin in the airways of mice. Interestingly, BALF from RSV-infected mice was 
sufficient to stimulate P. aeruginosa biofilm growth in vitro. Together, these data demonstrated 
that respiratory viral infection alters iron homeostasis in the lung to increase bioavailable iron to 
promote secondary bacterial infection. Interestingly, we have also demonstrated that EVs 
isolated from RSV-infected cells stimulate P. aeruginosa biofilm growth. During RSV infection, 
EV secretion from AECs was significantly enhanced, which led to an increase in iron and 
transcytosed transferrin associated with EVs. Importantly, we observed that free iron or iron-
bound transferrin, added at the same concentration as found in EVs released by RSV-infected 
cells, did not stimulate P. aeruginosa biofilm growth, suggesting that (i) EVs interact with P. 
aeruginosa to bring nutrients into proximity with the bacteria or (ii) EVs contain other molecules 
that work in tandem with iron to promote the development of biofilms. These are not mutually 
exclusive hypotheses. We show preliminary data that suggests EVs associate with P. aeruginosa, 
but more experiments are required to validate this observation. Collectively, the two studies 
presented in this dissertation demonstrate that RSV infection alters the nutritional environment in 
the airways by promoting the release of iron-bound transferrin. Finally, the innate immune 
response to virus infection, measured by type I and III interferon (IFN–β and –λ, respectively) 
production, peaks at the same time as virus-induced biofilm growth, and interestingly, treatment 
of AECs with IFN–β or –λ replicates the enhanced biofilm formation observed during virus co-
infection. However, we did not observe that IFN treatment alone was sufficient to increase iron 
and transferrin release from AECs (Appendix B), suggesting that IFN treatment activates a 
parallel pathway that stimulates P. aeruginosa biofilm growth in the absence of virus infection. 
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Follow-up studies are now underway to address how IFN treatment enhances P. aeruginosa 
biofilm growth (Appendix B). The observations presented here provide the foundation for 
answering important questions about the early acquisition of bacterial infections in the airways 
and provide novel insight into nutritional immunity in the lung. 
5.1 THERAPEUTIC IMPLICATIONS 
By understanding the mechanisms that contribute to the development of chronic bacterial 
infections, we have an opportunity to identify new therapeutic targets that limit the development 
of these infections. The studies presented in this dissertation suggest that respiratory viral 
infection alters the nutritional environment, in the airways, making it more hospitable for P. 
aeruginosa colonization.  We specifically focused on the nutrient iron in this dissertation, but as 
we have shown, EVs play a role in the ability of respiratory viral infection to promote P. 
aeruginosa biofilm growth. Because EVs contain proteins, lipids and RNAs that can exert 
biological effects on recipient cells, it is also conceivable that EVs may also be a source of 
additional nutrients that promote secondary bacterial infection. Therefore, based on our results, 
we hypothesize that EVs are a source of metals, such as iron and other nutrients, that are utilized 
by bacteria to colonize and survive in the host. Because iron is critical for P. aeruginosa growth 
and biofilm development, targeting bacterial iron uptake may represent a novel therapeutic 
strategy to prevent and/or treat chronic P. aeruginosa infections in the CF lung. Currently, a 
number of approaches are being pursued in the CF field to develop such therapeutics that disrupt 
bacterial iron homeostasis, and we propose that these therapeutic strategies will be useful 
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prophylactics during respiratory viral seasons to limit iron availability and prevent the 
acquisition of bacterial infections in the CF lung.  
5.1.1 Iron Chelators  
In the CF lung, a strong correlation has been reported between bacterial load, disease severity, 
and increased iron levels [28]. Iron is required for P. aeruginosa growth and biofilm 
development [27, 37, 43, 204], which has led to many investigations of iron chelation as a 
therapeutic strategy to limit iron availability in the airways of CF patients and limit bacterial 
colonization. Although the effect of respiratory viral infection on iron levels has not been 
previously examined, the studies presented in this dissertation have found that RSV infection 
increases the apical iron release on EVs from the respiratory epithelium. Importantly, we 
demonstrate that iron chelation reduces virus-mediated P. aeruginosa biofilm growth, suggesting 
exogenous iron chelators may be an effective therapeutic strategy to counteract virus-mediated 
iron release and biofilm growth.      
Lactoferrin is a multifunctional glycoprotein of the transferrin-family of host iron-binding 
proteins that sequesters iron from bacteria and has been shown to inhibit P. aeruginosa biofilm 
growth  in vitro [37]. In these studies, the antibiofilm activity of lactoferrin is attributed to its 
ability to sequester iron based on the observation that iron-loaded lactoferrin was unable to 
inhibit P. aeruginosa biofilm growth, suggesting that iron saturation neutralized the antibiofilm 
activity of lactoferrin [37]. Further studies have also demonstrated that iron chelation reduces P. 
aeruginosa biofilm growth on respiratory epithelial cells [27]. In addition to its iron 
sequestration abilities, lactoferrin possesses antimicrobial activity due to the cationic domains 
found in the N lobe of the protein that facilitate interaction with microbial membranes. The dual 
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functionality of lactoferrin could make it a particularly effective therapeutic supplement that 
chelates iron and thus, neutralizes virus-mediated iron release and P. aeruginosa biofilm growth 
in the CF lung. However, lactoferrin undergoes proteolytic degradation in the airways of CF 
patients due to the presence of host and bacterial proteases; not surprisingly, P. aeruginosa 
infection was associated with greater lactoferrin cleavage [210, 356]. This may limit of the 
efficacy lactoferrin supplementation in vivo, but further studies will be required to determine the 
impact of exogenous lactoferrin on P. aeruginosa burden in the airways of CF patients.   
The effect of the FDA-approved iron chelators deferasirox (DSX) and deferoxamine 
(DFO), used for the treatment of conditions associated with iron overload (i.e. thalassemia and 
hemochromatosis), have also been investigated for their ability to inhibit P. aeruginosa biofilm 
growth on respiratory epithelial cells. These studies found that DSX is much more effective at 
chelating iron and inhibiting P. aeruginosa biofilm formation on AECs [49], which is likely due 
to the fact that P. aeruginosa can use DFO as an iron source [204]. Although P. aeruginosa 
biofilms grown on AECs have significantly higher antibiotic resistance than biofilms formed on 
abiotic surfaces, these studies demonstrated that in combination with tobramycin, both DSX and 
DFO can significantly disrupt and reduce established P. aeruginosa biofilms [49]. A 
combination of lactoferrin and hypothiocyanite have also been shown to increase the ability of 
antibiotics to disrupt established P. aeruginosa biofilms [354]. Taken together, these studies 
strongly suggest that iron chelation used in combination with other therapies may be an effective 
therapeutic strategy for preventing and treating P. aeruginosa infections in the CF lung. The 
significance of this observation is important to consider in the context of the data presented in 
this dissertation. We have shown that respiratory viral infection enhances apical iron release 
from AECs, implying that prophylactic iron chelation or co-administration of antibiotics with 
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iron chelators may be effective strategy to limit P. aeruginosa infections in the CF lung during 
respiratory viral seasons. However, it is not known if prophylactic iron chelation therapy can be 
used in CF patients or if this may exacerbate lung disease, and it is not known if these 
compounds would be stable in the CF lung. 
5.1.2 Gallium: Disruption of bacterial iron metabolism with an iron mimetic  
The transition metal gallium (Ga3+) shares many chemical properties with iron and can bind to 
iron-binding proteins, including transferrin [357]. Because of its ability to disrupt iron 
homeostasis in bacteria and P. aeruginosa biofilm growth, Ga(NO3)3 has been proposed as a 
potential therapeutic to inhibit P. aeruginosa chronic colonization in CF patients [334, 335]. 
Whereas iron has the potential to redox cycle between Fe2+ and Fe3+ oxidation states, which is 
important for many of its biological functions, Ga3+ lacks this ability. Thus, Ga3+ competitively 
inhibits iron-dependent processes by disrupting proteins that function by utilizing iron as a 
cofactor. Currently, Ga3+ is FDA-approved to treat hypercalcemia and is administered 
intravenously as gallium nitrate (Ga(NO3)3; Ganite) and its use as an antimicrobial therapeutic 
is currently being investigated. Because of the ability to interfere with iron-dependent processes, 
a potential approach to inhibiting and treating P. aeruginosa growth and biofilm formation in the 
CF lung is the use of Ga3+ to disrupt bacterial iron metabolism. In vitro studies have shown that 
Ga(NO3)3 both inhibited P. aeruginosa biofilm growth and disrupted established P. aeruginosa 
biofilms [334]. This observation is notable since current antibiotic treatment strategies do not 
prevent the establishment of chronic P. aeruginosa infections and are not effective in clearing 
chronic infections. Clinical studies are now underway to determine the efficacy Ga(NO3)3 in 
improving pulmonary function and for the treatment of P. aeruginosa infections in CF patients 
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[clinicaltrials.gov/ct2 (Identification Numbers: NCT01093521 and NCT02354859)]. Moreover, 
Ga3+ conjugated to DFO (Ga-DFO) has also been investigated, and shown to also inhibit P. 
aeruginosa biofilm growth and disrupt established biofilms [335]. Whether DFO-Ga is more 
effective than Ga(NO3)3 in the CF lung is not known. Moreover, Ga3+ compounds are also 
effective against other bacterial pathogens, suggesting the Ga3+-based therapeutics may be useful 
for the treatment of other bacterial infections in the CF lung, as well at other sites [357]. 
In regards to the data presented in this dissertation and the potential use of Ga(NO3)3 as a 
therapeutic strategy to limit virus-mediated P. aeruginosa biofilm growth, two important points 
need to be considered. First, what is the bioavailability of Ga3+ in the respiratory tract after 
Ga(NO3)3 has been administered to patients? In previous studies where the in vitro antibiofilm 
activity of Ga(NO3)3 was shown, Ga(NO3)3 was added directly to bacteria [334]. However, 
Ga(NO3)3 is currently administered intravenously, and it is currently not known how much Ga3+ 
is found in the lungs during treatment. Second, is Ga3+ able to competitively inhibit microbial 
iron homeostasis in the high iron environment of the CF lung? It has been shown that iron levels 
in the CF airway are significantly elevated [23-26, 29, 30]. Our results show that RSV infection 
further increases iron levels, respiratory viral infection may further exacerbate potential 
competition between iron and Ga3+ and reduce the effectiveness of Ga(NO3)3 as a therapeutic for 
P. aeruginosa infection in the CF lung. We have also demonstrated in this dissertation that RSV 
infection enhances the transcytosis of transferrin from the basolateral to apical compartment of 
the respiratory epithelium (Chapter 4 and Appendix A). Because Ga3+ binds transferrin and 
undergoes TfnR-dependent uptake into cells, our work also has implications for the delivery of 
Ga3+ into the airways. One hypothesis, based on our results, is that respiratory viral infection 
enhances Ga3+-loaded transferrin transcytosis from the basolateral to apical compartment of 
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AECs. This directional transport of Ga3+ corresponds to the movement of Ga3+ into the lumen of 
the respiratory tract during Ga(NO3)3 treatment. Whether respiratory viral infection facilitates 
such a process is an area of interesting investigation and should be included in future research 
that focuses on understanding Ga3+ trafficking in patients.  
5.1.3 Other treatment strategies  
It has been previously shown that respiratory viral infection predisposes the airways to secondary 
bacterial pneumonias by modifying the immune response in the lung [156-158, 160]. The 
connection between respiratory viral infection and the increased release of nutrients (i.e. iron and 
EVs) provides another mechanism by which respiratory viral infection reshapes the environment 
in the respiratory tract to promote secondary bacterial infection. Taken together, the data in the 
respiratory viral-bacterial coinfection field combined with our data emphasize that preventing 
respiratory viral infection through the use of vaccines or prophylaxis may be a strategy that 
limits the acquisition of severe secondary bacterial infections in the airways, such as the chronic 
bacterial infections that are associated with respiratory virus infection in CF patients [53, 55, 71, 
72, 79, 330].  
Influenza virus, hRV and RSV are the three most common viruses detected in CF 
patients. RSV is the most common cause of early respiratory tract morbidity, and palivizumab (a 
monoclonal antibody targeting RSV) prophylaxis has been investigated in CF patients to 
determine its effectiveness on RSV-related infections. These studies have indicated that CF 
patients that received palivizumab prophylaxis had slightly, but not significantly, decreased 
hospitalization rates compared to patients that did not receive prophylaxis [358, 359]. Conflicting 
results have been reported for the effect of palivizumab on first P. aeruginosa acquisition [359, 
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360]. Several factors could contribute to these results, but most importantly to our studies, 
multiple respiratory viruses trigger P. aeruginosa biofilm growth. Thus, targeting a single virus 
may not be efficacious in preventing virally–mediated exacerbations and bacterial infections in 
CF patients. Broader approaches will likely be required to successfully treat viral-bacterial 
coinfections. As an example, it was recently demonstrated by our lab that an engineered 
antimicrobial peptide, WLBU2, was effective at reducing both biomass and viability of P. 
aeruginosa biofilms as well RSV infectivity [361].  
5.2 OUTSTANDING QUESTIONS AND FUTURE DIRECTIONS 
The studies in this dissertation demonstrate that respiratory viral infections promote the 
formation of P. aeruginosa biofilms through a mechanism dependent upon the release of iron-
bound transferrin. Iron is required for P. aeruginosa biofilm growth, and our studies now extend 
the role of iron to viral-bacterial interactions in the airway. Although our research demonstrates 
that RSV increases iron-loaded transferrin in the airway, further research is required to fully 
determine the mechanism by which RSV promotes the release of iron into the airways. As a 
follow-up to the studies presented in this dissertation, we have preliminary results showing that 
iron and transferrin levels in paranasal sinus washes of CF patients are elevated during 
respiratory viral infection. These preliminary studies were conducted in collaboration with Dr. 
Stella Lee in the Department of Otolaryngology at the University of Pittsburgh, who collected 
the sinonasal washes. The therapeutic implications for this work focuses mainly on ways to limit 
iron abundance in the CF respiratory tract during respiratory viral seasons. However, this body of 
work has other important implications that will be discussed below.   
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5.2.1 Viral-bacterial interactions 
An interesting observation from this dissertation is that respiratory viral infection stimulates P. 
aeruginosa biofilm growth through the release of iron-bound transferrin. Viral-bacterial 
interactions are mostly studied in the context of a preceding or concurrent virus infection 
predisposing to secondary bacterial infection. Multiple mechanisms have been described by 
which respiratory viral infections promote secondary bacterial infection, but in general, the net 
result is a failure to clear bacterial infections due to increased bacterial adherence to cells or 
augmented mucosal immunity during a respiratory viral infection [352, 362]. Our study is one of 
the first to demonstrate that a preceding viral infection alters the nutritional landscape in the 
airways to promote secondary bacterial infection. Previously, it has been demonstrated that 
influenza infection increases the abundance of sialylated mucins in the respiratory tract, 
promoting S. pneumoniae growth [353]. Additionally, our studies demonstrate virus infection 
increases iron abundance in the airways to promote bacterial infection. This is consistent with 
previous reports that lipocalin-2 levels are decreased in the airways during influenza A virus 
infection, and exogenous lipocalin-2 decreases S. aureus growth during influenza A co-infection 
by reducing levels of iron in the airway [160]. Lipocalin-2 is a host-derived protein that 
sequesters siderophores, and thus, inhibits bacterial growth by sequestering iron from bacteria 
[363]. Collectively, these studies provide novel insight into viral-bacterial interactions in the 
lung, suggesting that viral dysregulation of nutritional immunity is another important aspect of 
viral-bacterial coinfections in the airway. Further investigation will be required to determine if 
other nutrients or host molecules are released by the airway epithelium during respiratory viral 
infection to increase bacterial colonization of the respiratory tract.  
 154 
In this dissertation, we focused on the interaction between a preceding RSV infection and 
P. aeruginosa. However, it is important to note that bacteria influence virus infectivity as well. 
For example, in the gastrointestinal tract, the microbiome directly interacts with enteric viruses 
to promote enteric virus infection [364]. Whether such interactions occur in the respiratory tract 
is unknown, but it would be intriguing to test if bacteria in the respiratory tract interact with 
respiratory viruses to promote infection. 
5.2.2 Extracellular vesicles in respiratory viral infections 
EVs are membrane-enclosed vesicles secreted by most cell types and transfer biologically active 
molecules between cells, and were one mechanism by which we observed iron-loaded transferrin 
was present in apical secretions from RSV-infected AECs. Interestingly, EVs released by RSV-
infected cells robustly stimulate P. aeruginosa biofilm growth, indicating a unique interaction 
between host cells, viruses and bacteria in the airways that involves iron. However, whether 
other nutrients besides iron are present on EVs released by AECs during RSV infection still 
needs to be elucidated. Moreover, whether viral infections of other mucosal sites produce EVs 
that have increased amounts of iron and other nutrients will be of interest to viral-bacterial 
interactions at other sites in the host. During viral infection, EVs have been shown to have both 
pro-viral and antiviral effects on uninfected neighboring cells [217, 226]. However, no function 
has yet been described for EVs during viral infection in the airways. In this regard, several 
interesting areas of investigation remain: What are the mechanisms by which EVs affect 
respiratory viral infections? Are EVs pro-viral or antiviral in the respiratory tract? Previous 
studies have suggested that EVs transfer antiviral molecules to uninfected cells as a mechanism 
to prevent viral infection [216, 266]. Whether this also occurs in the airways still requires 
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investigation. And more generally, will new technologies be developed that allow for 
purification of functional EVs from viruses and virus-like particles during a virus infection? This 
will be key to addressing whether the net biological effect of EV production during viral 
infection is due to the entire mixed populations of EVs, or whether certain EV subpopulations 
drive biological outcomes to disease. In this regard, a two-step purification process has been 
described that utilizes CD63 (a common protein found on exosomes) immunoprecipitation to 
separate EVs from virions [250]. The limitation of this approach is that EVs are eluted from 
CD63+ beads with low pH wash. In our own studies, we have demonstrated that the biological 
activity of our EVs is sensitive to low pH wash (Figure 33). This likely occurs because low pH 
disrupts the interaction between iron and transferrin, and therefore, a low pH wash would 
potentially release iron and transferrin from EVs in our studies. This suggests that two-step 
purification approach may have limitations for studying biologically active molecules loaded on 
the outside of EVs. In addition, this selects only for CD63+ EVs, which may mask important 
biology that occurs with CD63- EVs. In our own studies, we could also use RSV antibodies to 
separate EVs from RSV virions by immunoprecipitation, but this approach has its own 
limitations. Namely, we observed that the EV population that contained transferrin and was 
responsible for the biofilm stimulatory activity of EVs isolated from RSV-infected cells also 
contained RSV antigens (Figure 29). Thus, important considerations must be made in future 
studies in the field to determine the proper method for the purification of functional EVs from 
viruses to address whether certain EV subpopulations drive biological phenotypes. 
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Figure 33: Low pH wash disrupts the biofilm stimulatory activity of EVs isolated from RSV-infected AECs. 
AECs were infected with RSV or mock-infected (MEM control). EVs were isolated from apical CM as outlined in 
section 2.2.6 after 72 hr but were resuspended in minimal essential media (MEM) supplemented with 2 mM L-
glutamine pH 7.4 or pH 5.0. EV pellets resuspended in pH 7.4 MEM are referred to as “Extracellular Vesicles – pH 
7.4 Wash” and EV pellets resuspended in pH 5.0 MEM are referred to as “Extracellular Vesicles – pH 5.0 Wash.” 
All EVs were pelleted again using ultracentrifuge and all pellets were resuspended in MEM supplemented with 2 
mM L-glutamine pH 7.4 before biofilm assays. P. aeruginosa (GFP) biofilms were grown in the presence of EVs in 
static abiotic biofilm assays. Fluorescent microscopy was used to measure the growth of P. aeruginosa. Nikon 
Elements (grid unit = 9.0 µm) was used to quantify P. aeruginosa biomass. n ≥ 3. Data are presented as mean ± SD; 
*P < 0.05 versus control. 
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Our preliminary data suggest that P. aeruginosa associates with EVs released from 
AECs, which raises several questions: Do bacteria interfere with EV functions in the airways and 
thus, affect respiratory viral infection? Do EVs interact with other bacteria besides P. 
aeruginosa? Is this interaction limited to Gram-negative pathogens or does it extend to Gram-
positive pathogens? How do EVs associate with P. aeruginosa? Understanding the interaction 
between host-derived EVs and bacteria in the respiratory tract is very exciting as it hypothesizes 
an additional component that likely influences the outcome of viral-bacterial infections in the CF 
lung and at other mucosal sites. If precise host-pathogen relationships are identified at the 
molecular level, it presents an entirely novel direction for therapeutic intervention in which 
specific processes could be targeted to minimize nutritional abundance and/or microbial 
utilization of nutrients in the airways to limit infections. 
5.2.3 Transferrin transcytosis at mucosal surfaces 
An interesting observation in this study was that respiratory viral infection increased transferrin 
transcytosis across the airway epithelium to the apical compartment of cells (Appendix A). It is 
known that cells, notably neutrophils, increases lactoferrin and calprotectin (a zinc and 
manganese-binding protein) concentration in infectious sites as part of the immune response, but 
less is known about transferrin. The ability of transferrin inhibit bacterial growth increases as 
transferrin saturation decreases due to its ability to sequester iron. Therefore, it is plausible that 
apo-transferrin would inhibit microbial growth at the site of infection. Regarding this hypothesis 
and the evolutionary arms race between iron sequestration and acquisition between host and 
microbes, an interesting question remains. That is, do pathogens actively increase the abundance 
of iron-loaded transferrin at the site of infection to promote their own growth? Recently, it was 
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shown that Helicobacter pylori, which colonizes the apical membrane of gastrointestinal 
epithelial cells, alters iron trafficking of host epithelial cells by promoting transferrin receptor 
mislocalization from the basolateral to apical membrane of cells [203]. This perturbation in 
transferrin trafficking results in the apical release of transferrin to promote H. pylori growth on 
cells [203], suggesting that pathogens have evolved mechanisms that increase the amounts of 
iron-loaded transferrin at the site of infection. More interestingly, this study demonstrated that 
microbes alter transferrin trafficking within epithelial cells, but the mechanism by which this 
trafficking pathway is altered remains undefined. It has previously been reported that transferrin 
transcytosis is increased in polarized epithelial cells due to loss of function of the epithelial 
basolateral sorting adaptor AP-1B, and that this mechanism is dependent upon Rab11a, Rab11a-
FIP2 and galectin-4 [365, 366]. The data from these studies support a model whereby transferrin 
and other basolateral proteins are trafficked to apical recycling endosomes and delivered via 
Rab11a-positive endosomes to the apical plasma membrane. Whether microbes target AP-1B or 
any of these other proteins to promote transferrin trafficking is unknown and an intriguing area 
of future investigation.  
Although our work has demonstrated that respiratory viral infection promotes transferrin 
transcytosis in AECs, a few stimulating questions remain: Why is iron-loaded transferrin 
transcytosed (i.e. why is the iron not delivered to cells)? What role do STEAP proteins play in 
transcytosis? In regards to our own work, why does RSV infection promote transferrin 
transcytosis, and are specific RSV proteins required for stimulating transcytosis? It is known that 
RSV utilizes proteins involved in the apical recycling pathway in cells to bud [97, 98]. Thus, one 
hypothesis that explains the increased transcytosis of transferrin during RSV infection is that 
while the virus hijacks apical recycling proteins it also downregulates or represses basolateral 
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recycling, which consequently would direct basolateral proteins to the apical membrane. 
Whether RSV stimulates the transcytosis of other basolateral proteins besides transferrin and if 
RSV degrades basolateral recycling proteins are interesting questions that would start testing this 
hypothesis.  
5.3 FINAL THOUGHTS 
Although clinical observations have noted for the last twenty years that respiratory viral 
infections trigger exacerbations and are associated with chronic P. aeruginosa infections in CF 
patients, the mechanisms underlying these interactions have remained poorly understood. This 
dissertation has contributed to our mechanistic understanding to fill this knowledge gap and 
demonstrated that respiratory viral infection of the airway epithelium alters nutritional 
abundance in the airways, creating an environment permissive to the growth of bacterial biofilms 
by increasing the release of iron-bound transferrin. We also observed that activation of the 
antiviral IFN response [via treatment of AECs with type I and type III IFNs (IFN-β and IFN-λ, 
respectively)] in the absence of viral infection was sufficient to stimulate P. aeruginosa biofilm 
growth. Although apical secretions from AECs infected with a respiratory virus or treated with 
IFN were sufficient to stimulate P. aeruginosa biofilms in the absence of cells, our data suggest 
the biofilm-stimulatory activity is driven by different factors in these two conditions. Whereas 
respiratory viral infection enhanced P. aeruginosa biofilm growth by increasing the abundance 
of iron and the host iron-binding protein transferrin in the airways, IFN treatment did not alter 
iron or transferrin release by AECs but still stimulated P. aeruginosa biofilm growth. Together, 
we interpret these observations to suggest that at least two parallel pathways contribute to 
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increased P. aeruginosa biofilm growth during respiratory viral infection. These two pathways 
are likely key components of the interactions that exist between respiratory viruses and 
secondary bacterial infection that determine host outcome. Although this dissertation has focused 
on P. aeruginosa biofilm formation in the airways during respiratory viral infection, the 
observations made here offer new insight into the complex interactions that occur between the 
host and pathogens at mucosal surfaces during polymicrobial infections. In addition, it is 
important to consider that while this dissertation has focused on how viral infection benefits 
secondary bacterial infection, the relationship between these two microbes is not a one-way road 
and there is a growing body of literature demonstrating the impact bacteria have on viral 
infection. For example, work in the gastrointestinal tract has shown that the intestinal 
microbiome promotes enteric viral infection through modulation of the immune system and by 
directly interacting with virions [367]. Confirming the precise interactions that exist between 
viruses and bacteria will be critical as this would be among the first steps needed for designing 
therapeutics that disrupt these relationships to limit the severity of secondary infections.  
The final portion of this thesis has demonstrated that RSV infection increases the release 
of EVs from the airway epithelium and importantly that these EVs stimulate P. aeruginosa 
biofilm growth through a mechanism dependent upon the release of iron-loaded transferrin on 
EVs. Although our studies expand our understanding of how a respiratory virus alters the 
nutritional landscape of the airways through EV release, these results set the stage for an 
interesting set of new studies that investigates the biological function of EVs in the airways 
during an infection. In particular, it will be of great interest to see what role EVs may play in 
transferring antiviral molecules between cells, and what other consequences EV association with 
P. aeruginosa has on bacterial infection besides promoting biofilm growth. In conclusion, the 
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work presented in this dissertation suggests that during viral infection, the nutritional landscape 
of the airways is altered, promoting secondary bacterial infections. Microbes do not exist in a 
vacuum and understanding the complex interplay between viruses, bacteria and the host 
environment is a very active area of research that may uncover novel therapeutic strategies for 




RESPIRATORY SYNCYTIAL VIRUS INFECTION DISRUPTS TRANSFERRIN 
TRAFFICKING IN THE RESPIRATORY EPITHELIUM 
The data included in this appendix is data I generated for a manuscript being prepared by Dr. 
Jeffrey Melvin, a postdoctoral associate in the Bomberger Lab, to understand how P. aeruginosa 
responds to the environment created by respiratory viral infection to form biofilms.  
A.1 RESULTS 
Our data suggest a model in which RSV infection increases apical release of transferrin to 
promote P. aeruginosa biofilm growth. To understand why increased levels of transferrin are 
released into CM during RSV infection, we looked at the transcription of transferrin in AECs, 
and found that the expression of transferrin is reduced in AECs in response to RSV infection 
(Figure 34A), implying that apically released transferrin originates outside the cell. Transferrin 
is responsible for shuttling iron throughout the body in the circulatory system. In our model, the 
only extracellular location that transferrin can originate from is the basolateral compartment of 
cells. Thus, we examined whether transferrin is transcytosed from the basolateral to apical 
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compartment of polarized AECs during RSV infection by adding biotinylated transferrin to the 
media in the basolateral compartment of cells 48 hours post-RSV infection. After 24 hours, we 
then measured the abundance of biotinylated transferrin in CM. We found that biotinylated 
transferrin was transcytosed across the epithelial layer to the apical compartment by both control 
and RSV-infected AECs, but during RSV infection there was approximately a three-fold increase 
in the amount of biotinylated transferrin in CM collected from RSV-infected cells as compared 
to uninfected monolayers after a total of 72-hour virus infection (Figure 34B). Additionally, the 
increase in transferrin transcytosis during RSV infection was time-dependent, since we observed 
no difference in the amount of biotinylated transferrin in CM collected from RSV-infected cells 
after only 24-hour virus infection (Figure 34B). We also measured the transcytosis of 
fluorescently-labeled, 70 kDa dextran from the basolateral to apical compartment of AECs 
during RSV infection to determine if the increase in transferrin transcytosis was due to 
paracellular leakage. Because paracellular leakage would rapidly increase transferrin transcytosis 
to the apical compartment, we added FITC-dextran to cells infected with RSV for 72 hours and 
measured FITC dextran transcytosis over time compared to either uninfected cells or filters alone 
(no cells; positive control for paracellular leakage). We found that the amount of dextran that 
was transported into the apical compartment of cells was unchanged after 72-hour RSV 
infection, and the overall amount of dextran transcytosed into the apical compartment by infected 
and uninfected cells was very low (Figure 34C). Because we did not observe an increase in 
dextran in the apical compartment of AECs, we concluded that RSV infection was not damaging 
the epithelial monolayers and causing non-specific leakage of basolateral proteins into the apical 
compartment of cells. This supports out earlier findings that RSV infection did not significantly 
damage the epithelial monolayer, as measured by lactate dehydrogenase (LDH) release and 
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transepithelial electrical resistance (TEER) (Figure 10). In addition, we found very little 
transcytosis from the apical to the basolateral compartment of cells, and RSV infection had no 
impact on this process (Figure 34D). This suggests that the transcytosis from the basolateral to 
apical compartment is a directionally specific process. Consistent with the transcytosis from the 
basolateral to apical compartment, we observed a slight, although not statistically significant, 
reduction in transferrin receptor (TfnR) abundance on the basolateral membrane (Figure 34E). 
Interestingly, we observed that RSV infection increased the apical release of TfnR that originated 
in the basolateral plasma membrane, suggesting that virus infection promoted the trafficking of 
TfnR from the basolateral membrane to the apical compartment of AECs. In light of our 
observations in Chapter 4 of this dissertation, we suspect this increase in basolateral TfnR that is 
secreted during RSV infection is due to the release of EVs. We hypothesize that basolateral TfnR 
is loaded onto EVs and is bound to transferrin. Whether this EV population is due to trafficking 
of the basolateral TfnR-transferrin complex to multivesicular bodies (MVBs) and released on 
exosomes, or the complex is trafficked the apical membrane of AECs and released on EVs that 
bleb from the apical plasma membrane is still to be determined and is an intriguing question 
moving forward. Taken together, these results support the conclusion that RSV infection 
promotes the transcytosis of transferrin into the apical compartment of AECs, increasing the 




Figure 34: RSV infection increases transferrin transcytosis. 
(A) RNA was prepared from AECs infected with RSV or mock-infected (MEM control) for 72 hr and probed by 
qRT-PCR for transferrin expression. (B) Biotin-transferrin was added to the basal chamber of RSV or mock-infected 
AECs 48 hpi at a final concentration of 25 µg/mL. The apical supernatants of AECs were collected 24 hours later. 
Biotinylated-transferrin was affinity-purified from apical secretions with streptavidin beads. Proteins were eluted 
from beads and separated by SDS-PAGE. Transcytosed transferrin was measured by Western blot analysis. (C) 70 
kDa FITC-dextran was added to the basal chamber of RSV or mock-infected AECs 72 hpi at a final concentration of 
25 µg/mL. The apical secretions were collected from cells were analyzed for FITC fluorescence by plate reader at 
the indicated time points after addition of FITC-dextran. RSV, RSV-infected AECs. (D) Biotin-transferrin was 
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added to the apical chamber of RSV or mock-infected (control MEM) AECs 48 hpi at a final concentration of 25 
µg/mL. The basolateral media was collected from AECs 24 hr later and biotinylated-transferrin was affinity-purified 
from apical secretions with streptavidin beads. Proteins were eluted from beads and separated by SDS-PAGE. 
Transcytosed transferrin was measured by Western blot analysis. (E) AECs were infected with RSV or mock-
infected (MEM control) for 72 hr. The apical and basolateral cell surface was biotinylated and biotinylated proteins 
were affinity purified from whole cell lysates (WCLs) with streptavidin beads. Proteins were eluted from beads, 
followed by SDS-PAGE and Western blot analysis to analyze the effect of RSV infection on apical and basolateral 
membrane TfnR abundance. Quantification of results found below representative blots. All quantifications were 
normalized to TfnR in whole cell lysate (WCL). (F) AECs were infected with RSV or mock-infected (MEM control) 
for 48 hr, followed by cell surface biotinylation of the apical or basolateral cell surface. CM was collected from cells 
24 hr later and biotinylated proteins from CM were affinity-purified with streptavidin beads followed by SDS-PAGE 
and Western blot analysis was performed to analyze the effect of RSV infection on the apical release of cell surface 




INTERFERON-STIMULATED REGULATORS OF PSEUDOMONAS AERUGINOSA 
BIOFILM GROWTH ON AIRWAY EPITHELIAL CELLS 
All data presented here is unpublished and represents a collaborative ongoing study in the 
Bomberger Lab interested in understanding how the innate antiviral IFN response and more 
specifically, individual interferon-stimulated genes (ISGs) contribute to P. aeruginosa biofilm 
growth. Dr. Jeffrey Melvin, a post-doc in the Bomberger Lab, and myself performed the ISG 
screen, and Brian R. Kocak, a laboratory technician in the Bomberger Lab, is now in the process 
of validating the hits from the ISG screen. Contributions of authors to individual figures are 
indicated in the figure legends. The cell-based screen used in this study was initially developed 
by Dr. John Schoggins (Department of Microbiology, University of Texas Southwestern Medical 
Center, Dallas, TX, United States of America), who we have collaborated with as part of the ISG 
screen described here. 
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B.1 RESULTS 
B.1.1 Apical secretions from IFN treated AECs promotes the growth of P. aeruginosa 
biofilms independent of transferrin and extracellular vesicles 
In the previous chapters, it has been established that AECs increase apical release of the host-
iron binding protein transferrin (Chapter 3) and extracellular vesicles (Chapter 4) during 
respiratory virus infection and that these factors are important for increased P. aeruginosa 
biofilm growth following viral co-infections. However, it is unknown if IFN signaling influences 
the release of iron from AECs, or whether extracellular vesicles isolated from cells treated with 
IFN interact with and stimulate bacterial growth. To begin addressing these questions, we first 
asked if CM from IFN treated AECs stimulated P. aeruginosa biofilm growth to determine if 
cells treated with IFN release factors that stimulate biofilm growth. We found that CM from 
IFN-β-treated AECs increased biofilm growth in static abiotic biofilm assays (Figure 35), 





Figure 35: CM from IFN-β treated AECs enhance P. aeruginosa biofilm growth.  
CM was collected from AECs were treated with IFN-β (1000 U/mL) for 18 hrs, and P. aeruginosa (GFP) was 
grown in the presence of CM in static abiotic biofilm assay and epifluorescence microscopy was used to measured 
biofilm growth (GFP, green). P. aeruginosa biofilm biomass was quantified using Nikon Elements (grid unit = 6 
µm). *P < 0.05, n > 3. 
 
Because we observed that apical secretions from both RSV infected and IFN-β treated 
AECs enhanced P. aeruginosa biofilm growth and we have shown that RSV enhances iron 
release from AECs to stimulate P. aeruginosa biofilm growth, we next examined if IFN-β 
treatment alters the release of iron from AECs. Interestingly, we found that IFN-β treatment did 
not change total iron levels in CM collected from IFN-treated cells (Figure 36A). This suggests 
that IFN signaling does not mediate the release of iron from AECs, or at the very least is not 
sufficient to promote iron release. In addition, this implies that the antiviral IFN response is not 
responsible for the increased iron release we observed from AECs during respiratory viral 
infection (Chapter 3). However, this does not rule out the possibility that IFN signaling 
increases the release of non-iron bound transferrin from AECs. Such a phenotype could be 
considered an appropriate immune response during viral infection as transferrin could sequester 
any free iron that is released during the course of the infection, specifically for the purpose of 
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preventing secondary bacterial infections. However, we observed that IFN-β treatment did not 
alter the transcytosis and apical release of transferrin into CM (Figure 36B). Collectively, these 
results demonstrate that IFN signaling does not disrupt nutritional immunity in AECs and 
increase the release of iron or the iron-binding protein transferrin. This implies that iron is not 
the only factor that is altered by respiratory viral infection, and that IFN signaling activates a 
parallel biofilm stimulatory mechanism. Thus, we hypothesized that IFN treatment activates 
specific ISGs that stimulate P. aeruginosa biofilm growth. To test this hypothesis and begin to 
understand the mechanism by which IFN treatment stimulates P. aeruginosa biofilm growth, we 
performed an ISG screen that will be described in the next section. 
 
 
Figure 36: Iron release and transferrin transcytosis from AECs treated with IFN-β.  
AECs were treated with IFN-β (1000 U/mL) for 18 hrs. (A) Total iron was measured in apical CM. (B) IFN-β 
treatment does not increase transferrin transcytosis from the basolateral to apical compartment of AECs. At the time 
of IFN-β treatment, 25 µg/mL of transferrin biotin-XX-conjugate was added to the basolateral compartment of 
AECs. Transferrin biotin-XX-conjugate was affinity purified from the apical CM and transferrin was measured by 
western blot analysis. n = 3.  
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B.1.2 ISG screen identifies potential regulators of P. aeruginosa biofilm growth in 
response to IFN signaling 
Because we observed that IFN treatment did not increase iron release from AECs, we propose 
that respiratory viruses and the antiviral IFN response to virus infection stimulate P. aeruginosa 
biofilm growth by two distinct but parallel mechanisms. We utilized a gain-of-function screening 
approach to identify ISGs that increase P. aeruginosa biofilm growth in CM, to gain a better 
understanding of the mechanisms by which IFN signaling enhances the release of biofilm 
stimulatory factor(s). To screen CM from hundreds of ISGs for biofilm stimulatory activity we 
utilized our static abiotic biofilm assay. Briefly, AECs were transduced, in a one-gene one well 
format, with bicistronic lentiviral vectors driving constitutive expression of genes for a single 
ISG and red fluorescent protein [368]. CM was collected from cells 72 hours post-transduction, 
and GFP-expressing bacteria were grown in the presence of the CM in static abiotic biofilm 
assays for 6 hours and biofilm growth was assessed by fluorescent microscopy (Figure 37A). 
Firefly luciferase was used as a negative control to ensure that protein overexpression was not 
driving the biofilm stimulatory activity of cells. As has been shown throughout this dissertation, 
this method allows for visualization of biofilm growth in the absence of AECs, which makes it 
possible to ascertain whether individual ISGs stimulate biofilm growth by promoting the 
secretion of biofilm stimulatory factor(s). Additionally, by visualizing biofilm growth, biofilm 
architecture can be analyzed to identify unique structures that may result due to environment 
changes in the CM induced by individual ISGs. Finally, our Nikon Ti-inverted fluorescent 
microscope is fitted with an automated stage, which allows for automated, unbiased imaging of 
biofilm formation in CM.  
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We expressed a library of approximately 390 ISGs previously described [368], and 
performed static abiotic biofilm assays as described above. Biofilm growth of P. aeruginosa 
from the average of two screen replicates is shown as a dot plot (Figure 37B). Some ISGs very 
robustly stimulate P. aeruginosa biofilm growth, whereas the majority had relatively little effect 
on biofilm formation. We determined ISGs that enhance P. aeruginosa biofilm growth as those 
ISGs that increased biofilm biomass 1.5 standard deviations above the population mean (Z-score 
greater than 1.5). Most of the ISGs had little effect on P. aeruginosa biofilm growth, as bacterial 
biomass for the majority of ISGs had a Z-score less than 1.5 (Figure 37B). Six ISGs were 
identified based on this criteria including MYDD88, APOBEC3A, HK2, TNFRSF10A, EHD4 




Figure 37: Gain-of-function screen identifies regulators of P. aeruginosa biofilm growth. 
(A) Schematic of gain-of-function screen for ISGs that enhance abiotic P. aeruginosa biofilm growth. Diagram of 
bicistronic lentiviral vector is shown; CMV, immediate early promoter from human cytomegalovirus; LTR, HIV-1 
long terminal repeat; RFP, red fluorescent protein. AECs were transduced with biscistronic lentiviral vector for 72 
hours, and CM was collected.  P. aeruginosa (GFP) was grown in the presence of CM in static abiotic biofilm 
assays. Epifluorescence microscopy was used to measure biofilm growth. (B) (Left) Dot plot of P. aeruginosa 
biofilm growth in the presence of CM in two replicate screens and presented as an averaged (error bars represent 
s.d.). n=2. (Right) Scatter plot of Z-scores of screen replicates 1 and 2. Genes selected as positive hits for further 
confirmation are boxed in scatter plot (Right) and labeled in dot plot (Left).  
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We are currently in the process of performing repeat trials of static abiotic biofilm assays 
with full-length cDNA clones of all six ISGs to confirm the biofilm stimulatory activity of these 
ISGs. Preliminary experiments using these cDNA clones have confirmed that overexpression of 
HK2 and EHD4 increase P. aeruginosa biofilm growth (Figure 38). As a negative control, we 
are using GFP, which does not stimulate biofilm growth. In addition, we have also measured the 
expression of all six ISGs in AECs during RSV infection and found that expression of five of the 




Figure 38: Validation of biofilm stimulatory activity of ISG screen hits. 
AECs were transfected with full-length cDNA clones of two genes identified in the gain-of-function ISG screen for 
72 hours, and CM was collected. P. aeruginosa (GFP) was grown in the presence of CM in static abiotic biofilm 
assay. Epifluorescence microscopy was used to measured biofilm growth (GFP, green) and biofilm biomass was 
quantified using Nikon Elements (grid unit = 6 µm). GFP cDNA clone was used as negative control to verify that 
gene overexpression by cDNA clones did not promote P. aeruginosa biofilm growth. Static abiotic biofilm assays 





Figure 39: Gene expression of ISG screen hits during RSV infection. 
AECs were infected with RSV or were mock-infected (MEM control) for 72 hours and RNA was collected. Gene 
expression was measured by quantitative RT-PCR (qRT-PCR) to monitor gene expression during RSV infection 
(red bar) compared to uninfected cells (black bar). *P < 0.05, **P < 0.005, ****P < 0.00005, n=3. Data provided by 
Brian R. Kocak.  
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